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CHAPTER 1
INTRODUCTION TO PREHOSPITAL THROMBOLYSIS
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1.1 Introduction
Prehospital thrombolysis in Nijmegen
Every ten years prehospital thrombolysis is re-invented,  said professor
Mervyn Gotsman during a meeting of the European Society of Cardiology in
Barcelona in 1999. Indeed, the earliest reports describing prehospital
administration of thrombolytic therapy emerged from Jerusalem, from where
Gotsman et al reported in the New England Journal of Medicine in 1985.
1
Following this, further studies were to appear in the international literature, not
only concerning prehospital treatment, but the importance of early therapy in
general, pioneered by the GISSI-report dealing with myocardial infarction and
treatment with streptokinase.
2
Largely as a result of this, cardiologists in the
Netherlands were made aware of the substantial delays involved in the treat-
ment of acute myocardial infarction as normally carried out. Working in close
cooperation with ambulance personnel, general practitioners and cardiologists,
in 1987, Nijmegen s Canisius-Wilhelmina hospital then became the first to
initiate a prehospital strategy in The Netherlands. Nijmegen was soon followed
by Rotterdam, a similar program being started in 1988. From that time on,
prehospital thrombolysis has had its roots in The Netherlands.
Nevertheless, prehospital thrombolysis was soon to be overshadowed by the
impact of the in-hospital ISIS-2 trial, published in 1988, in which randomized
treatments using aspirin and/or streptokinase, or neither, were administered to
patients with suspected acute myocardial infarction.
3
To the surprise of all,
these two relatively simple and inexpensive drugs could be applied to reduce
in-hospital mortality by some 50%. This success soon pushed the relatively
complicated, outside-hospital diagnosis of acute myocardial infarction, together
with the concomitant prehospital drug supply required, along with the budget
reallocations thus entailed, to the background. In the area of acute myocardial
infarction, prehospital thrombolysis thus lost some of its momentum.
But not for long. Numerous studies on the effects of streptokinase and, later,
rt-PA, appeared in the literature, leading to a renewed recognition of the various
delays inherent in treating acute myocardial infarction.
4
Time delays were
recorded
5
and hospital strategies were changed so as to reduce in-hospital treat-
ment delays.
6
This renewed attention on the importance of speed restimulated
interest in prehospital treatment, leading to the publication of three major
-10-
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reports published in the early nineties,
7-10
involving randomized allocations of
pre- versus in-hospital treatments. However, the long-expected reduction in
mortality for the prehospital treated patient group failed to materialize. In fact,
mortality reached statistical significance only in the GREAT study
8
, in which
prehospital therapy reduced the time to treatment by 130 minutes. 
In retrospect, this randomization between prehospital and in-hospital treat-
ments seems less of a good idea, allowing in both groups, as it does, patients
presenting early as well as late after onset of symptoms. A better course is to
analyse the outcome of patients with myocardial infarction according to their
time to treatment. Boersma et al provided this analysis, publishing their reap-
praisal of the Golden Hour  in 1996.
11
In this, early treated patients from
previous studies of prehospital thrombolysis were included so as to provide
data concerning treatment within the first hour after onset of symptoms. 
That is, roughly 10 years following Gotsman s report on his experience with
prehospital treatment in 1985, the real importance of treatment within one hour
finally became clear. But only by means of prehospital therapy could treatment
within the Golden Hour be achieved. And from that moment on, more or less,
prehospital treatment became re-invented. Once the turning point of the Golden
Hour had been reached, along came a new generation of easy-to-administer
thrombolytics in single or bolus form ready for testing in the field.
Furthermore, publications began to appear describing mechanical methods for
the opening of blocked coronary arteries rather than thrombolytic therapy. But
although the results of primary angioplasty in acute myocardial infarction were
promising, the time to treatment reached with prehospital triage and throm-
bolysis could not be matched.
Basis for this thesis
In Nijmegen, prehospital therapy has been implemented since 1987. The afore-
mentioned ups and downs in the history of prehospital treatment are reflected
in the number of patients treated over the years. Following a learning process
in the use of transtelephonic transmission for achieving prehospital diagnosis
of acute myocardial infarction, only 10% or less of patients with acute myocar-
dial infarction were actually treated prehospitally. Fax transmission of ambu-
lance-ECG s from the CCU to the cardiologist s home during the early hours
-11-
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(using the first generation fax machines of that time), was also initiated, in
1987. Following a period of training in the two Nijmegen hospitals involved in
prehospital thrombolysis, in 1992 the author joined the advisory board of the
Nijmegen ambulance service, together with two general practitioners from the
region. Prehospital thrombolysis proved to be a good catalyst for improving
cooperation among general practitioners, ambulance staff and hospital specialists.
After a number of exploratory sessions involving cardiologists, general practi-
tioners and ambulance crew, during which the principles of thrombolysis and
importance of time to treatment were explained, the local advisory board of
general practitioners made the decision to adopt prehospital diagnosis and
thrombolytic therapy in their guidelines for standard family care. From that
time on, inclusion of patients in the prehospital strategy increased again to
about 75% of all patients with acute ST segment elevation myocardial infarction.
The greater part of the Nijmegen patient database was built up at this time. 
Hypotheses
According to the available literature (chapter 2) dealing with the importance of
early treatment, no more than 25% of patients are treated within 2 hours using
in-hospital thrombolysis. The number of patients treated within the golden
hour  is thus inevitably much smaller. Accordingly, our first question is: How
many prehospitally treated patients can be treated within 1 or 2 hours after
symptom onset, in comparison with those who receive in-hospital treatment?
The STIMIS-study, discussed in chapter 3, is an attempt to answer this question. 
Whether the time gained using prehospital thrombolysis is specific to the
Nijmegen situation or can be realized equally in other regions is discussed in
chapter 4. In examining the data we can discern two groups of patients: those
treated relatively early, and those treated relatively late. Can anything be said
about the differences between these two in respect of prognosis? We hypothe-
size that early treatment results in fewer deaths and fewer heart failures than
late treatment. Moreover, experience in practice has given rise to the concept
of aborted myocardial infarction, a condition hitherto unrecognized in the
literature. Mortality, heart failure and aborted myocardial infarction are exami-
ned in chapters 5, 6 and 7.
Primary angioplasty plays an important role in the treatment of acute myocar-
dial infarction. Although associated with a very high reperfusion rate and low
-12-
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mortality, there remain questions about the time to reperfusion and whether the
concept of aborted myocardial infarction is applicable to primary angioplasty.
Chapter 8 considers the results represented by a combination of databases from
one of the Dutch leading primary angioplasty centres, Zwolle, together with
our own prehospital database in Nijmegen.
New generation bolus thrombolytics are ideally suited to prehospital use.
Chapter 9 discusses their effects on time to treatment, as revealed in a combi-
nation of our Nijmegen database with that of a second large prehospital throm-
bolysis centre in Rotterdam. 
Ever since the introduction of thrombolysis, clinicians have been wary of
unjustified fibrinolysis, a wariness that becomes only heightened in the pre-
hospital situation. We compare two prehospital databases, the data in each
based upon differing ECG methods for the diagnosis of acute myocardial
infarction, in an attempt to explain their relative incidence of unjustified fibri-
nolysis. Finally, it is clear that the introduction of prehospital thrombolysis
must entail hospital budget re-allocations, and this in a health system notori-
ously preoccupied with costs. In chapter 11, different methods are applied for
the calculation of the cost per life year gained with prehospital thrombolysis as
compared with in-hospital treatment. 
In summary, the following questions are to be answered:
1. Looking at different regions across The Netherlands, what is the time to
treatment, and what percentage of patients is treated within one and two
hours, respectively, by means of prehospital therapy?
2. How do mortality, incidence of heart failure, and incidence of aborted 
myocardial infarction compare in the early and late treatment groups 
using prehos-pital versus in-hospital thrombolysis?
3. Is the incidence of aborted myocardial infarction the same in primary 
angioplasty as it is in prehospital thrombolysis? 
4. Is there a difference in time to treatment using newer generation bolus
therapy, as opposed to the current infusion strategy, when we compare
two regions in which prehospital thrombolysis is an established therapy?
5. What is the incidence of unjustified fibrinolysis using two different 
means of ECG-diagnosis?
-13-
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6. What is the cost per life year gained by prehospital thrombolysis in our
region?
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CHAPTER 2
THE IMPORTANCE OF EARLY TREATMENT OF
ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION; A REVIEW
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2.1 Definition of acute myocardial infarction
Cell death
Central to the definition of acute myocardial infarction is the loss of cardiac
myocytes, caused by prolonged ischaemia. Ischaemia is caused by the imbal-
ance of demand and supply of oxygen. In most cases this imbalance is initiat-
ed by rupture of an atherosclerotic plaque, followed by thrombosis, which
gives rise to total occlusion of a coronary artery.
1
The loss of cardiac myocytes is measured by the release of various markers in
blood samples. Electrocardiographically, the loss of cardiac myocytes is
accompanied by ST-segment changes and/or the development of pathological
Q-waves. Using imaging techniques such as echocardiography or radionuclide
techniques, the loss of myocardial tissue can be detected by wall motion abnor-
malities and/or the loss of tissue perfusion. One must realize that the defining
characteristic of myocardial infarction, cell death, is a histopathologic event
and that the development of cell death costs time. After coronary occlusion, at
least 15 minutes must pass before an ischemic myocyte dies. It takes at least 6
hours before myocardial necrosis can be identified with standard pathology
techniques, and this time span depends on the presence of collateral blood flow
and the sensivity of myocytes for ischemia. So, time plays a considerable role
in the development of cardiac necrosis, and thus in the efforts to limit the
impact of ischaemia.
Classification of myocardial infarction in time
Myocardial infarcts are classified according to their histopathologic appear-
ance as acute (6—12 hours from onset of symptoms), ongoing (from 12 hours
to 7 days), healing (7 days to 28 days) and healed (from 28 days onward). No
or only minimal histopathologic characteristics of cell death may be found in
myocardial infarctions with symptoms less than 6 hours.
WHO definition of acute myocardial infarction
In the past the World Health Organisation defined acute myocardial infarction
as the combination of two of three characteristics: (1) typical symptoms of
myocardial infarction (chest pain or discomfort), (2) typical enzyme rise (cre-
atinephosphokinase and cardiac aspartate aminotransferase) and (3) a typical
-17-
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ECG pattern with ST-segment elevation and development of Q waves. It is
important to note that in this definition typical enzyme rise is not necessary, as
only two characteristics are needed. However, in the wake of the development
of more specific serologic markers and image techniques, problems arose in
defining myocardial infarction as we used to know it. The specific markers
such as the troponins identify patients with small infarctions that would not be
considered to be an infarction according to the WHO definition. So new defi-
nitions of acute myocardial infarction were proposed.
2
Most recent definition of acute myocardial infarction
In the newest definition of myocardial infarction, recorded cell death fulfills a
more central role than in the WHO-definition. Cell death must be made plausi-
ble by a typical course of biochemical markers, such as troponin-I or —T, CK
or CK-MB, or signs of myocardial necrosis by histopathologic investigation.
These must be accompanied by at least one of the following signs:
¥ typical symptoms
¥ development of Q waves on the ECG
¥ ECG-signs of ischaemia (ST-segment elevation or depression)
¥ The above in the wake of coronary intervention such as angioplasty
Troponin-I or -T have almost absolute myocardial tissue specificity, as well as
a high sensivity, so measuring this marker can be regarded as the golden stan-
dard for assessing myocardial damage. CK-MB is the best alternative for tro-
ponins, although less tissue-specific. As with cardiac troponin, an increased
value is defined as one that exceeds the 99
th
percentile of CK-MB values in a
reference control group. Total CK is less specific, and the cut-off limit is
regarded as at least twice the upper reference limit for CK. The degree of
increase is related to the extent of the damage, but must be seen together with
other clinical factors, such as signs of reperfusion, development of definitive
Q-waves and loss of voltage on the ECG and signs of residual left ventricular
function. 
ST elevation myocardial infarction versus other categories
With these new serum markers of myocardial cell death new categories of
-18-
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acute myocardial infarction present themselves, each with their own
histopathologic characteristics (fig 2.1-1). In these definitions all patients with
non-ST elevation and ST elevation myocardial infarction and some with unsta-
ble angina pectoris will have a rise in troponin-I or T. These are all caused by
acute changes in a coronary atherosclerotic plaque and all have their own prog-
nosis, treated or not. 
Acute coronary syndromes in this thesis
In the following text we concentrate on the acute coronary syndrome charac-
terized by ST-segment elevation on the presenting ECG. Although signs of cell
death are pivotal in the latest definition of acute ST elevation myocardial
infarction, one must realise that patients can be treated in such a way and with-
in such time span that cell necrosis is averted. These patients present them-
selves with pain and ST-segment elevation on the ECG but, usually after some
sort of intervention, there is no significant rise in cardiac enzymes. In such
patients myocardial infarction is aborted.
2
Although this possibility is men-
tioned in the various reviews about acute coronary syndromes
2,3
, it is not elab-
orated further in these texts.
Thrombolysis and ST elevation myocardial infarction 
To start therapy with thrombolysis acute ST elevation myocardial infarction
-19-
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Figure 2.1-1. Acute coronary syndrome and its histopathologic characteristics.
Adapted from
3
.
stable unstable non-q wave q-wave
angina angina infarction infarction
non-ST elevation ST elevation
coronary syndrome myocardial infarction
acute coronary 0-1% 10-25% >90%
occlusion
thrombus formation 0-1% 40-75% >90%
must be suspected, but of course can not be proven, because the latter is only
possible by a rise in cardiac enzymes, which is time dependent. The combina-
tion of chest discomfort together with ST-segment elevation points to suspected
acute myocardial infarction, whereas these two criteria plus a rise in cardiac
enzymes diagnoses proofs acute myocardial infarction. In the case of suspect-
ed acute myocardial infarction, not followed by a rise in cardiac enzymes, there
are two possibilities:
¥ Acute myocardial infarction and its cell death is averted, i.e. aborted 
myocardial infarction.
¥ There has been no acute myocardial infarction, but another cardiac or 
non-cardiac condition causing chest pain together with ST-segment 
abnormalities on the ECG, but not accompanied by myocardial necrosis.
In trials of acute ST elevation myocardial infarction there has been different thresh-
olds for the rise of cardiac enzymes. Usually a threshold of CK-MB of twice or
more the upper limit of normal has been taken to identify myocardial damage.
2
ST elevation myocardial infarction in this thesis
So, in the following text acute ST elevation myocardial infarction is defined as
(fig 2.1-2) 
-20-
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Fig 2.1-2. Acute ST elevation myocardial infarction and thrombolytic therapy in this thesis.
Working diagnosis Thrombolytic Results of serial serum markers and ECG
therapy
serum markers positive proven infarction i.e. justified therapy
or
established infarction
suspected ST elevation MI
typical ECG changes aborted infarction i.e. justified therapy
serum markers negative
no typical ECG changes i.e. unjustified therapy
MI = myocardial infarction
¥ suspected, based on chest comfort and ST-segment elevation on the ECG 
characteristic of acute myocardial infarction
On this ground treatment can be started; following results of serial ECG s and
blood samples: 
¥ the infarction has been proven, or established, based on the above criteria, 
with a rise in cardiac enzymes more than twice the upper limit of normal
¥ the infarction has been aborted, or reversed, which is a suspected acute 
myocardial infarction with dynamic ECG changes, but not accompanied 
by a rise in cardiac enzymes more than twice the upper limit of normal.
Treatment based on the suspicion of myocardial infarction, ending in either
aborted or proven myocardial infarction was justified. If the diagnosis after serial
ECG s and blood samples proves to be incorrect, the treatment was unjustified.
The role of the rise of cardiac enzymes is important, because an aborted
myocardial infarction, based on a not significant rise of cardiac enzymes, can be
viewed as the ultimate goal of therapy; unjustified treatment, with its danger of
inducing side effects and complications of the drug, clearly is not. 
Spontaneous reperfusion
Aborted myocardial infarction may be confused with spontaneous reperfusion.
DeWood found in 16 of 126 patients (13%) an open infarct related vessel,
1
using angiography which was performed within 4 hours after onset of symptoms.
All these patients had symptoms and ECG-changes consistent with acute
myocardial infarction, together with a rise in cardiac enzymes. Spontaneous
reperfusion is confirmed by the results of primary angioplasty for acute ST
elevation myocardial infarction, and the primary angioplasty studies can be
used to demonstrate the difference between spontaneous reperfusion and a
borted myocardial infarction (fig 2.1-3). The incidence of TIMI 2-3 flow for
patients with ST elevation myocardial infarction presented for primary 
angioplasty varies between 13 and 19.6%, 
4-6
comparable with the results of De
Wood. The difference between spontaneous reperfusion and abortion of
myocardial infarction is the rise in enzymes in the first condition, and its
absence in the latter.
-21-
Chapter 2                                                                                                          Overvieuw
In summary, the newest definition of acute ST elevation myocardial infarction
consists of characteristic symptoms plus ECG-changes plus evidence of cell
death measured by troponins, or, less specific, CK-MB and transaminases in
the patients blood samples. To start an intervention as thrombolysis or primary
angioplasty, the rise in serum markers is not needed, and treatment can be
administered according to a suspicion of the diagnosis. This can result in 
justified therapy, ending in proven or aborted infarction, or unjustified therapy,
if the suspicion of acute ST elevation myocardial infarction was incorrect. 
2.2 The wave front phenomenon of myocardial necrosis of acute myocardial
infarction: time to reperfusion, myocardial damage and viability
When time to treatment after onset of pain in acute myocardial infarction is
concerned, often is referred to experiments done by Reimer & Jennings
7
and
Bergmann,
8
who investigated the extent of myocardial damage as a function of
time. These authors preceded the routine use of thrombolytic agents for acute
myocardial infarction by about 5 years; much of the benefits of early treatment
were based on the results of these experiments. Because of the emphasis laid
-22-
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Fig 2.1-3. Difference between aborted myocardial infarction and spontaneous reperfusion, as
demonstrated with primary angioplasty
immediate angiography preceding primary angioplasty
open infarct related vessel
aborted MI
spontaneous reperfusion
ST elevation MI
enzymes -
closed infarct related vessel PCI
enzymes +
MI = myocardial infarction
PCI = percutaneous coronary intervention (angioplasty)
on the time to treatment in the following chapters, it seems apt to summarize
these classical experiments and discuss their results.
Salvage of myocardial tissue as a function of time
Reimer & Jennings hypothesised that myocardial tissue could be salvaged if
the occlusion of the coronary artery was limited in time. The duration of the
period dictating the amount of necrosis being unknown, the authors set up
experiments, in which instrumentated dogs were exposed to coronary occlusion of
various duration, after which the amount of viable and necrotic myocardial 
tissue was determined. 
Mongrel dogs (n=58) were operated upon in such a way that the circumflex
coronary artery could be occluded and reopened. The dogs were assigned to
five groups: one group had a 40 minute occlusion, one group a 3 hour occlusion
and one group a 6 hour occlusion. In 2 other groups the occlusion was permanent
and these dogs were sacrificed at 24 and 96 hours respectively, together with
the dogs from the other 3 groups with reperfusion. The extent of necrosis was
determined by various means of quantitative stain techniques, whereby the
amount of necrosis was expressed as the overall percentage of a transmural
slice cut from each heart.
All dogs showed myocardial necrosis. The dogs exposed to 40 minutes occlusion
showed necrosis throughout the region supplied by the circumflex artery, but
the necrosis was restricted to the subendocardial myocardium. The hearts
reperfused after 3 and 6 hours of coronary occlusion showed considerable larger
areas of necrosis, extending from the subendocardial layer to the subepicardial
myocardium, the latter especially in the group with six-hour occlusion. It is
important to note that 55% of the affected ischemic myocardium remained
viable when reperfusion was implemented after 40 minutes. Less than 17%
remained viable when reperfused after 6 hours (fig 2.2-1). In the 3- and 6-hour
occlusion groups subendocardial haemorrhage was also prominent. These areas
of haemorrhage surrounded areas of myocardial tissue undergoing autolysis; in
the subepicardial myocardium, however, the areas with autolytic material were
interspaced with islands of viable cells, often adjacent to small penetrating
arteries, with signs of inflammation and repair. Infarcts resulting from permanent
coronary occlusion were very similar to those resulting from 6 hours of
-23-
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temporary occlusion, differing most according to the age at sacrifice. At 24
hours haemorrhage was relatively mild, at 96 hours of permanent occlusion
haemorrhage was prominent and appeared equivalent to haemorrhage 
produced in 3 and 6 hours of temporary occlusion.
The authors concluded that in dogs with both temporary and permanent occlusion
of the circumflex artery a wavefront of irreversible ischaemic injury occurs,
first of all endocardially and gradually extending towards the subepicardial 
layers of myocardium. The development of this wavefront takes about 6 hours.
Reperfusion later than 40 minutes cannot prevent subendocardial necrosis,
which after 6 to 24 hours is almost transmural. The authors explained this
wavefront from subendocardial to subepicardium by the distribution of the
coronary collateral blood flow. Reperfusion preserved viable myocytes, accel-
erated the disruption of irreversible damaged myocytes and induced inflam-
mation and repair. Furthermore, reperfusion is associated with interstitial
-24-
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Fig 2.2-1. Proportion of ischaemic muscle, viable as a function of time to reperfusion.
From
7
with permission.
Proportion of ischaemic muscle, which is viable and potentially
salvageable as a function of time after coronary occlusion. Data are
plotted as a percent of 24-hour infarct size.
haemorrhage from vessels which had been injured but not occluded at the time
of reflow, but had no effect on areas which became nonperfusable. Viability of
ischemic myocardium is a function of time before reperfusion and is lost after
about 6 to 8 hours. Interstitial haemorrhage is undesirable, because it is fol-
lowed by the occurrence of no reflow, which results in further deterioration of
the myocardial function.
Positron emission tomography and salvage of myocardium
Bergmann et al refined these experiments by using positron emission tomo-
grams to assess the salvage of myocardium jeopardized by ischaemia.
8
Positron
emission tomography measures the metabolic integrity of myocardium, and is
useful to assess whether an intervention has lead to maintenance or restoration
of myocardial viability. Intracoronary streptokinase was used to reperfuse
experimentally induced thrombotic artery occlusion, also in dogs. Twenty-
three dogs were instrumentalized and thrombotic coronary occlusion was
induced. Reperfusion was created by intracoronary administered streptokinase
at different time intervals: 1-2 hours after reperfusion (4 dogs), 2-4 hours (6
dogs), 4-6 hours (4 dogs) and 12-14 hours (3 dogs). The response to reperfu-
sion varied with the duration of the occlusion. Six dogs did not undergo reper-
fusion and served as controls. Positron emission tomography was performed
before streptokinase was given and repeated after establishing reperfusion by
angiography. No change of expected infarct size occurred in dogs without
thrombolysis (fig 2.2-2). Occlusion for one to two hours led to an about 50%
decrease of metabolic compromised zones and to a 50% decrease of expected
infarct size. In contrast, reperfusion after 6 hours resulted in no significant sal-
vage. The authors could not establish rescue of myocardium after occlusion for
more than 90 minutes in these experiments with dogs, even after angiograpi-
cally demonstrable lysis of thrombus.
-25-
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Although half of the ischemic myocardium that was necrotic at 24 hours has
already died at 40 minutes, about a third of this area was still salvageable at 1
to 4 hours, whereby most of the myocardial tissue at risk could be salvaged if
reperfusion is established within 1 hour. 
Salvage of myocardial tissue and stunning of myocardial infarction
In a recent article
9
these classic experiments have been reviewed together with
more extensive explanation of the harmful effects of reperfusion. Within 8 sec-
onds of a sudden occlusion of a major branch of a coronary artery of a dog a
shift from aerobic to anaerobic glycolysis appears, followed by stretching
rather than shortening of myocardial tissue. Intracellular high energy phos-
phates decrease after 30 seconds of ischemia, whereby anaerobic glycolysis is
not able to provide enough high energy phosphate and the amount provided is
produced very inefficiently with accumulation of lactate, decreasing the intra-
cellular pH after 10 minutes of ischaemia. Sudden restoration of arterial flow
to ischemic myocardial tissue produces marked hyperemia, with its peak dur-
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Fig 2.2-2. Estimated and real infarct size as calculated from positron emission tomography
before and after streptokinase. From
8
with permission.
Histogram of tomographically estimated infarct size in all groups studied. Infarct
size refers to the extend of compromised zones defined based on the number of
pixels containing less than 50% of peak left ventricular wall activity divided by
the number of pixels in the left ventricular wall. Values indicate means + SE.
SK = streptokinase
ing the first 5 minutes of reperfusion. Arterial flow returns to control after
about 20 minutes of reperfusion. Together with a rise of O2-derived free radi-
cals, marked mitochondrial and cell swelling appear. After about 2 minutes the
intracellular pH has been returned to normal levels. It will take many hours to
resynthesise the depleted pool of high-energy phosphates. An unexpected by-
product of reperfused, reversibly injured myocardium is, that it is precondi-
tioned to overcome another ischemic period, in such a way that it will tolerate
another episode, which can be longer than the first episode of ischemia.
Although the myocardium is reperfused and cell death is prevented, the
myocardial tissue exhibits temporary contractile failure, which has been called
stunning . This phenomenon lasts hours to days before function is totally
restored. An important property of stunned myocardium is, that it is able to
contract when exposed to inotropic agents like dobutamine or dopamine. Some
experiments show that stunning is the effect of the oxygen-derived free radi-
cals, generated during reperfusion; however, stunning is also dependent on the
time the myocardial tissue has been ischemic. 
This research has been performed to try to limit the infarct size by pharmaco-
logical or other interventions. Although convincing in the instrumentated dog,
these experiments could not automatically be translated to humans with acute
ST elevation myocardial infarction. In man, the impact of coronary occlusion
is dependent on the underlying atherosclerotic disease in the coronary arteries,
the extent of the collateral network and the patency of the coronary artery after
24 hours, when viability of the myocardium at risk is supposed to be lost.
9
To
assess the importance of early treatment in humans, thrombolytic trials have
been analysed in the literature, and outcome related to the time of treatment.
2.3 First reports of the importance of early treatment in man
After recognition of streptokinase as an agent to lyse human blood clots in
1933, it was used for acute myocardial infarction in 1954, with the first series
of patients reported in 1958.
10,11
Several studies followed, but acceptance of
streptokinase was limited, probably because of the unclear pathophysiology of
acute myocardial infarction at that time.
3
One of the largest of those early tri-
als was reported by the European Cooperative Study Group and involved 512
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patients treated with placebo or intravenous streptokinase and reported halving
the 6-month mortality in the treatment group.
12
Although the benefit of intra-
venous administration was thus established, attention was drawn to intracoro-
nary use of the drug. Treating patients with acute ST elevation myocardial
infarction using intracoronary streptokinase was associated not only with a bet-
ter survival,
13
but also with limitation of infarct size as showed by a better left
ventricular performance in patients randomised to streptokinase compared to
those randomised to control treatment.
14,15
Intracoronary administration limited
the possibility of treating patients with acute myocardial infarction to hospitals
with angiography facilities. This meant the transport of patients to these cen-
tres, with considerable consequences in time to treatment; furthermore, intra-
coronary administration was not without risk.
16
Therefore, efforts were made to
introduce an easier and faster way of therapy. Intravenous thrombolysis with
streptokinase appeared again, first in combination with intracoronary streptok-
inase,
17
later on its own, resulting in a comparable reperfusion rate and mortal-
ity reduction when administered in either way.
18,19
The GISSI-1 study
From 1986 onwards, reports were published on trials proving the efficacy of
intravenous thrombolysis. The GISSI study, published in 1986
20
and 1987
21
,
was the first to show that the reduction of mortality in patients treated with
intravenous thrombolytic therapy was related to the time of treatment. In 176
Cardiac Care Units in Italy 11,712 patients with chest pain and ECG-abnor-
malities suggesting acute myocardial infarction were evaluated. They had been
randomised between streptokinase and control. The 21-day mortality rate as the
12-month mortality rates showed significant reduction (table 2.3-1). 
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Furthermore, an even larger mortality reduction of 21% was found in patients
treated with streptokinase within 3 hours, compared to patients treated later
than that (table 2.3-2). 
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Mortality reduction of patients treated with streptokinase later than 6 hours was
not significantly greater than of patients in the control group. Consequently,
patients treated with streptokinase within 1 hour showed the greatest benefit,
compared with patients treated with placebo (table 2.3-3). 
Although mortality reduction was greatest in the patients treated early, it was
immediately clear that not many patients could be treated within 1 hour: only
1275 patients of the 11697 (11%) received their treatment (streptokinase or not)
within this time frame.
ISIS-2 and GUSTO-I
From the many trials favoring thrombolytic therapy, the ISIS-2 trial, published
in 1988,
22
and the GUSTO-I trial, published in 1996,
23
also highlighted the
importance of early treatment. 
The ISIS-2
22
study tested the risks and benefits of streptokinase alone, aspirin
alone, and the combination of aspirin and streptokinase, against placebo in
patients suspected of acute myocardial infarction. A total of 17,187 patients
were enrolled. Mortality reduction versus placebo was greatest for the combi-
nation aspirin plus streptokinase group (35-day mortality reduction of 42%),
-30-
Table 2.3-3. 12-month mortality and time to treatment. GISSI-study.
21
Mortality Total
%
Streptokinase
%
Control
%
RR
%
p
TTT< 1 hour 17.1 12.9 21.2 0.61 0.00001
TTT< 3 hours 16.2 15.1 17.3 0.89 0.02
TTT 3-6 hours 19.7 18.3 21.2 0.87 0.02
TTT 6-9 hours 21.2 21.1 21.4 0.98 n.s.
TTT 9-12 hours 20.1 21.9 18.5 1.18 n.s.
TTT = time to treatment, RR= relative risk, n.s. = not statistically significant
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especially in those patients treated within 6 hours after onset of pain (35-day
mortality reduction of 53%). These findings concurred with those of the AIMS
study, reported in the same year. In this study, patients were treated with
anistreplase or placebo, and it showed an extra 35% 30-day mortality reduction
in the 334 patients treated within 4 hours with anistreplase compared with 168
patients treated later than that.
23
In the GUSTO-1 trial
24
41,021 patients with ST-segment elevation acute
myocardial infarction were randomised to one of 4 thrombolytic treatments: 
rt-PA followed by intravenous heparin, intravenous streptokinase followed by
intravenous heparin, intravenous streptokinase followed by subcutaneous
heparin or half dose intravenous recombinant tissue-Plasminogen Activator 
(rt-PA) plus streptokinase. The results were classified according the time of
treatment, with 10,611 patients treated within 2 hours, 20,213 patients treated
between 2 and 4 hours, 7,650 patients treated between 4 and 6 hours and 1,359
patients treated later than 6 hours. Only 26.6% of patients were treated within
2 hours of symptom onset. Increasing with the time to treatment were overall
mortality, stroke, shock and congestive heart failure, with less or no obvious
increasing percentages of re-infarction and ischemia (table 2.3-4). 
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Table 2.3-4. Time from symptom onset to treatment related to clinical events; GUSTO-1 study.
24
TTT
< 2 hours
n=10,611
TTT
2-4 hours
n=20,213
TTT
4-6 hours
n=7,650
TTT
> 6 hours
n=1,359
In-hospital
mortality
5.3% 5.9% 8.5% 8.9%
Stroke 1.3% 1.5% 1.6% 2.0%
Re-infarction 4.7% 4.0% 3.2% 3.6%
Recurrent
ischaemia
21% 20% 19% 18%
Shock 5.7% 5.6% 6.4% 7.0%
Congestive
heart failure
14% 16% 19% 19%
TTT= time to treatment
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Although there was a greater benefit in patients treated earlier, no significance
could be found for the one thrombolytic therapy rather than the other 
(fig 2.3-1), with the exception of anterior infarction, which showed better mor-
tality when treated with rt-PA.
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Fig 2.3-1. Mortality related to treatment from onset of symptoms. From
24
with permission.
Probability of 30-day mortality as a function of time from symptom onset to
treatment and assignment to streptokinase with subcutaneous heparin (short dash),
streptokinase with intravenous heparin (light solid line), streptokinase and tissue-
type plasminogen activator (t-PA) with intravenous heparin (long dash) or
accelerated t-PA with intravenous heparin (line with diamonds). The heavy solid
line shows the probability for the combined streptokinase groups.
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The TIMI-2 study
The TIMI-2 trial25 was designed to study the effect of immediate angioplasty
compared to conservative treatment after rt-PA for patients with acute myocar-
dial infarction. Of the 3,262 patients enrolled in this study a subgroup of 1,390
patients was randomised to be treated with early or with deferred betablockade
(fig 2.3-2). 
Analysis of these patients showed a significant lower 6-week mortality or
recurrent myocardial infarction in the patients treated within 2 hours after onset
of symptoms, compared to patients treated later (table 2.3-5). The 6-week mor-
tality was especially better in the patients treated within 1 hour (3.2%) than in
patients treated later. There was also a benefit of early treatment on left ven-
tricular function. Incidentally, only immediate beta-blocker therapy had a sig-
nificant effect in diminishing recurrent ischaemia. The TIMI-2 group observed
that for each hour earlier that patients were treated with thrombolytic therapy
the absolute mortality was reduced by 1%. 
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Fig 2.3-2. Patients of TIMI-2 substudy treated within or later than 2 hours.
25
Patients randomised for betablocker therapy after receiving rt-PA
n=1390
Immediate betablocker therapy deferred betablocker therapy
n=696 n=694
< 2 hours TTT 2-4 hours TTT < 2 hours TTT 2-4 hours TTT
n=181 (26%) n=515 (74%) n=190 (27%) n=504 (73%)
TTT=time to treatment with rt-PA
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Benefit of early time to treatment
Using combined data from the Reimer & Jennings and Bergmann experiments
and from the GISSI-1 study, which represented the time-dependent benefit of
coronary reperfusion, Tiefenbrunn
26
drew a time-benefit curve, extrapolating to
early treatment (fig 2.3-3). From this curve we learn that the highest reduction
in mortality is achieved in treatment within one or two hours, although the
author referring to this data admits that only 5% or less of patients are indeed
treated within this time frame. As can be seen from figure 2.3-3, after 6 to 12
hours there is still a small benefit to be gained from thrombolysis.
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Benefit of early treatment with other than thrombolytic drugs
The early administration of other than thrombolytic drugs may benefit the out-
come of patients with ST elevation myocardial infarction. Of 1,720 patients in
a recently published study using primary angioplasty for acute ST elevation
myocardial infarction,
27
a group of 860 patients were prehospitally treated with
heparin and aspirin. The other group was treated after arrival at the hospital.
Both groups had a successful angioplasty in 92% and 90% of patients respec-
tively. Prior to angioplasty there was a significant higher incidence of TIMI 3
flow in the prehospitally treated patient group, compared with the hospital
treatment group (17% versus 10%). Pre-treatment with aspirin before throm-
bolytic administration results in a lower mortality (both 7 days as 1 year) than
giving aspirin after thrombolytic therapy. This according to a study with 364
patients treated before and 836 patients treated after thrombolysis.
28
Both stud-
ies suggest a time dependent benefit from aspirin and heparin or aspirin alone
for ST elevation myocardial infarction.
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Fig. 2.3-3. Time benefit from reperfusion. From
26
with permission
Reperfusion time-benefit curve depicts combined data representing
the time-dependent benefit anticipated depending on the interval
between coronary artery occlusion and reperfusion; data from
Reimer et al
7
, Bergmann et al
8
, and GISSI-1.
18
The shaded area
represents an estimate of the portion of total benefit that is not time-
dependent. Benefit (%) indicates percentage of myocardial salvage
and percentage reduction in mortality.
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2.4 Prehospital and in hospital thrombolysis; trials and meta-analysis
Shortly after the importance of time to fibrinolysis became clear, attempts have
been undertaken to shorten the various time delays in the treatment of patients
with acute myocardial infarction. 
The delays can be divided into 5 phases: patient delay, doctor s delay, on-scene
time and transport delay, door to needle delay and the time it takes for the
thrombolytic drug to establish reperfusion.
29
The first delay can hardly be influ-
enced
30
and the last delay is characteristic of the specific drug to be used.
Patient s delay is the time from symptom onset to seeking help, presentation
delay the combination of patient s delay, doctor s delay, on-scene time and
transport delay.  In the 41.021 patients of the GUSTO-I study, patients charac-
teristics were related to time to treatment variables.
24
The study investigated 3
variables: time from symptom onset to hospital arrival (presentation delay),
time from arrival to initiation of therapy (treatment delay) and total time to
treatment. Overall time to treatment < 4 hours was found in 77% of patients,
with only 27% of patients treated within 2 hours. Female, hypertensive and dia-
betic patients were found in greater proportions in the later treatment groups,
as were patients with prior myocardial infarction. On the contrary, current or
former cigarette smokers were more frequent in the earlier group. Another
study confirmed the presentation delay of female patients from a registry of
1178 patients.
31
The presentation delay of a mean of 1.89 hours was 49 minutes
longer for women than for men. Not only the patient s delay, but also the in
hospital delay was longer in female patients. Probably less typical symptoms
can explain these time differences, but also other factors, like time of day,
symptom severity and whether advice is sought from co-workers or family
members. 
In this section attention is drawn to the attempts to shorten the delay caused by
transport to the hospital and the in-hospital delay, by administering thrombolysis
prehospitally. From 1989 onwards, reports have been published about the fea-
sibility of diagnosing acute myocardial infarction prehospitally, with the intro-
duction of the administration of fibrinolysis before the patient is transported to
the hospital. Later on, reports of studies were published in which patients were
randomised between prehospital and in-hospital treatment, in order to try to
establish the mortality reduction expected on the basis of early treatment. 
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Gotsman
32
was the first to show that diagnosis and treatment of myocardial
infarction prehospitally was safe and feasible. Since then many reports about
early and prehospital thrombolysis have been published.
33
Time measurements
from 8 cities in the United States showed a remarkable uniform delay from hos-
pital admission to initiation of thrombolytic therapy (average 83.8 minutes),
34
which emphasized the importance of prehospital treatment even further. Three
basic protocols for prehospital thrombolysis exists: (a) physician operated
mobile intensive care unit, (b) prehospital physician evaluation followed by
mobile intensive care unit and (c) paramedic evaluation with ECG-transmis-
sion of one way or another. In a review of these protocols a potential time sav-
ing was observed of about 60 minutes with the protocol using paramedic eval-
uation and ECG-transmission, and this was expected to become the accepted
method for diagnosing and treating acute myocardial infarction.
33
Since then a
number of randomised trials have been done to compare pre- and in-hospital
thrombolysis.
35-37
Mortality reduction was difficult to prove in these trials. This
is partly due to the fact that in a hospital participating in a trial with prehospi-
tal treatment, in-hospital treatment was also remarkably shorter than in hospi-
tals not participating in such a program.
37
Table 2.4-1 gives the results of 6 tri-
als randomising between pre- and in-hospital thrombolysis.
38
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Inclusion criteria in these trials were similar and restricted to symptoms and
signs of acute myocardial infarction, with the exception of the GREAT trial,
36
for which ECG-diagnosis was not a prerequisite. In the GREAT
36
, EMIP
35
and
MITI
37
trial, patients were randomised to pre- or inhospitally treatment. In the
Roth
39
, Schofer
40
and Castaigne
41
studies prehospital treated patients were ran-
domly compared with in-hospital treated patients without randomisation. 
The time difference between the prehospital group (104 minutes) and the in-
hospital group (162 minutes) is about 60 minutes (p=0.007), and without the
GREAT study, being conducted in the remote county of Aberdeenshire, 45 min-
utes (p=0.01). None of the studies showed a statistically significant difference
in favour of prehospital thrombolysis. GREAT and MITI measured 1-year mor-
tality, only the GREAT study reported 5-year mortality data. All studies
favoured prehospital thrombolysis but only in the GREAT study, with the
largest time interval between pre-and in-hospital thrombolysis, this reached
statistically significant differences in mortality. Pooling the results favoured
prehospital thrombolysis,
38
lowering the risk of all-cause hospital mortality
with 17%. Taking all early treated patients together, pre-or in-hospitally treat-
ed, the MITI study showed that a statistically significant reduction on the com-
bined outcome of hospital mortality, ejection fraction and infarct size was seen
in patients treated within 70 minutes of onset of symptoms. The absolute risk
reduction of 2% compared to in-hospital treatment translates into 1 life saved
for every 62 patients treated. 
2.5 The Golden Hour of thrombolysis 
In 1994 the Fibrinolytic Therapy Trialists Collaborative Group (FTT) pub-
lished a meta-analysis of 9 trials, randomising more than 1000 patients between
fibrinolysis and control, in order to evaluate the effects of treatment on mortal-
ity and morbidity (table 2.5-1).
42
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In total 58,600 patients were included. Most of these patients had ST-segment
elevation on the presenting ECG (68%), but it is important to note that not
always ECG-abnormalities were needed for diagnosis (5% had near-normal
ECG s). There was an 18% reduction of 35-day mortality in the thrombolytic
group, which was highly significant. Risk reduction was greatest in patients
with ST elevation (21%), especially with ST-segment elevation in the anterior
leads (25%). The earlier a patient was treated, the greater the mortality reduc-
tion (fig. 2.5-1). Regression analysis of the absolute benefit versus the mean
delay from symptom onset indicated an approximately straight line relation-
ship, as can be seen from figure 2.5-1, and pointed out that every additional
hour of treatment delay was associated with a reduction in benefit by about 1.6
lives per 1000 patients treated.
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Fig 2.5-1. Mortality reduction at 35 days and time to treatment. From
40
with permission
BBB = bundle branch block
ABSOLUTE
BENEFIT per
1000 patients
with ST
elevation or
BBB allocated to
fibrinolytic
therapy (+ 1 SD)
Absolute reduction in 35-day mortality versus delay from symptom onset to
randomisation among 45000 patients with ST elevation or BBB
Loss of benefit per hour of
delay to randomisation:
1.6 SD 0.6 per 1000
patients
Hours from symptom onset to randomisation
In 1996 Boersma, helped by the Reimer & Jennings and Bergmann experi-
ments, investigated early fibrinolysis in further detail.
43
The FTT authors did
not find an additional treatment benefit in the patients treated within 0-1 hours,
but this could be explained by not including trials with small numbers of
patients, for instance those trials with a prehospital strategy and, thus, early
treated patients. So, in the Boersma analysis, smaller trials consisting of at least
100 patients, some with prehospital treated patients, were included.
Furthermore, contrary to the FTT-analysis, both linear and non-linear regres-
sion analyses were used to test the relation between benefit and early treatment. 
In the 22 trials, only 11% of patients were treated within 2 hours of symptom
onset.
Figure 2.5-2 gives the results of their best-fit curve, whereby the non-linear
regression curve resulted in a closer match than the linear regression analysis.
Very early reperfusion of the occluded coronary artery, for instance within 30
minutes, may lead to full recovery of ischaemic tissue and, thus, to prevention
-40-
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Fig. 2.5-2. Best-fit curve relating mortality reduction and time to treatment. From
43
with
permission from Elsevier Science (Lancet 1996;348:771-775).
Absolute 35-day mortality reduction versus treatment delay.
* Small closed dots: information from FTT-trials.
* Open dots: additional trials.
* Small squares: data beyond scale of x/y cross.
* The linear and non-linear regression lines are fitted within these data weighted by
inverse of the variance of the absolute benefit in each data point.
* Black squares: average effects in six time to treatment groups.
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of necrosis. The concept of aborted myocardial infarction, explained in section
2.1 of this overview, thus comes into view. The advantage of very early thera-
py in the prehospital studies is much larger than the effect of 1 hour earlier ther-
apy as reported in the FTT-analysis. Patients with a shorter treatment delay,
however, may well differ from later presenting patients: e.g. larger infarcts,
younger patients, men rather than women. Boersma concludes that the assess-
ment of prehospital treatment is likely to be better by dividing all patients (pre-
hospital and hospital) in an early and a late treatment group, rather than com-
paring prehospital with in-hospital patients. Comparing only in-hospital treat-
ed patients yields too few patients to compile an early treatment group, as only
an average of 6% of in-hospitally treated patients are treated within 1 hour.
43
Prehospital thrombolysis is thus the only way to compile an 1- and 2-hour treat-
ment group large enough to make such an assessment possible.
2.6 Time to reperfusion in primary angioplasty
Besides early administration of therapy, achieving complete reperfusion of the
infarct-related artery is another important predictor of improved outcome. In
angiographic studies, the degree of reperfusion is expressed in TIMI-flow at 90
minutes after initiation of therapy. TIMI grade 0 means no reperfusion, grade 1
penetration of contrast without reperfusion, grade 2 partial and grade 3 com-
plete reperfusion.
44
Many studies have shown that TIMI-3 flow 90 minutes
after initiation of thrombolytic therapy is associated with the best mortality
reduction.
45
However, using thrombolytic therapy, 90 minutes TIMI-3 flow is
established within that time frame in 60% of patients with frontloaded rt-PA.
2
Primary angioplasty is expected to achieve TIMI-3 flow in a higher percentage
of patients and so could result in a better clinical outcome. But arranging
mechanical opening of an occluded coronary artery after presentation a patient
in the hospital usually costs considerable time. A review of 10 randomized
studies of primary angioplasty versus various regimens of fibrinolysis showed
that the time to angioplasty was 17 to 59 minutes later than the time to treat-
ment using thrombolytic therapy.
2
The largest of those studies, GUSTO-IIb,
had 565 patients randomized to primary angioplasty and 573 patients random-
ized to fibrinolysis. After a time to presentation of 1.9 and 1.8 hours respec-
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tively, the time to treatment was 50 minutes longer in the angioplasty group.
The endpoints of death, re-infarction and nonfatal stroke were significantly
lower in the primary angioplasty group (9.6% versus 13.6%) compared to fib-
rinolysis, but were primarily lower because of the difference in re-infarction.
46
In these randomized studies, mortality reduction, re-infarction rate and hemor-
rhagic stroke favored primary angioplasty, although the short-term benefits
were more favorable than the endpoints at follow-up. Furthermore, many of
these trials were performed in the early nineties, when door-to-needle time in
thrombolysis exceeded 40 minutes and patients randomized to fibrinolysis
were treated late. Treatment of either fibrinolysis or angioplasty in the real
world  showed an average time-to-hospital admission of 2.5 hours in both
groups, none of the patients treated within one hour and only a few within two
hours, with no mortality benefit for primary angioplasty.
47
In the National
Registry of Myocardial Infarction with 27,080 patients treated with primary
angioplasty the median time from onset of chest pain to hospital arrival was 1.6
hours and the median time from onset to angioplasty 3.9 hours. The multivari-
ate-adjusted odds of mortality was 40% to 60% higher in patients with a door-
to-balloon time longer than 2 hours, which was in 53% of patients.
48
In contrary
with thrombolysis where mortality increases with time to treatment, mortality
with primary angioplasty and door-to-balloon times longer than 2 hours does
not increase. This can be explained by the high rate of reperfusion established
with angioplasty in late presenting patients, whereas thrombolysis will have
less effect in realizing patency.
48
Assuming that the benefits of reperfusion are
independent of the way it is established, time to and completeness of reperfu-
sion, the rate of stroke and of re-infarction together with experience of the car-
diologist performing the angioplasty can explain the favorable outcome of
angioplasty.
49
Focusing on time to reperfusion: A recently presented study ran-
domizing 840 patients with prehospital thrombolysis versus primary angio-
plasty revealed no significant difference (death, non-fatal reinfarction and non-
fatal disabling stroke) between both treatment arms, although the need for
urgent angioplasty because of re-infarction was higher in the thrombolysis
group.6 Another study combining prehospital thrombolysis and standby rescue
angioplasty in 170 patients resulted in 91% TIMI-3 patency, with time-to-
thrombolysis in 151 + 61 minutes and rescue angioplasty performed in 50
patients (29%). Time to TIMI-3 flow in these group was 264 + 78 minutes. This
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group was compared with 170 matched patients treated with primary angio-
plasty; the comparison resulted in the same TIMI-3 patency of 91%, and a com-
parable 30 day mortality of 4.1% in the prehospital thrombolysis group and
4.7% in the primary angioplasty group, with the time to TIMI-3 flow of the pri-
mary angioplasty group of 232 + 94 minutes.
50
In other words, if the time to
reperfusion using angioplasty or thrombolysis becomes similar, it is expected
that the benefit of angioplasty becomes comparable to the benefit of thrombol-
ysis.
51
In the current guidelines primary angioplasty is advocated in patients
with acute ST-segment elevation myocardial infarction if can be performed
within 90 — 120 minutes after presentation by skilled operators in high-volume
centers. Perhaps the best of both worlds should be implemented: early treat-
ment using prehospital thrombolysis combined with establishing TIMI-3 flow
with (rescue)-angioplasty.
50,52
2.7 Summary
Acute ST elevation myocardial infarction, caused by a thrombotic occlusion of
a coronary artery, results in myocardial cell death, occurring as a wavefront
from endocardial tissue to epicardial tissue. The amount of cell death is
dependent of the duration of coronary artery occlusion, cell death being appar-
ent after 40 minutes in experiments with dogs. The viability of myocardial cells
in the dog experiment is reflected by many trials using thrombolytic drugs,
where the mortality is reduced when treatment is started early after onset of
symptoms. Meta-analysis of randomized trials showed that the gain from this
treatment is optimal if it is started in the first hour, the Golden Hour. However,
in-hospital only few patients can be treated within that hour, so attention has
been drawn to prehospital treatment. Prehospital thrombolysis leads to a time
gain of 30-60 minutes and saves about 1 extra life in 60 patients treated in com-
parison to in-hospital therapy. The literature of primary angioplasty is also
emphasizing early treatment, certainly within 2 hours after presentation at the
hospital. Thus, the importance of early therapy cannot be exaggerated and it
seems from the literature that prehospital initiated triage and thrombolysis is
one of the means to accomplish this.
-43-
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3.1 Abstract 
In the STIMIS-study the various points in time of every event between onset
of chest pain and completed hospital admission were assessed in 1,152 patients
with chest pain of possible cardiac origin. This study was part of the Nijmegen
Home Thrombolysis Program. Of these patients 200 were actually treated with
thrombolytic therapy: 141 at home and 59 after hospital arrival. After final
analysis, 393 patients proved to have myocardial infarction. In comparison
with the whole group of patients with chest pain, the time points of every event
occurred earlier in patients with myocardial infarction. There was a median
time interval of 89 minutes between onset of symptoms and treatment in
patients treated prehospitally, and 152 minutes in patients treated in-hospitally.
Of the prehospital thrombolysis group 28% of the patients and of the hospital
thrombolysis group no patients were treated within one hour. Within two hours
these values were 65 and 25%, respectively.
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3.2 Introduction
Timely reperfusion of an occluded coronary artery, salvages left ventricular
function,
1-3
and reduces mortality risk in patients with acute myocardial infarc-
tion.
4-9
Every hour thrombolytic therapy can be given earlier 23 more lives are
saved per 1000 treated patients; if thrombolytic therapy is administered within
the first hour of onset of symptoms, even 65 to 69 lives per 1000 treated
patients can be saved.
10,11
From the early years of thrombolysis on, the two Nijmegen hospitals have
spent much energy in shortening the door-to-needle time. This was 83 minutes
in 1985, and reduced to 48 minutes in 1995.
To shorten the treatment intervals, a prehospital thrombolysis project was start-
ed in 1987 (figure 3.2-1).  At the start of the project, the general practitioners
feared the time delays of ECG-transmission, ECG-interpretation and prepara-
tion of thrombolytic treatment at the patient s home, and thus of the actual time
gain which could be reached. The STIMIS (Study of Time Intervals in
Myocardial Ischaemic Syndromes) study entailed a detailed measurement of
all time intervals of diagnosis and treatment of patients with a suspected acute
coronary syndrome. The STIMIS-study is a joint project of the regional ambu-
lance service, the general practitioners and the Nijmegen cardiologists. 
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For acute coronary syndrome suspected chest pain
Yes
Pain longer than 15 minutes & shorter than 12 hours
Yes
Pain subsides totally after s.l. nitrates
No
Make ECG-transmission to CCU
ECG concurs with acute ST-elevation myocardial infarction
Yes
Is there a contraindication to prehospital thrombolysis
 Any trauma, surgery or biopsy within 2 months
 Resuscitation with chest compression and intubation in the previous 2 weeks
 Any known history of stroke
 Any illness with bleeding risk
 Any active bleeding situation
 Menstruation or possibility of (early) pregnancy
 Malignancy with limited prognosis
 Treatment with streptokinase or anistreplase within 6 months
 Hypertension with systolic blood pressure > 180 mm Hg
and/or diastolic blood pressure > 110 mm Hg
 Left bundle branch block or paced rhythm or Wolf Parkinson White syndrome
No
Administer i.v. thrombolysis after consent of attending cardiologist
Fig. 3.2-1. Flow chart used by ambulance service.
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3.3 Patients and methods
Various time intervals of treatment for acute myocardial infarction in the
Nijmegen region were carefully collected to assess the time gain of prehospi-
tal treatment, from the onset of pain to administering treatment pre- or in-hos-
pitally. The registration of time intervals started at October 1, 1995 and ended
Augustus 1, 1997, and included all patients complaining of characteristic chest
pain. Time intervals were noted by the ambulance service, by attending CCU-
doctors and by nurses of the cardiac care units of the two Nijmegen hospitals.
To facilitate the registration, a portfolio was used with a mounted digital clock,
containing a specially designed form on which details of various time intervals
could be noted (figure 3.3-1). The general practitioner or ambulance staff
regarded characteristic chest pain of more than 30 minutes and less than 6
hours duration an indication for starting the procedure, regardless of the defin-
itive diagnosis. An ECG was made by the ambulance staff, and transmitted to
the CCU of the Canisius-Wilhelmina Hospital using an analog transtelephonic
transmission method. If the transmitted ECG showed signs of acute myocardial
infarction and a checklist did not reveal a contra-indication for thrombolytic
therapy, patients were treated with 30 mg of anistreplase before transport to one
of the 2 Nijmegen hospitals (Canisius-Wilhelmina Hospital and University
Medical Center St Radboud).
Statistical test used were t-test for numbers, Wilcoxon test for time intervals
and Chi-square test for percentages.
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3.4 Results
A total of 1,152 patients were included in the study. After final analysis, 393
patients proved to have an established myocardial infarction. Figure 3.4-1 pres-
ents the time intervals of all 1,152 patients, in minutes and in median values.
Between onset of symptoms and arrival of the general practitioner 73 minutes
elapsed; the general practitioner took 13 minutes to assess the situation, fol-
lowed by the arrival of the ambulance by 13 minutes. The ambulance staff took
24 minutes to stabilise and connect the patient to the monitor and to transmit
the ECG. It took 13 minutes to transport the patient to one of the two Nijmegen
hospitals, and 9 minutes to produce an ECG in the hospital. Fifteen minutes
later the hospital doctor arrived and used 5 minutes to make a diagnosis.
Time intervals of 200 patients with acute ST-elevation myocardial infarction,
compared to all 1152 patients (fig 3.4-2).
The process of alarming the general practitioner was considerably and signifi-
cantly faster in the case of an acute ST-segment elevation myocardial infarction
(43 minutes versus 73 minutes; p<0.0001, Wilcoxon-test). The on-scene time
is longer in patients with myocardial infarction, probably because of the admin-
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Fig 3.4-1
istration of the thrombolytic drug. The difference is, however, not significant
from no thrombolysis. The diagnostic process in hospital is faster in the
patients having acute myocardial infarction compared to all patients with chest
pain.
Time intervals of 200 patients with acute ST-segment elevation myocardial
infarction; 141 treated prehospitally and 59 treated inhospitally (fig 3.4-3).
Figure 3.4-3 shows the time intervals of patients treated prehospitally versus
inhospitally. The on scene time of the ambulance service was longer in the
patients treated prehospitally (33 versus 24 minutes). The time between arrival
of the ambulance and prehospital diagnosis is 16 minutes in both groups; the
difference in on-scene time is explained by the extra 11 minutes between pre-
hospital diagnosis and administration of the thrombolytic drug (p<0.05, Chi-
square test). There was a median time interval of 89 minutes between onset of
symptoms and treatment in patients treated prehospitally. In-hospital confir-
mation of the diagnosis of the patients treated prehospital is faster than of the
patients treated inhospital (15 versus 28 minutes). Between hospital diagnosis
and thrombolysis another 20 minutes elapse, adding up to 152 minutes between
onset of symptoms and treatment in patients treated inhospitally. The total ST-
segment deviation of the prehospital treated group of 1.8 mV is significantly
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Fig 3.4-2
Fig 3.4-2
greater than those of the in-hospital group of 1.0 mV.
Difference in time between prehospital thrombolytic therapy and in-hospital
thrombolysis (fig 3.4-4).
There was a 63 minutes time gain by treating patients prehospitally. If correct-
ed for the fact that the ambulance service arrived 8 minutes earlier in the pre-
hospital treated patients, the time gain was 55 minutes. 
-59-
Chapter 3                                                                                                                Stimis
Fig 3.4-3
Fig 3.4-4
Percentage of patients treated prehospitally or in hospitally as function of time
to treatment (fig 3.4-5).
The earliest patient treated prehospitally was within 25 minutes after onset of
pain, while the earliest in-hospital patient could be treated within 65 minutes.
Within the first hour 40 patients were treated using prehospital treatment
(28%), and within the second hour 92 patients (65%). None of the in-hospital
patients were treated within one hour and within 2 hours only 15 patients
(25%); this difference is statistically significant (p<0.01).
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Fig 3.4-5
3.5 Discussion
Patients in the Nijmegen region with chest pain sought medical help fairly fast
after onset of symptoms: 73 minutes. In the case of acute myocardial infarction
this interval is reduced to about 40 minutes. Apparently, both patient and gen-
eral practitioner clearly recognized the pressing need for medical help.  This is
a selection, because this study included only those patients for whom the gen-
eral practitioner called the ambulance service immediately. In less urgent cases
possibly more time is spent at the patient s home.
12
The time of the ambulance
to arrive at the patient was within the limits of 15 minutes as determined by the
Dutch health authorities. 
The ambulance staff needed 24 minutes to prepare the patient, to introduce him
or herself, to consult the general practitioner, to connect the patient to the
portable monitor and to register the ECG. The administration of the medication
was fast: the total on-scene time was only 9 minutes longer in a prehospital
treated patient while the total on-scene time of 33 minutes concurs with the 26
minutes of other studies.
13
The transport time of 13 minutes to the hospital con-
curs with the 13 minutes of Kereiakes registration.
14
At arrival at the cardiac
care unit patients are immediately attended by the CCU-staff, but the arrival of
the hospital physician took a precious 15 minutes. After a fast diagnosis of 5
minutes it took 20 minutes before the treatment was started. 
The total door to needle time of 48 minutes was 12 minutes longer than the 36
minutes from the REPAIR-trial, although decidedly shorter than the 83 minutes
from the early days of thrombolysis and comparable with the 49 minutes in a
fast-track strategy.
15
Only Chamberlain had better results of 25 minutes.
16
Prehospital treatment of acute myocardial infarction gained 63 minutes.
Subtracting 8 minutes from the ambulance service arriving earlier at this group
the time gain of 55 minutes concurs with the EMIP-study.
17
The Nijmegen reg-
istration can be compared with other time studies, both in rural and urban
areas.
18,19
Prehospital thrombolysis is limited to patients having chest pain of 6 hours or
less duration. However, our survey did include in-hospital treated patients with
chest pain of 24 hours duration, thus making the time gain artificially favorable.
Excluding 7 patients with chest pain longer than 6 hours resulted in the median
door-to-needle time in this group to be 47 minutes instead of 48 minutes. 
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With prehospital thrombolysis 28% of patients could be treated within one hour
and 65% within 2 hours. Administering fibrinolytic therapy in the hospital is
associated with no patient treated within the golden hour and only 25% with-
in 2 hours. The MITI- and the REPAIR-study came to the same conclusion of
only 1% of patients treated within 1 hour.
18,20
However, using a prehospital
strategy the number of patients treated within 1 hour varied between 13% in the
GREAT-study
11
to 40% in the REPAIR-study.
20
3.6 Conclusion 
The STIMIS-registration was set up to register time intervals in our own
Nijmegen hospitals, to assess the time that could be gained by performing pre-
hospital thrombolysis and to compare the results with data from the literature.
On the one hand insight is gained of the time intervals involved, on the other
hand shortcomings were revealed. With prehospital thrombolysis in the
Nijmegen one quarter of patients can be treated within 1 hour and two thirds
within 2 hours, which is significantly better than the results of in-hospital treat-
ment. 
The STIMIS-registration confirmed other studies, that only with prehospital
thrombolysis it is possible to treat a considerable percentage of patients within
the Golden Hour. Registrations such as these have been done in other cities of
the area, and will be of great importance in the triage and treatment with pre-
hospital treatment or primary angioplasty of patients with acute coronary syn-
dromes.
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4.1 Abstract
Background: To facilitate discussions about the need for prehospital throm-
bolysis in regions other than Nijmegen, where such a strategy already exists,
in-hospital time intervals of diagnosis and treatment of patients with chest pain
must be collected and an estimation of percentages of patients that can be treat-
ed within 2 hours with this strategy must be made.
Patients and methods: In 4 regional hospitals around the city of Nijmegen
time intervals were noted on a special form. To calculate the time gain prehos-
pital treatment could have provided in the 4 regions to the median time from
onset of pain to arrival of the ambulance 27 minutes was added, which is the
time it takes in Nijmegen to diagnose and treat the patient in the prehospital
approach.
Results: Door-to-needle times in the 4 regions varied between 39 and 50 min-
utes and are comparable with the 48 minutes of in-hospital treatment in
Nijmegen. Total time to treatment varied between 145 and 167 minutes. If a
prehospital strategy had been present, there would have been a time gain in the
4 regions varying between 32 and 51 minutes, resulting in 55% patients treat-
ed within 2 hours instead of the current 25%.
Conclusion: With a prehospital strategy the 4 regions could reduce the time to
treatment, resulting in doubling the number of patients treated within 2 hours.
-67-
Chapter 4                                                                                                      Other regions
4.2 Introduction
Prehospital thrombolysis of acute myocardial infarction in the city of Nijmegen
results in a median time gain of about one hour, resulting in 28% of patients
treated within one hour after onset of pain.1 Physicians in other regions how-
ever, are reluctant to start a prehospital strategy for the treatment of acute
myocardial infarction. Many physicians are not aware of the long door-to-nee-
dle time in their own institutions. Health authorities and general practitioners
do not realize that as soon a patient has entered a hospital, diagnosis and treat-
ment take considerable time. 
To facilitate discussions about the need for prehospital thrombolysis in cities
other than Nijmegen, the cardiology departments and ambulance services of 4
other regions agreed to participate in a registration of the in-hospital time inter-
vals of diagnosing and treating patients with chest pain. The aim of this study
was to obtain insight in the percentage of patients treated within two hours after
onset of pain. Furthermore, using on-scene times of prehospital treatment and
diagnosis in Nijmegen, an estimation can be made of the time gain prehospital
treatment could provide in those regions.
4.3 Patients and methods
All patients with chest pain suggestive of acute coronary syndrome were
included in the registration. The same form was used as in the STIMIS-regis-
tration in Nijmegen,1 with an extra box to enter the region and city the patient
was referred to. All time intervals were entered in an Excel-database, and aver-
age and median time intervals were calculated. To calculate the point in time
where prehospital treatment could have been administered provided in the 4
regions, 27 minutes was added to the moment of ambulance arrival. Twenty-
seven minutes is the on-scene time it takes in Nijmegen to diagnose and treat
the patient in the prehospital strategy. 
4.4 Results
The registration was made from August 1, 1997 till July 30, 1998. In Arnhem
375 patients were registered with chest pain, of whom 120 patients had a con-
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firmed acute ST elevation myocardial infarction. In Boxmeer 94 patients were
registered, from whom 41 had acute ST elevation myocardial infarction con-
firmed. In Deventer these numbers were 98 and 29 respectively, and in
Zevenaar 15 with confirmed ST elevation myocardial infarctions in all. 
Table 4.4-1 gives the summary of the door-to-needle time and the time to treat-
ment while table 4.4-2 gives the percentages of patients, which could be treated
within one, two, three hours or later than that. 
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Table 4.4-1. Summary of time intervals and time from onset to treatment, median, minutes
Nijmegen
n=1,152
Arnhem
n=375
Boxmeer
n=94
Deventer
n=98
Zevenaar
n=15
Door-to-needle 48 50 39 50 47
Time to treatment 153 166 145 167 150
Table 4.4-3 gives the time to treatment together with the calculated time to
treatment if a prehospital program would have been present. 
Figure 4.4-1 gives the results of the time intervals of patients with acute
myocardial infarction of all sites. The door to needle time varies from 39 min-
utes in Boxmeer to 50 minutes in Deventer and Arnhem, and seems compara-
ble to the 48 minutes in the Nijmegen hospitals. 
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Table 4.4-3. Time gain calculated from the Nijmegen time intervals, if a prehospital strategy
would have been present.
Time to
treatment
hospital
therapy
Time to
treatment
prehospital
therapy
Calculated time to
treatment
if a prehospital
strategy would have
been present
Calculated time
gain if a
prehospital
strategy would
have been present
Nijmegen 153 91 --- ---
Arnhem 166 --- 115 51
Boxmeer 145 --- 106 39
Deventer 167 --- 122 45
Zevenaar 150 --- 115 32
Fig 4.4-1
In figure 4.4-2 Arnhem is chosen as an example to show the time gain that
could be achieved by performing prehospital thrombolysis in Arnhem, starting
from the principle that an on-scene time of 27 minutes for prehospital treatment
would be the same in Arnhem as it is in Nijmegen.
The same calculation can be done in other sites (figure 4.4-3), resulting in an
estimation of 55% of patients treated within 2 hours instead of about 25% using
in-hospital treatment (table 4.4-4). 
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Fig 4.4-2
Fig 4.4-3
4.5 Discussion
This registration suggests, that implementation of a prehospital thrombolysis 
program may shorten the time to treatment of acute ST elevation myocardial
infarction up to 50 minutes. This concurs with time gains from the literature of
prehospital treatment, which varies between 33 minutes in a large US city 
dedicated to early treatment and 130 minutes in a Scottish rural region. 
(table 4.5-1).
1-9
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Table 4.4-4. Percentage of patients treated within 2 hours if a prehospital program in other
sites would have been started.
Site
Nijmegen Prehospital thrombolysis 66%
Other sites Potential prehospital
thrombolysis
55%
HP=prehospitally treated
IH=hospitally treated
TTT=time to treatment
It matches the 55 minutes of the EMIP study.
7
Although the importance of time
to treatment in acute myocardial infarction has been stressed, there is no dif-
ference in time to treatment in the early years of prehospital thrombolysis
10
compared to this strategy in later years: the REPAIR-study, performed in
Rotterdam from 1988 to 1993 described a mean time gain of 47 minutes with
prehospital thrombolysis and a prehospital thrombolysis study performed
around Belfast between 1998 and 2001 found a median time gain of 1.7 hours.
11
In our study, time from pain onset till arrival of the ambulance varies between
78 minutes and 95 minutes. The on-scene time of the ambulance at the patient
is decidedly longer in Nijmegen (with prehospital thrombolysis) than the 11 to
17 minutes in other regions, probably because of the time the transmission of
the ECG and consultation with the CCU-physician took. Transport from the
patient s home to the hospital is comparable in all cities and varied between 9
and 16 minutes. In all hospitals it took rather long to make a diagnosis: 15 to
34 minutes. Deciding the treatment and starting it is very short in one region (5
minutes) and can take 35 minutes in another. This means that the door-to-nee-
dle time varies between 37 and 52 minutes. This is in line with a report from
an infarct registry, where from 1,302 patients with ST-segment elevation
myocardial infarction a median door-to-needle time was measured of 52 min-
utes.
12
Furthermore, recent reports confirm that the door-to-needle time has
been shortened from more than 1 hour in the early nineties to about 40 minutes,
but that the goal of 30 minutes has not been reached.
13
Interestingly, patients
developing acute myocardial infarction while being already admitted on a gen-
eral ward had a median time to treatment of 120 minutes, according to an
English survey,
14
more than 30 minutes longer than the prehospital treated
patients in Nijmegen.
1
The median of 43 minutes between symptom onset and
arrival of the GP concurs with the results of a study in Rotterdam, where 50%
of patients with acute myocardial infarction sought medical help within a medi-
an of 45 minutes.
15
The potential time gain by performing prehospital treatment is determined by
two parameters: the on-scene time by the ambulance and the door-to-needle
time in the hospitals. Although in some districts the time gain will be deter-
mined by the transport time, for instance when rural regions are involved,
8
it
seems that in cities this does not seem to play a major role. More important is
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the time it takes in the hospital to diagnose acute myocardial infarction, to
decide to thrombolyse the patient and to prepare the drug. Because the time
from symptom onset to thrombolytic treatment in the four cities is not marked-
ly shorter than that of the large trials
16
(fig 4.4-1) or hospital audits
17
, it is not
expected that hospital delays will be reduced further. With nurse initiated
thrombolysis the attending physician on call could safely be bypassed with a
median door-to-needle time of 15 minutes; however, this scheme can only
cover 66% of time,
5
and is thus inefficient compared to thrombolysis by ambu-
lance staff.
17
Achieving a time to treatment of less than 2 hours in a substantial
number of patients, for instance more than 50%, is only possible by treatment
outside the hospital.
Study limitations
A limitation of our registration is that the time intervals of the diagnosis and in-
hospital treatment of acute myocardial infarction, although meticulously noted
by four hospitals, were compared to those of Nijmegen, where a prehospital
strategy of thrombolysis is used, and where prehospital time intervals were
noted by the ambulance staff. Yet, the time intervals between Nijmegen and the
other regions are quite comparable. 
4.6 Conclusion
Patients delay and hospital delay (door-to-needle time) are the most important
factors in the delay of treatment of acute myocardial infarction. None of the
hospitals managed to treat their patients as early as could be managed by pre-
hospital treatment. If a prehospital strategy would be implemented in the four
hospitals of the region, 55% of patients could be treated within 2 hours instead
of current 25%.
Acknowledgements
We would like to thank the general practitioners, ambulance personnel, CCU-
personnel and cardiologists of the various regions of the contributing hospitals
for their help in making this study possible. We are grateful to Fred Marcus,
Pietje and Ton Hooghoudt, for making the drawings.
-74-
Chapter 4                                                                                                      Other regions
4.7 References
1. Hooghoudt TEH, Lamfers EJP, Uppelschoten A, Verheugt FWA. Study of
Time Intervals in Myocardial Ischaemic Syndromes (STIMIS).
Cardiologie; 1998;5:23-31.
2. McNeill AJ, Cunningham SR, Flannery DJ, Dalzell GWN et al. A double
blind placebo controlled study of early and late administration of recom-
binant tissue plasminogen activator in acute myocardial infarction. Br Med
J 1989;61:316-21.
3. Castaigne AD, Herve C, Duval-Moulin AM, et al. Prehospital use of APSAC:
results of a placebo-controlled study. Am J Cardiol 1989;64:30A-33A.
4. Barbash GI, Roth A, Hod H et al. Improved survival but not left ventricular
function with early and prehospital treatment with tissue plasminogen acti-
vator in acute myocardial infarction. Am J Cardiol 1990;66:261-266.
5. Schofer J, Buettner J, Geng G, et al. Prehospital thrombolysis in acute
myocardial infarction. Am J Cardiol 1990;66:1429-1433.
6. McAleer B, Ruane B, Burke E. Prehospital thrombolysis in a rural commu-
nity; short and long term survival. Cardiovasc Drugs Ther 1992;6:369-72.
7. EMIP-group. Prehospital thrombolytic therapy in patients with suspected
acute myocardial infarction. N Engl J Med 1993;329:383-389.
8. GREAT-group. Halving mortality at 1 year by domiciliary thrombolysis in
the Grampian region early anistreplase trial (GREAT). J Am Coll Cardiol
1994;23:1-5.
9. Weaver WD, Cerqueira M, Hallstrom AP et al. Prehospital vs. hospital-ini-
tiated thrombolytic therapy. The myocardial infarction triage and interven-
tion trial. JAMA 1993;270:1211-1216.
-75-
Chapter 4                                                                                                      Other regions
10. Grijseels E, Bouten MJM, Lenderink T, Deckers JW, Hoes AW, Hartman
JAM, Van der Does E, Simoons ML. Prehospital thrombolytic therapy
with either alteplase or streptokinase; practical application, complications
and longterm results in 529 patients. Eur Heart J 1995;16:1831-1838.
11. Mathew TP, Menown IBA, McCarty D, Gracey H, Hill L, Adgey AAJ.
Impact of prehospital care in patients with acute myocardial infarction
compared with those first managed in-hospital. Eur Heart J 2003;24:161-171.
12. Lambrew CT, Bowlby RN, Rogers WJ, Chandra NC, Weaver WD for the
Time to Thrombolysis Substudy of the National Registry of Myocardial
Infarction-1. Factors influencing the time to thrombolysis in acute
myocardial infarction. Arch Intern Med 1997;157:2577-2582.
13. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, et al. Temporal
trends in the treatment of over 1.5 million patients with myocardial infarc-
tion in the US from 1990 through 1999. The National Registry of
Myocardial Infarction 1,2 and 3. J Am Coll Cardiol 2000;36:2056-63.
14. Mumford AD, Banning AP. Minimizing delays to thrombolysis in patients
developing acute myocardial infarction in hospital. Brit Med J
1997;73:491-495.
15. Bleeker JK, Broer J, Bouma J, Erdman RAM, Walma EP, Simoons ML. 
How to reduce GP’s delay in acute myocardial infarction. Cardiologie
2000;7:367-372.
16. Gibson CM. Time is myocardium and time is outcomes. Circulation
2001;104:2532-2634.
17. Wilmshurst P, Purchase A, Webb C, Quinn T. Improving door to needle
times with nurse initiated thrombolysis. Heart 2000;84:262-266.
-76-
Chapter 4                                                                                                      Other regions
CHAPTER 5
TIME FROM SYMPTOM ONSET TO TREATMENT AND OUT-
COME IN PREHOSPITAL THROMBOLYSIS FOR ACUTE
ST ELEVATION MYOCARDIAL INFARCTION
E.J.P. Lamfers
1
T.E.H. Hooghoudt
1
A. Schut
1
T. de Boo
2
F.W.A. Verheugt
3
Departments of Cardiology, Canisius-Wilhelmina Hospital
2
, Medical
Statistics
3
and Heart Center, University Medical Center St Radboud
3
,
Nijmegen, the Netherlands.
Published in: Netherlands Heart Journal 2002;10:449-454.
-77-
5.1 Abstract
Background: Prehospital thrombolysis for acute ST elevation myocardial
infarction shortened treatment by 60 minutes, and created a large patient group
with treatment within 2 hours.
Objectives: We analyzed our database of patients prehospitally treated for
acute ST elevation myocardial infarction in search of characteristics for a bet-
ter outcome in the early treatment group.
Methods: From 1994 to 2000 a total of 475 patients were treated using pre-
hospital administration of anistreplase (in 407 patients) or reteplase (in 68
patients) after diagnosis was confirmed with transtelephonic transmission of
the ECG. There was no age limit. The patient data were divided into 2 groups:
one treated within 2 hours after onset of pain (291 patients, 62%), and one
treated later (171 patients, 37%). Thirty-day mortality, symptoms and clinical
signs of heart failure were used as parameters of outcome. Both univariate and
stepwise logistic regression analyses were used to test 30-day mortality against
age, actual time to treatment, prior myocardial infarction, hypertension, dia-
betes, hyperlipidaemia, anterior myocardial infarction, Killip class, systolic
blood pressure and heart rate at presentation. 
Results: Overall 30-day mortality was 9.0%. Overall heart failure was in
16.4% of patients. Both mortality (5.5% vs. 15.2%, p<0.02) and heart failure
(12.7% vs. 23.2%, p<0.02) were significantly lower in the early treatment
group compared to the group treated late. Independent parameters showing a
relation with 30-day mortality were age, time to treatment, hypertension and
prior myocardial infarction. Age, time to treatment, hypertension and hyperlip-
idaemia were identified as predicting heart failure within the first 30 days.
Conclusion: In prehospital thrombolysis both 30-day mortality and heart fail-
ure were lower in an early treatment group of acute ST elevation myocardial
infarction. Independent variables for 30-day mortality were age, hypertension,
prior myocardial infarction and time to treatment and age, hypertension, hyper-
lipidaemia and time to treatment for independent predictors for heart failure.
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5.2 Introduction
Many studies have shown that timing of thrombolytic therapy is a major deter-
minant for the outcome of acute myocardial infarction. Shortening the time to
treatment by 60 minutes means a decrease in mortality from 11.1 to 9.7%.
1
Administering thrombolysis within 1 hour after symptom onset should result in
the best treatment outcome.
2
Although the importance of early thrombolysis is
well established, registration of treatment delays have shown that only 10 %
and not more than 25 % of patients are treated within 1 and 2 hours respec-
tively. 
To shorten the delay between coronary occlusion and thrombolytic treatment,
we initiated a prehospital thrombolysis program, working in close cooperation
with local general practitioners and ambulance service. Treatment could here-
by be shortened by 60 minutes, a speed not matched in a comparable hospital
group.
3
Furthermore, 25% of patients could be treated within 1 hour and 66 %
within 2 hours, also not matched by hospital treatment. Based on these results,
one would expect prehospital thrombolysis and early treatment to result in a
better outcome than hospital treatment.  A drawback may be that patients with
larger infarcts tend to seek medical help early and confound early treatment
with a less favorable prognosis. Moreover, those patients are more easily diag-
nosed because of decisive ECG changes, making them more favorable candi-
dates for prehospital diagnosis and treatment than patients showing less dis-
tinctive ST-segment elevation.
We analyzed our database of prehospital treated patients in search for a better
outcome in the early treatment group, using a stepwise logistic regression
analysis. 
5.3 Patients and methods 
From 1994 to 2000 a total of 475 patients were treated for acute myocardial
infarction using prehospital administration of anistreplase (in 407 patients) or
reteplase (in 68 patients), after diagnosis was confirmed with transtelephonic
transmission of the ECG.  The general practitioner or ambulance staff regard-
ed pain of more than 30 minutes and less than 6 hours duration, characteristic
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of acute coronary syndrome not relieved by nitroglycerin, the reason for start-
ing the procedure. There was no age limit. Aspirin was given orally. If the
transmitted ECG showed more than 0.1 mV of ST-segment elevation in two
anatomically contiguous leads or more than 0.2 mV in leads V1 and V2 and a
checklist did not reveal contraindications for thrombolytic therapy, 30 mg of
anistreplase or two times 10 MU of reteplase was given intravenously. Patients
were transported to one of the two Nijmegen hospitals and details of the time
intervals were noted on specially designed forms. Patients were divided into 2
groups: one with treatment within 2 hours after onset of pain, and one treated
later than that. Thirty-day mortality and symptoms and clinical signs of heart
failure were used as parameters of outcome. The diagnosis of heart failure was
based on analysis of the patient hospital records and included mentioning of
exertional dyspnea, orthopnea, nocturnal dyspnea, signs of peripheral edema or
congested jugular veins plus the subsiding of symptoms following diuretic
therapy. Patients with heart failure were classified according to Killip class I to IV.
Rescue angioplasty was performed when pain and ECG abnormalities did not
subside within 2 hours after start of treatment. The data were collected retro-
spectively. For comparison we choose the GUSTO-I time interval of 2 hours as
the division point between early and late treatment.
4
Univariate contingency
tables were analyzed with the uncorrected chi-square test. Stepwise logistic
regression analysis was used to test 30-day mortality and heart failure against
age (years), actual time to treatment (minutes), prior myocardial infarction,
hypertension, diabetes, hyperlipidaemia, anterior myocardial infarction, Killip
class, systolic blood pressure and heart rate at presentation. The level of sig-
nificance used was 5%.
5.4 Results
Baseline characteristics
Table 5.4-1 gives the results of the baseline characteristics of 468 patients.
Excluded were 7 patients (1.3%) who (1) did not have an increase in cardiac
enzymes, and (2) had no dynamic ecg changes characteristic of abortion of
myocardial infarction
3
and (3) from whom, in retrospect, the history and elec-
trocardiograms suggested no myocardial ischemia. 
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A total of 98 patients (20.9%) were treated within one hour, 291 (62.2%) with-
in 2 hours, and 171 (36.5%) later than that. From 6 patients (1.3%) the time to
treatment was unknown. A significant higher number of men presented within
2 hours after onset of pain rather than later. Other patient characteristics, as
shown in table 5.4-1, showed no relevant differences. 
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Table 5.4-1. Baseline characteristics of 468 prehospitally treated patients, with subdivision in
time to treatment.
Time to treatment (TTT) all patients
n=468 (100%)
TTT < 2 hours
n=291 (62%)
TTT > 2 hours
n=171 (37%)
TTT unknown
n=6(1%)
p
Age (mean + SD; yrs) 62.9+11.9 61.6+12.0 65.3+11.6 61.3+9.9 n.s.
Male (%) 322 (68.8) 218 (74.9) 100 (58.5) 4 (66.7) p<0.02
Risk factors
 hypertension
 prior myocardial infarction
 current smoker
 diabetes
 hyperlipidaemia
134/459 (29.2)
73/467 (15.6)
234/438 (53.4)
41/459 ( 8.9)
240/419 (57.3)
81/285 (28.4)
41/290 (14.1)
155/273 (56.8)
24/288 ( 8.3)
141/255 (55.3)
52/168 (31.0)
31/171 (18.1)
77/159 (48.4)
17/171 ( 9.9)
96/158 (60.8)
1/6 (16.7)
1/6 (16.7)
2/6 (33.3)
0
3/6 (50.0)
n.s.
n.s.
n.s.
n.s.
n.s.
Presentation
 heart rate (mean + SD; beats/min)
 systolic blood pressure (mean + SD; mm Hg)
 diastolic blood pressure (mean + SD; mm Hg)
 Killip class II-IV
74.8+20.1
128+26
71+16
65 (13.9)
71.2+17.1
127+25
70+17
34 (11.7)
81.6+22.3
131+27
72.+16
31 (18.1)
56.7+29.2
116+33
72+22
0
n.s.
n.s.
n.s.
n.s.
Location of infarction
 anterior
 inferior
 inferior + right ventricle
 other
201 (43.0)
135 (28.8)
105 (22.4)
27 ( 5.8)
121 (41.6)
86 (29.6)
70 (24.1)
14 ( 4.8)
77 (45.0)
49 (28.7)
33 (19.3)
12 ( 7.0)
3 (50.0)
0
2 (33.3)
1 (16.7)
n.s.
n.s.
n.s.
n.s.
Time to treatment
 median (min)
 mean + SD (min)
97
128+107
75
72+25
177
223+126
n.a.
n.a.
-
-
ECG characteristics
 mean sum of ST-segment deviation+ SD (mV)
 mean sum of ST-segment elevation+ SD (mV)
1.88+9.7
1.66+9.7
1.87+0.9
1.64+0.9
1.90+1.0
1.71+1.0
1.1+0.5
0.8+0.5
n.s.
n.s.
Data presented are numbers of patients with available data, with percentages between
brackets
Time gain 
In an earlier study performed in the Nijmegen region, time intervals of ambu-
lance arrival, prehospital assessment, transport times and hospital delays were
recorded and compared in patients treated prehospitally or in-hospitally.5 Using
the median time interval between ambulance arrival and in-hospital treatment
from the aforementioned study, a median time gain of 60 minutes could be
calculated, compared to the in-hospital time to treatment if no prehospital
treatment would have been available. 
Outcome
Patients are divided according to time to treatment (table 5.4-2). The median
time to treatment was 75 minutes in the patients treated early and almost 100
minutes later in the late treatment group. Stroke did not differ in both groups,
with 1 patient suffering a haemorrhagic stroke in the reteplase group, and 9
patients in the anistreplase group (7 haemorrhagic stroke, 2 patients cerebral
infarction). 
There is a trend to a lower incidence of rescue angioplasty in the late treatment
group, but this did not reach statistical significance. Overall heart failure was
recorded in 16.4% of patients. Both mortality and heart failure were respec-
tively 5.5% and 12.7% in the early treatment group, which was significantly
lower compared to the late treatment group. 
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Table 5.4-2. Outcome according to time to treatment.
Variable All patients
n=468 (100%)
TTT < 2 hours
n=291 (62%)
TTT > 2 hours
n=171 (37%)
TTT unknown
n=6 (1%)
p
time to treatment (median,
min)
97 75 177 n.a.
stroke 10/459 (2.2) 4/288 (1.4) 6/171 (3.5) 0 (0.0) n.s.
rescue angioplasty 29/467 (6.2) 25/291 (8.6) 4/170 (2.4) 0/6 (0.0) n.s.
heart failure in 30 days 75/458 (16.4) 36/284 (12.7) 39/168 (23.2) 0/6 (0.0) p<0.02
30 day mortality 42/468 (9.0) 16/291 (5.5) 26/171 (15.2) 0/6 (0.0) p<0.02
Overall 30-day mortality was 9.0% (table 5.4-3). Cardiogenic shock, ventricu-
lar septum rupture, tamponade and electromechanical dissociation were taken
together (13 patients, 30.9%), because of similar clinical features in their pres-
entation. Both stroke and heart failure were more common (11.9% and 19.0%
respectively) compared with other causes of death.
Stepwise logistic regression analysis included time to treatment, site of infarc-
tion, Killip class, systolic blood pressure and heart frequency at presentation
and age, sex, and risk factors as hypertension, prior infarction, hyperlipidaemia
and diabetes. Using this analysis the following parameters showed a relation
with 30-day mortality: age, actual time to treatment, hypertension and prior
myocardial infarction. (table 5.4-4). 
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Table 5.4-3. Overall 30-day mortality and its causes.
Cardiogenic shock, VSR, tamponade, EMD 13 (30.9%)
Heart failure 8 (19.0%)
Re-infarction 3 ( 7.1%)
Intractable arrhythmia 3 ( 7.1%)
Hemorrhagic or non-hemorrhagic stroke 5 (11.9%)
Intestinal bleeding 1 ( 2.4%)
Other 6 (14.3%)
Total 42 (100%)
VSR = ventricular septum rupture
EMD = electromechanical dissociation
Table 5.4-4. Stepwise logistic regression analysis for prediction of 30-day mortality.
Variable Odds ratio Wald 95% confidence limits Parameter estimate P
Age (year) 1.06 1.03 - 1.09 0.06 0.0001
Time to treatment (minutes) 1.005 1.002 - 1.007 0.005 0.0001
Prior infarction (yes/no) 2.4 1.2 - 4.8 0.86 0.018
Hypertension (yes/no) 2.4 1.3 - 4.5 0.88 0.0059
Intercept
.
-7.16
Age, hypertension and time to treatment were also identified as predicting heart
failure within the first 30 days, as was hyperlipidemia. (table 5.4-5).
5.5 Discussion
There is general consensus to treat patients with acute ST elevation myocardial
infarction as soon as possible after onset of symptoms. It agrees with the con-
cept of evolving myocardial infarction, and also with studies and meta-analy-
ses linking infarct salvage and mortality with time to treatment. 
However, in the literature about thrombolysis there are few reports of patients
treated within one or two hours after onset of pain. This means that the gain in
mortality is estimated by combining data from various trials, as has been per-
formed by a linear regression analysis
6
and by a best-fit non-linear regression
analysis.
2
Awareness of the importance of time to treatment have significantly
shortened delays in patients treated in-hospital in the period from 1990-1998,
7
which may be the reason that in individual randomized trials comparing pre-
hospital and hospital therapy mortality reduction is difficult to prove.
1
Furthermore, the time to treatment in-hospital is positively influenced, if the
same hospital has a prehospital treatment program.
8
Moreover, patients with an
extensive myocardial infarction seek medical help in an early phase and have
a higher mortality
4
, thus confounding prognosis in an early treatment group.
However, a meta-analysis of 6 individual trials comparing pre- and in-hospital
thrombolysis favored prehospital treatment, where prehospital thrombolysis
reduced the relative risk of all-cause hospital mortality by 17%.
9
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Table 5.4-5. Stepwise logistic regression analysis for prediction of heart failure.
Age (year) 1.05 1.02 - 1.07 0.044 0.0014
Time to treatment
(minutes)
1.002 1.00 - 1.004 0.002 0.0464
Hyperlipidaemia (yes/no) 2.4 1.3 - 4.5 0.87 0.0072
Hypertension (yes/no) 1.9 1.1 - 3.4 0.64 0.0327
Intercept -5.68
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Time to treatment 
Calculating hypothetical in-hospital treatment on the basis of the recorded time
intervals and the known time delays in the Nijmegen region, presented in an
earlier study
5
, we found a gain of time to treatment of 60 minutes. This agrees
with the results of a meta-analysis of prehospital therapy.
9
In this study, as in
others,
10
women with ST-elevation myocardial infarction present later than
men, which has been suggested in the literature as the result of less typical
symptoms.
10
Early and late treatment
One should realize that in trials comparing prehospital and hospital thrombol-
ysis the patients groups are confounded with patients treated late in the pre-
hospital group and patients treated early in the hospital group. Seen in that light
it seems a better idea to compare patients treated within 2 hours with those
treated later than that. Because prehospital thrombolysis is the only way to treat
early, such a comparison can only be performed using data from patients treat-
ed early, i.e. prehospitally.
Mortality
The GUSTO-I study provides the largest database of hospital treated patients
treated within 2 hours, although this is confined to only 27 % of the patients in
their study.
4,11
In our study 62 % of patients are treated within 2 hours. Overall
30-day mortality in our study is 9.0%, in agreement with hospital registries like
the Fibrinolytic Therapy Trialists Collaborative Group
5
and of GISSI,
12
where
there is no age limit for treatment, as in our study. One must realize that
patients eligible for prehospital therapy are those with conclusive electrocar-
diographic changes, and thus with larger infarctions, with a worse prognosis
than those with less outspoken ECG abnormalities. Nevertheless, we find a sig-
nificant lower 30-day mortality rate of 5.5% in the early group compared to
15.2% in the late treatment group. This is comparable with the mortality of
patients treated within 2 hours in the GUSTO-I study, which was 5.3%.
4
Age is
one of the 4 significant independent risk factors for 30-day mortality. This con-
curs with the results of the GUSTO-1 study, which is based on the data of
41,021 patients treated with streptokinase and/or rt-PA,
11
and with the TIMI-
risk score of ST-elevation myocardial infarction, based on data from 15,060
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patients treated with lanoteplase.
13
In this risk score age over 75 years and sys-
tolic blood pressure lower than 100 mm Hg is scored as 3 points, age from 65-
74, heart rate more than 100 beats per minute and Killip class II-IV scored as
2 points and a anterior myocardial infarction, a history of prior infarction,
hypertension and diabetes scored as 1 point. Time to treatment later than 4
hours (24.3% of patients) is also allotted 1 point. Mortality at 30 days ranges
from 0.9% with a score of 0 to 32.2% with more than 8 points. Since the num-
ber of patients treated very early is the main difference between our patient data
and those of the TIMI-risk group, it is possible that time to treatment shorter
than 2 hours overrules the statistical significance of several of the other vari-
ables investigated in the TIMI-risk analysis. This concurs with Boersma s find-
ings, in which treatment within one hour shows an exponential mortality ben-
efit.
2
Furthermore, a logistic regression analysis performed from the data from
the pre-and in-hospital treated patients of the GREAT study, in which also 60%
of patients are treated within 2 hours with prehospital thrombolysis, found age
and time to treatment as the only variables predicting outcome.
14
Heart failure
Heart failure was not registered in the GUSTO-trial and the TIMI-risk analy-
sis, but is significantly lower in our early treatment group and confirms the
findings of Milavetz,
15
who describes a greater degree of myocardial salvage,
measured with technetium-99m sestamibi, in patients treated within 2 hours
with angioplasty or thrombolysis. Our findings confirm those of Gotsman s
group,
16
who describes 34.5 % less heart failure in a patient group treated with-
in 1.5 hours after onset of symptoms.  Hypertension as a predictor of heart fail-
ure after myocardial infarction is to be expected, as it is a traditional factor for
heart failure. Hyperlipidaemia, although a well-known risk factor for coronary
artery disease, is more difficult to explain as a risk factor for heart failure after
myocardial infarction. It can be seen, however, as a marker of more advanced
atherosclerotic disease.
Rescue angioplasty
Rescue angioplasty was not routinely performed in the period we started our
prehospital thrombolysis program. A total of 29 patients (6.2%) were treated
with angioplasty if on clinical grounds (no subsiding of both ST-segment ele-
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vation and pain within 2 hours after starting treatment) thrombolysis was con-
sidered to have failed. Many authors have recently advocated rescue angio-
plasty on a routine base, for instance by transporting patients to angioplasty
centers immediately after administration of thrombolytic therapy. In one study
35% of 165 patients needed rescue angioplasty because of angiographic con-
firmed failed thrombolysis.
17
Another study compared primary angioplasty
with prehospital thrombolysis followed by routine angiographic assessment of
reperfusion. Of 170 patients 29% were treated by rescue angioplasty; their 30-
day mortality was comparable to 170 patients treated by primary angioplasty.
18
Seen in this light it is possible that a more liberal intervention strategy would
have resulted in a lower mortality rate in the late treatment group. 
Stroke
Eight patients suffered a haemorrhagic stroke (1.7%), 2 patients a cerebral
infarction. The incidence of stroke of 1.7% may be higher than expected, but
the figures are small. Anistreplase or reteplase, used in our study are both bolus
thrombolytics. A meta-analysis has shown that bolus treatment with throm-
bolytics is associated with a risk of intracranial hemorrhage, varying between
0.6% and 1.1%, whereas in infusion therapy this risk varies between 0.4% and
0.9%.
19
In a study comparing double bolus reteplase with alteplase, intracranial
hemorrhage is the same in both treatment groups, 0.91% and 0.87% respec-
tively.
20
Our study investigated the importance of the 30-mortality reduction
associated prehospital thrombolysis, and the incidence of stroke is not influ-
enced by early treatment.
Implications
The American Heart Association and the American College of Cardiology Task
Force for Thrombolytic Therapy recommend a door-to-needle time of 30 min-
utes.
21
This seems not realizable in a routine hospital practice so that prehospi-
tal treatment of myocardial infarction is the only way of treating early. We find
a statistically significant lower mortality and heart failure rate in the early treat-
ment group, which is comprised of 60% of the whole group, with a time to
treatment not realizable by hospital treatment. The authors of the GREAT study
estimated 21 deaths per 1000 patients treated extra by delaying treatment by 1
hour, underlining their argument that the treatment of acute myocardial infarc-
tion should take on the urgency of a cardiac arrest.
14
Both our data and the
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review of the literature implicate the institution of a prehospital thrombolysis
program. 
5.6 Conclusion
Prehospital thrombolysis results in about two thirds of patients being treated
within 2 hours after onset of symptoms in this study. Stepwise logistic regres-
sion analysis of multiple variables selected elderly patients, those with hyper-
tension or prior myocardial infarction and time to treatment as predictors for
30-day mortality, and age, hypertension, hyperlipidemia and time to treatment
as predictors for heart failure. The findings underline the importance of imple-
menting a prehospital thrombolysis program.
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6.1 Abstract
On administering thrombolysis in a prehospital setting, we found a threefold
increase in the incidence of abortion of myocardial infarction, compared with
the in-hospital program of a nearby hospital. Assessment of aborted myocardial
infarction may be a better criterion for the efficacy of early thrombolysis than
mortality data.
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6.2 Introduction
To shorten the delay between coronary occlusion and thrombolytic treatment,
we initiated a prehospital thrombolysis program, working in close cooperation
with our local general practitioners and ambulance service. We found that
thrombolytic treatment could be instituted 63 minutes earlier than in hospital.
Furthermore, 28% of patients in the prehospital group were treated within 1
hour of symptom onset, a speed not matched by any patient in the hospital
group. After 2 hours these percentages became 65% and 25% respectively.
1
Although a lower mortality rate is expected in earlier treated patients, this has
been difficult to prove statistically with randomized trials.
2
Patients with an
extensive acute myocardial infarction and thus a high mortality tend to seek
help earlier, are easily diagnosed because of decisive electrocardiographic
changes, and are thus favorable candidates for very early - prehospital - throm-
bolysis. A high mortality rate is thus found in the very early treated group, part
of which would never have survived long enough for in-hospital thrombolysis.
Indeed, the GUSTO-trial confirms a higher mortality in very early treated
patients.
3
We therefore evaluated our prehospital thrombolysis program by
comparing the number of aborted myocardial infarcts against those of patients
treated in a nearby hospital lacking such a prehospital program.
6.3 Patients and methods
Transtelephonic electrocardiograms from patients with chest pain and the sus-
picion of acute myocardial infarction by general practitioner or ambulance staff
(duration of pain more than thirty minutes and less than six hours, not relieved
by sublingual nitroglycerin) were transmitted to the coronary care unit of one
of our hospitals. More than 0.1 mV ST-segment elevation in two anatomically
contiguous leads or more than 0.2 mV in V1 and V2 confirmed the diagnosis
of transmural myocardial ischaemia. A checklist was used to assess contra-indi-
cations for thrombolytic therapy, following which 30 mg of anistreplase was
given intravenously, as well as 160 mg of aspirin chewed. A total of 227
patients were treated in the prehospital setting. Their data were compared ret-
rospectively with those of 269 patients who underwent in-hospital thrombolyt-
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ic therapy (1.5 million units of intravenous streptokinase or 100 mg of intra-
venous recombinant tissue plasminogen activator (rt-PA) and intravenous
heparin) in the same period in a nearby hospital not using a prehospital throm-
bolysis program (Hospital Rijnstate in Arnhem). Details are given in table 6.3-
1. The diagnosis of aborted myocardial infarction was made for both groups if
1) the combination of chest pain and transient electrocardiographic changes
suggested transmural ischaemia and 2) if a rise in creatine kinase and its iso-
enzym > 2 times the normal value failed to appear, and 3) the cumulative ST-
segment elevation and depression decreased to less than 50% within 2 hours of
treatment. All ST-segment shifts were measured by the same observer, using
handheld calipers at 80 msec after the J-point in all 12 leads.
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Table 6.3-1 Patient characteristics
Prehospital Thrombolysis In-hospital Thrombolysis
N=227 N=269
Age (mean) 63 62
Men (number) 171 (75%) 192 (71%)
Minutes to Treatment 90* 155*
Transmural ischaemia on initial ECG
 anteroseptal 100 (44%) 120 (45%)
 inferior 62 (28%) 76 (29%)
 inferior + right ventricle 47 (21%) 60 (23%)
 lateral or other 18 (8%) 13 (5%)
Inadvertently treated 3 5
Aborted Infarction 30 (13%)* 12 (4%)*
Total ST-segment shift (mean) 1.9 mV 1.5 mV
Coronary angiography 78 (34%) 98 (36%)
 no visible disease 3 5
 1 vessel 41 50
 2 vessel 21 23
 3 vessel 13 20
Treatment
 conservative 160 (71%) 207 (77%)
 angioplasty 46 (20%) 38 (14%)
 bypass surgery 21 (9%) 24 (9%)
Mortality at 12 months 24 (11%) 25 (9.2%)
* p < 0.05 prehospital versus in-hospital thrombolysis
6.4 Results
In the prehospital group 3 patients (1.3%) who underwent thrombolytic thera-
py showed no rise in cardiac enzymes, while, viewed retrospectively, the his-
tory and electrocardiograms of these patients suggested no myocardial
ischaemia. In the hospital group 5 patients (1.9%) also received thrombolytic
therapy without justification. Our analysis excluded all these patients  (table
6.3-1).
A total of 30 of the 224 patients (13.4 %) of the prehospital group and 12 of the
266 (4.5 %) in-hospital group thus fulfilled the criteria for an aborted myocar-
dial infarction (p < 0.05, chi-square-test). 
Seven of the prehospital thrombolysis patients with aborted infarction were
treated within 1 hour, but none of the in-hospital thrombolysis patients
achieved this. About half of the patients in both groups had one vessel disease.
Three of the prehospital treated patients and 2 of the hospital treated patients
had no visible disease at angiography although they had shown an extensive
ST-segment shift in the acute phase, suggesting acute anterior infarction, and a
hypokinetic segment at ventriculography or echocardiography (table 6.4-1).
None of the patients of either group died during their stay in hospital or before
the follow up at 12 months. 
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Table 6.4-1 Aborted myocardial infarction after pre- and in-hospital thrombolysis
Prehospital Thrombolysis In-hospital Thrombolysis
n=30 n=12
Age (mean) 62 55
Men (number) 22 9
Minutes to treatment 85* 165*
Transmural ischaemia
 anteroseptal 13 (43%) 9 (75%)
 inferior 13 (43%) 2 (17%)
 inferior + right ventricle 3 (10%) 1 ( 8%)
 lateral 1 ( 3%) 0
Total ST-segment shift (mean) 1.2 mV 0.9 mV
Coronary angiography
 no visible disease 3 2
 1 vessel 10 5
 2 vessel 4 1
 3 vessel 2 3
Treatment
 conservative 17 3
 angioplasty 9 6
 bypass surgery 4 3
Mortality at 12 months 0 0
* p < 0.05 pre- versus in-hospital thrombolysis
6.5 Discussion
Prehospital initiation of thrombolytic therapy bodes well for patients with acute
myocardial infarction, but is fraught with medical, legal and organizational
problems. Training of ambulance personnel and general practitioners is time
consuming, and many health providers wonder whether the effort is worth-
while. Our prehospital thrombolysis program has reduced time to treatment by
a median of 63 minutes,
1
but has shown no mortality benefits, due to the huge
patient cohort and/or lengthy period between prehospital and hospital throm-
bolysis needed to detect any significant reduction in mortality.
4
The GUSTO-I
study with 41021 patients found an increase in mortality as time to treatment
increased, although patients treated within one hour after symptom onset
showed a higher mortality than those treated between one and three hours.
3
The
study of Barbash which compared early and late treated patients, found more
revascularisation procedures in patients in the early treated group, confirming
the idea that this group contains patients with a worse prognosis.
5
Furthermore,
a  patient with a large ST-segment shift on the prehospital electrocardiogram,
and thus with a larger infarction, is easier to diagnose in the prehospital setting
than one with only minimal ST-segment changes who will thus be assessed and
treated in hospital.  Also, the GREAT study showed that patients with a large
infarct and a worse prognosis tend to seek help earlier, thus confounding the
mortality analysis of prehospital thrombolysis trials.
4
However, the meta-analy-
sis of randomized prehospital thrombolysis trials as performed by Boersma et
al revealed a highly significant mortality reduction in favor of early treatment
and thus of prehospital thrombolysis.
6
Hence, comparison of patients without a
randomization procedure will result in a population with larger infarcts and a
higher mortality rate in the prehospital situation, and renders mortality a dubi-
ous criterion. An alternative parameter was therefore sought. In light of Reimer
and Jennings model of evolving myocardial infarction,
7
we hypothesized that
earlier thrombolytic treatment might result in a larger percentage of abortion of
myocardial infarction. 
Aborted myocardial infarctions have not previously been suggested as an indi-
cator for the efficacy of prehospital thrombolysis, although most studies
emphasize the importance of very early thrombolytic treatment. The GREAT
study found less q-wave infarctions in the prehospital group, which could indi-
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cate a greater number of aborted infarctions.
4
Also, in a ECG-substudy, the
GREAT-authors found that the proportion of patients showing a reduction in
ST elevation of >25% or even >50% between the home and hospital recordings
was significantly greater in the early than in the late group. Although not men-
tioned, this is also suggestive of abortion of myocardial infarction.
8
In another
study a highly significant salvage of myocardium in patients treated within 2
hours of onset of pain was reported using Technetium-99m sestamibi injections
before thrombolysis and again at hospital discharge.
9
By definition, patients with an aborted infarction lack an enzyme rise, just as
do patients inadvertently treated with thrombolysis. Retrospective analysis of
the electrocardiograms showed the same number of inadvertently treated
patients in both prehospital and hospital groups. This compares well with 1%
false positive electrocardiograms mentioned in the REPAIR study,
10
and the
1.1% reported in a study examining inadvertent thrombolytic therapy.
11
After
correction for these data we found a significantly higher number of aborted
infarctions in the prehospital group than in the group receiving treatment in
hospital. This is probably due to the earlier time to treatment, since 7 of the 30
prehospital treated patients with aborted infarction had a time to treatment of
less than one hour. None of the 12 hospital treated patients with aborted
myocardial infarction were treated within one hour. So, although infarction can
be aborted by thrombolytic treatment in a hospital setting, probably because
myocardial tissue is preserved by collateral blood flow before the artery is
opened (stuttering infarction), an infarction can also be aborted by giving very
early treatment, which in our experience is only possible via prehospital throm-
bolysis.
6.6 Conclusion
Very early - prehospital - thrombolysis is associated with a 3-fold increase in
abortion of myocardial infarction when compared with in-hospital treatment.
Assessment of the number of aborted myocardial infarctions may well be a bet-
ter criterion than mortality for the efficacy of early thrombolysis, in especially
when small patient cohorts are studied. 
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7.1 Abstract
Objectives: We studied the incidence of reversal or abortion of myocardial
infarction with prehospital thrombolysis compared with in-hospital treatment.
Furthermore, the time-span was investigated, in which abortion of myocardial
infarction can be expected, and the characteristics of patients with aborted ver-
sus established myocardial infarction. 
Methods: From patients suspected of acute myocardial infarctions, ECG s
were transmitted by the ambulance service to the coronary care units of one of
our two hospitals here in Nijmegen. Myocardial infarction was confirmed in
475 patients, who were treated with prehospital thrombolysis. Their data were
retrospectively compared with those of 269 in-hospital thrombolised patients at
another (Arnhem) hospital that does not use a prehospital thrombolysis pro-
gram. Aborted myocardial infarction is defined as the combination of subsid-
ing of the cumulative ST-segment elevation and depression to less than 50% of
the level at presentation, together with a rise of creatine phosphokinase of less
than 2 times the upper normal value. A stepwise regression analysis was used
to test independent predictors for aborted myocardial infarction. 
Results: After correction for unjustified thrombolysis, 80 patients (17.1%) of
the 468 prehospital treated patients and 12 (4.5%) of the 264 in-hospital treat-
ed patients fulfilled the criteria of aborted myocardial infarction. There was no
difference in age, sex, risk factors, hemodynamic status at presentation, and
location of infarction of aborted myocardial infarction compared to established
ST elevation myocardial infarction. More than 30% of these patients who
underwent angiography had 2- or 3-vessel disease. Apart from time to treat-
ment, which was significantly shorter in the patients with aborted myocardial
infarction (86 versus 123 minutes, p=0.05), a lower ST elevation and a higher
incidence of preinfarction angina were independent predictors for abortion of
myocardial infarction. The prognosis of patients with aborted myocardial
infarction is significantly better compared with established myocardial infarc-
tion: 12 month mortality of 2.2% and 11.6%, respectively.
Conclusion: Prehospital thrombolysis is associated with a fourfold increase of
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abortion of myocardial infarction when compared to in-hospital treatment. A
shorter time to treatment, a lower amount of ST elevation and a higher inci-
dence of preinfarction angina were predictors of abortion of myocardial infarc-
tion.
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7.2 Introduction
In an earlier study using a prehospital strategy, we found that thrombolytic
treatment could be instituted on average 60 minutes earlier than in-hospital
thrombolysis.
1
Considering the Reimer and Jennings experiments, where the
amount of myocardial damage brought about by temporary closure of a coro-
nary artery is found to be time dependent,
2
the possibility of reversal or abort-
ed myocardial infarction being a factor in our results suggested itself.
We found an almost threefold higher incidence of aborted myocardial infarc-
tion in the prehospital group.
1
The database of prehospital treated patients has
been extended. In this report the time-span between symptom onset and treat-
ment during which abortion of myocardial infarction can be expected is stud-
ied, as well as the patients parameters of aborted myocardial infarction com-
pared with established ST-segment elevation myocardial infarction. 
7.3 Patients and methods
Transtelephonic ECG s from patients with chest pain and suspected acute
myocardial infarction (duration of chest pain more than thirty minutes and less
than six hours duration, not relieved by sublingual nitroglycerin) were trans-
mitted to the coronary care unit of one of two Nijmegen hospitals.
Transmissions were performed by the ambulance staff. More than 0.1 mV ST-
segment elevation in two anatomically contiguous leads or more than 0.2 mV
in V1 and V2 confirmed the diagnosis of transmural myocardial ischaemia. A
checklist was used to assess the contra-indications for thrombolytic therapy,
and 30 mg of intravenous anistreplase or 10 U of reteplase double bolus i.v.
was given, as well as 160 mg of aspirin chewed. A total of 475 patients were
treated from 1995 to 2000, in the prehospital setting: 407 (86%) with anistre-
plase and 68 (14%) with reteplase. Their data were compared retrospectively
with those of 269 patients, treated between 1995 and 1997, who underwent in-
hospital thrombolytic therapy with either 1.5 million units of intravenous strep-
tokinase (212 patients, 79%), or 100 mg of frontloaded intravenous recombi-
nant tissue plasminogen activator (57 patients, 21%) and intravenous heparin.
The latter patients were all treated in an Arnhem hospital not then using a pre-
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hospital thrombolysis program.
For the purpose of this analysis, the names of treated patients were collected by
ambulance staff in Nijmegen (using the prehospital strategy), or by the hospi-
tal pharmacist of the Arnhem hospital (using in-hospital thrombolysis). In this
way all patients treated with fibrinolysis were included in the survey, regard-
less of the diagnosis at hospital discharge.
Apart from the ambulance recorded ECG s of the prehospital group, ECG s
were made at submission in hospital, 2 hours after time to treatment, the fol-
lowing day, a week after submission and at hospital discharge. All ST-segment
shifts in the ECG s of both groups were measured by the same observer, using
handheld calipers at 80 msec after the J-point in all 12 leads. This observer was
not informed about the cardiac enzyme concentration of the patients.
Blood samples for the determination of cardiac enzymes  (creatine kinase or
creatine kinase-MB-fraction and aspartate aminotransferase) were collected, at
hospital admission and at 8-hour intervals, until 2 successive drops in the level
of creatine kinase.
A diagnosis of aborted myocardial infarction was reached as follows: 1) when
the combination of chest pain and transient ECG changes suggested transmur-
al ischaemia, and 2) a rise in creatine kinase or creatine kinase-MB-fraction
more than double the normal value failed to appear, and 3) the cumulative ST-
segment elevation and depression decreased to less than 50% of the value at
presentation within 2 hours of treatment. Two groups are analyzed, patients
diagnosed with aborted myocardial infarction, and those with established
myocardial infarction. Fibrinolysis was considered to be unjustified  when 1)
creatine phosphokinase levels remained less than twice the upper level of nor-
mal, and 2) the ST elevation on the ECG at presentation did not change during
48 hours following thrombolytic therapy. 
Stepwise logistic regression analysis was used to test the incidence of aborted
myocardial infarction against time to treatment, prior myocardial infarction,
prior angina pectoris, hypertension, smoking habit at presentation, diabetes,
anterior myocardial infarction, Killip class greater than 1, TIMI-risk score, sys-
tolic blood pressure and heart rate at presentation. Prior angina pectoris was
present if patients had been complaining of characteristic chest discomfort
within 2 weeks before presentation. Because of large standard deviations in
both the aborted infarction group and the established infarction group, the
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parameter time to treatment was used dichotomized in time to treatment < 2
hours and > 2 hours.
Statistical analysis was performed using standard methods, the baseline char-
acteristics of the two groups being compared by means of the Student t test, and
the frequencies in each group by means of chi-square analysis. The time inter-
vals of patients treated prehospitally or inhospitally and of aborted and estab-
lished groups were compared using the Wilcoxon rank test. Univariate contin-
gency tables were analyzed with the uncorrected chi-square test. The level of
significance used was 5%.
7.4 Results
Patient characteristics
Table 7.4-1 shows the basic characteristics of the prehospital and in-hospital
treated patients. There were no clinical significant differences between the pre-
hospital and the in-hospital fibrinolytic treatment groups, except the time to
treatment, which was nearly 1 hour shorter in the prehospital group.
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Table 7.4-1. Characteristics of all patients.
Prehospital
thrombolysis
n = 475
In-hospital thrombolysis
n = 269
p
Age (mean) (years)
Men, n (%)
63
329 (69)
62
192 (71)
n.s.
n.s.
Minutes to treatment
(median, minutes)
98 155 p< 0.05
Transmural ischaemia
on initial ECG,* (n, %)
 anteroseptal
 inferior
 inferior + right
ventricle
 lateral
 other
 unknown
207 (44)
135 (28)
105 (22)
19 (4)
9 (2)
0
120 (45)
76 (29)
60 (23)
7 (3)
3 (1)
3 (1)
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
Unjustified fibrinolysis 7 (1.5) 5 (1.9) n.s.
* unjustified thrombolysis included
Unjustified fibrinolysis
Of the 475 prehospital patients, 7 (1.5%) of those treated with thrombolytic
therapy showed no rise in cardiac enzymes, while retrospectively, the history
and ECG s of these patients suggested no myocardial ischaemia. Two of these
patients had gastritis, 1 patient esophagitis. One patient was diagnosed as
having pericarditis, 2 patients showed early repolarisation on the presenting
ECG, and 1 patient had left bundle branch block, which was in fact an exclu-
sion criterion for prehospital thrombolysis. In the in-hospital group, 5 patients
(1.9%) were unjustifiably treated with fibrinolysis, 4 had coronary artery
disease, and one showed pericarditis. None of these patients had complications
from the  fibrinolytic therapy; all were excluded from this analysis.
Table 7.4-2 again shows the characteristics of prehospital and in-hospital treated
patients, excluding those who received unjustified treatment.
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A total of 92 patients fulfilled the criteria of abortion of myocardial infarction,
12  (4.5%) in the in-hospital treated patients and 80 (17.1%) in the prehospital
group.  In the case of patients who died within 24 hours, a peak creatine kinase
cannot be measured. In this way they can defy inclusion among the group diag-
nosed as aborted myocardial infarction cases. In our database, we found 12
patients who died within 24 hours, each of them showing a normal creatine
kinase at presentation, but in whom peak creatine kinase could not be assessed.
Among these patients, 7 presented with cardiogenic shock. No patient experi-
enced a decrease of pain or ST-segment elevation within 2 hours after presen-
tation, so that although no creatine kinase-peak was known, none of these
patients fulfilled the criteria for diagnosis as aborted myocardial infarction.
Three of the in-hospital treated patients died within 24 hours; all had CK-MB
concentrations 2 times higher than the upper level of normal. There was a sig-
nificantly higher number of patients with Killip class II, III or IV at presenta-
tion in the prehospital group, together with a higher mean TIMI-risk score. Five
of the prehospital thrombolysis patients presented with Killip IV, of whom 4
died within 30 days. In the in-hospital group 2 patients had Killip IV at pres-
entation; both survived.
Time to treatment and abortion of myocardial infarction
Eight of the 264 in-hospital thrombolysis patients (3%) and 98 of the 468 pre-
hospital thrombolysis patients (20.9%) were treated within one hour of symp-
tom onset. A total of 80 of the 468 patients (17.1%) belonging to the prehospi-
tal group, and 12 of the 264 (4.5%) of the in-hospital group, fulfilled the crite-
ria of an aborted myocardial infarction (p < 0.05).
Coronary angiography
Coronary angiography was performed, at the discretion of the attending cardi-
ologist, in 44.2% of the prehospital and 41.3 % of the in-hospital treated
patients (Table 7.4-3). In both groups, less than half of the patients had one ves-
sel disease. Seven prehospital treated patients, and 5 in-hospital treated patients
revealed no significant disease at angiography, although they had shown exten-
sive dynamic ST-segment shifts in the acute phase, and a hypokinetic segment
in the 4 cases in which ventriculography was performed.
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Treatment at follow up
There were no differences in treatment at 12 months follow up, nor differences
in mortality between the prehospital and in-hospital treatment groups (table
7.4-3).
Patients characteristics of aborted myocardial infarction
Table 7.4-4 compares patients diagnosed with aborted myocardial infarction
(whether from the pre- or in-hospital groups) with those diagnosed with estab-
lished myocardial infarction (again, from whichever group). The median time
to treatment of aborted myocardial infarction was 86 minutes, which was sig-
nificantly shorter than the 123 minutes of established myocardial infarction.
Aborted myocardial infarction was not confined to early treated patients;
41.3% of patients diagnosed with aborted myocardial infarction were treated
later than 2 hours. 
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Aborted myocardial patients show no differences in risk factors, characteristics
at presentation, infarct location, or findings at coronary angiography (Table
7.4-4), compared with established myocardial infarction, although there is a
tendency toward an increased incidence of one vessel disease. 
A stepwise logistic regression analysis showed time to treatment < 2 hours, a
history of angina pectoris, and a lower level of cumulative ST-segment eleva-
tion at presentation as independent predictors for abortion of myocardial
infarction (table 7.4-5). Compared with established myocardial infarction, their
mortality at 12 months is significantly lower.
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7.5 Discussion
In this controlled analysis we found a fourfold increase of abortion of myocar-
dial infarction, associated with prehospital thrombolysis, in a large patient
group. This result could be explained by a nearly one-hour time gain in time to
treatment.  
Our prehospital thrombolysis program reduces the time to treatment by a medi-
an of 56 minutes. However, it reveals no mortality benefits. This seems to con-
tradict Boersma s meta-analysis of 22 thrombolysis trials, which shows a high-
ly significant mortality reduction in favor of early treatment and, thus, in favor
of prehospital thrombolysis.
3
However, only 11% of patients in this meta-
analysis were randomized within 2 hours, while the percentage of patients
actually treated within 2 hours will consequently be lower. With our prehospi-
tal thrombolysis program 66% of patients were treated within 2 hours. It thus
is possible that with prehospital hospital thrombolysis a selection is made of
early presenting patients with a worse prognosis. For instance, the GUSTO-I
study with 41,021 patients, found a rise in mortality as time to treatment
increased, although patients treated within one hour of symptom onset yielded
a higher mortality than those treated between one and three hours.
4
The GREAT
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Table 7.4-5. Stepwise logistic regression analysis for prediction of abortion of myocardial
infarction.
Variable Parameter
estimate
Standard error Wald chi square p
Time to
treatment < 2 hr
-0.6932 0.2452 7.9905 0.005
ST elevation -0.0668 0.0165 16.3159 <0.0001
Angina pectoris 0.05543 0.2415 5.2709 0.0217
Intercept -0.9201 0.2842 10.4843 0.0012
study also showed that patients with a large infarct and a worse prognosis tend
to seek help earlier, thus confounding the mortality analysis of prehospital
thrombolysis trials.
5
As a result, comparisons made without using a random-
ization procedure are bound to result in populations containing larger infarcts,
and thus higher mortality rates, for pre-hospital treated groups, which shows
that mortality is a doubtful indicator by which to judge. Furthermore, a larger
number of patients than in our study is needed to find a significant reduction in
mortality.
Abortion of myocardial infarction has not previously been suggested as an
indicator of the efficacy of prehospital thrombolysis. A highly significant sal-
vage of myocardium in patients treated within two hours after onset of pain was
reported using Technetium-99m sestamibi injections before thrombolysis, and
again at hospital discharge, to assess the myocardium at risk.
6
The GREAT
study found fewer Q-wave infarctions in the prehospital group, which might
indicate a greater number of aborted infarctions, although this was not speci-
fied.
5
In a sub-study, the GREAT-authors also found that the proportion of
patients showing electrocardiographic reduction of ischemia up to 50%, as
compared between home and hospital recordings, was significantly greater in
the early rather than in the late group. Although not mentioned in this study,
this is suggestive of abortion of myocardial infarction.
7
The same was found in
13,100 patients treated with either tenecteplase or alteplase and analyzed
according to resolution of ST-segment on the ECG at presentation.
8
This same
study observed a significantly lower peak creatine kinase MB level in patients
with complete ST resolution, compared with patients with partial or no resolu-
tion. Furthermore, the extent of ST resolution became significantly less with
increasing time to treatment. 
By definition, patients with an aborted infarction exhibit dynamic ECG
changes, while lacking an enzyme rise, just as do patients who are unjustifiably
treated with thrombolysis. Retrospective analysis of ECG s found the same
number of unjustified treated patients in our pre-hospital and hospital groups.
This compares well with 1% false positive ECG s mentioned in the REPAIR
study,
9
and the 1% reported in another study examining inadvertent fibrinolyt-
ic therapy.
10
No visible disease at coronary angiography can be seen in up to 5% of patients.
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However, most patients with aborted myocardial infarction do have coronary
artery disease, and do not differ from patients with established infarction. It
may be that infarction can also be aborted by late thrombolytic treatment, the
probable cause being myocardial tissue preserved by collateral blood flow
before the artery is opened, or by intermittent occlusion (stuttering infarction).
This phenomenon of intermittent coronary occlusion in acute myocardial
infarction has been observed at coronary angiography combined with ST-seg-
ment monitoring, up to 5 hours after onset of pain, but was most distinctive in
patients presenting within 3 hours. It is accompanied by improvement of ST-
segment elevation. In the latter cases, the coronary artery showing intermittent
occlusion could be kept open with nitrates and intracoronary streptokinase.
11
This reflects the importance of early therapy for inducing abortion of acute
myocardial infarction even further. 
Apart from time to treatment, a lower amount of ST elevation and a higher inci-
dence of preinfarct angina are independent predictors of aborted myocardial
infarction. One must realise that the amount of ST elevation is not a sensitive
predictor of the area at risk. Nevertheless, it is likely that timely opening of an
occluded coronary artery will result in preservation of myocardial tissue only
if the area at risk is not too extensive.
Preinfarction angina has been associated with early coronary thrombolysis in
patients with acute ST elevation myocardial infarction.
12
Furthermore, a
prospective study showed significantly less 30-day events in patients with
onset of angina 24 hours before a ST elevation myocardial infarction.
13
This has
been explained by the phenomenon of preconditioning;
14
this may be the expla-
nation that in our database preinfarct angina is an independent predictor for
aborted myocardial infarction.
Limitations 
This study was not randomized and not performed prospectively. In the throm-
bolytic situation, time to treatment is all-important, so that design of studies in
which patients are assigned to either pre-hospital or in-hospital treatment
becomes ethically unjustifiable. The Arnhem situation is comparable to that of
Nijmegen in terms of population, degree of urbanization, transport times for
ambulances and CCU-facilities, the key difference being that no pre-hospital
treatment was available in Arnhem during the period of the study. This, togeth-
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er with the fact that both patient groups reveal baseline characteristics in rea-
sonable agreement with those occurring in the literature, we expect them to be
comparable.
Both the pre-hospital and in-hospital treatment groups contain patients treated
with streptokinase, rt-PA, or reteplase, in various percentages. Nevertheless, it
seems unlikely that the difference in aborted myocardial infarctions is caused
by different thrombolytic regimens. This is because the number of patients
treated with rt-PA is higher in the in-hospital group, whereas the incidence of
aborted myocardial infarction is lower for this group than it is for the prehos-
pital group.
7.6 Conclusion
Prehospital thrombolysis in acute myocardial infarction results in a one hour
gain in time to treatment and in a fourfold increase in abortion of myocardial
infarction, over that found with in-hospital treatment. A shorter time to treat-
ment, a lower amount of ST elevation and a higher incidence of preinfarction
angina were predictors of abortion of myocardial infarction. Assessment of the
number of aborted myocardial infarctions may well be a better indicator for the
efficacy of early thrombolysis than the currently used mortality rates, especial-
ly when small patient cohorts are studied. 
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8.1 Abstract 
Objectives: Earlier studies showed a three times higher rate of aborted
myocardial infarction in patients treated by prehospital thrombolysis, com-
pared to in-hospital thrombolytic treatment. Combining prehospital infarct
triage with angioplasty has reduced symptom-to-balloon times considerably.
Reperfusion times with primary angioplasty and prehospital triage were com-
pared with prehospital thrombolysis. The incidence of aborted myocardial
infarction was assessed in groups of patients treated with either strategy.
Methods: Abortion of acute ST elevation myocardial infarction is defined by
resolution of characteristic symptoms and ECG-changes, combined with a less
than 2 times rise of cardiac enzymes. A total of 545 patients were treated pre-
hospitally in the cities Rotterdam and Nijmegen and compared with 236
patients treated with primary angioplasty after prehospital triage in Zwolle. All
patients were treated with aspirin prehospitally. Prehospital thrombolysis con-
sisted of streptokinase or anistreplase in Nijmegen or Rotterdam and 10.000 IU
heparin intravenously in Zwolle before transport. Time to reperfusion is
defined as symptom to balloon time in primary angioplasty or symptom to
thrombolysis plus 60 minutes in prehospital thrombolysis.
Results: Aborted myocardial infarction is seen in 16% of the prehospital
thrombolysis patients and 11% in the primary angioplasty with prehospital
triage group. In primary angioplasty, reperfusion time categorised as earlier
and later than 2 hours, showed a significantly higher incidence of aborted
myocardial infarction in the early treatment group. A shorter time to treatment
and lower ST elevation were independent variables for aborted myocardial
infarction.
Conclusion: Both prehospital thrombolysis and primary angioplasty with pre-
hospital triage is associated with abortion of myocardial infarction, showing
comparable reperfusion times. In the case of primary angioplasty a significant-
ly higher incidence of aborted myocardial infarction is seen in patients treated 
within 2 hours after symptom onset.
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8.2 Introduction
Reperfusion therapy in acute ST elevation myocardial infarction is aimed at
restoration of coronary flow. To abort an ongoing acute ST-elevation myocar-
dial infarction may be regarded as the ultimate goal of treatment. The charac-
teristics of aborted myocardial infarction are early improvement of ECG-
changes combined with a less than 2 times rise of the cardiac enzymes creatine
kinase or creatine kinase-MB. Earlier we reported a three times higher rate of
aborted myocardial infarction in a group of patients treated by prehospital
thrombolysis compared to another group treated in-hospitally.
1
Aborted
myocardial infarction has an excellent prognosis and is probably associated
with early treatment. This concurs with the results of the meta-analysis of
thrombolytic trials, which favours the golden  first hour of treatment.
2
Although there are many reports of the benefit of primary angioplasty com-
pared to thrombolytic treatment,
3-5
abortion of myocardial infarction has rarely
been mentioned in the literature of primary angioplasty. One of the reasons
could be the longer time to treatment of primary angioplasty compared to pre-
hospital thrombolysis. Combining prehospital infarct triage with angioplasty
has reduced door to balloon times considerably and could make time to treat-
ment comparable to in-hospital thrombolysis. 
The incidence of aborted myocardial infarction in a group of patients treated
early with primary angioplasty may affirm the concept of abortion of myocar-
dial infarction. 
In prehospital thrombolysis, a shorter time to treatment, lower ST elevation and
a history of pre-infarct angina are independent variables for the incidence of
aborted myocardial infarction.
6
In this paper we report the reperfusion times
using a prehospital thrombolysis strategy and a strategy using primary angio-
plasty with prehospital triage. Furthermore, the incidence of aborted myocar-
dial infarction in the two populations of patients is assessed and correlated with
the (estimated) reperfusion time in the two populations. 
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8.3 Patients and methods
Prehospital thrombolysis group
Data were reviewed of 562 patients diagnosed with acute ST-segment elevation
myocardial infarction and treated prehospitally from 1994 until 2000 in the
cities of Nijmegen and Rotterdam, The Netherlands. In Nijmegen, a cardiolo-
gist-assisted diagnosis of transtelephonic transmission of ECG s from the
ambulance to the CCU was used. In Rotterdam, a computer-assisted method in
the ambulance was applied. The ambulance crew, or a general practitioner,
treated patients, after checking indications and contraindications. In Nijmegen,
patients were given sublingual nitroglycerin, oral aspirin and a bolus of
anistreplase intravenously. In Rotterdam, patients were treated with sublingual
nitroglycerin, oral aspirin and intravenous streptokinase. From 1999 onwards
both cities used double bolus reteplase instead of anistreplase or streptokinase.
For this analysis data derived from patients between 20 and 81 years at pres-
entation were used (n=545).
Primary angioplasty group
From November 1998 until December 2000 in the city of Zwolle 284 patients
between 20 and 81 years with chest pain underwent prehospital triage by the
ambulance crew, using a computer-assisted method. Where the computer crite-
ria for ST-elevation myocardial infarction were met (see below), patients were
treated with 900 mg of aspirin and 10,000 IU of heparin intravenously, and
transported to hospital for immediate angioplasty. For this analysis, patients
with out-of-hospital cardiac arrest and ischaemic times longer than 13 hours
(n=21) were excluded, leaving 263 patients for use.
ECG-criteria of both populations
For prehospital thrombolysis an ST-segment rise of at least 0.1 mV in at least
two consecutive leads of leads II, III and aVF was necessary, or more than 0.2
mV ST elevation in more than 2 precordial leads. For primary angioplasty the
same prehospital criteria were stipulated, with ST elevation in I, II, III and aVF
plus ST depression V1-V6 exceeding 0.5 mV.
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TIMI-risk score
To describe the risk profile of the two populations, a modified TIMI-risk score
7
was used (weight was excluded because of lack of data). Since cardiogenic
shock is not assessed in this risk score, Killip class 3 and 4 were noted sepa-
rately. Parameters are scored and weighed in such a way that age over 75 years
and systolic blood pressure lower than 100 mm Hg are scored as 3 points, age
from 65-74, heart rate more than 100 beats a minute and Killip class II-IV
scored as 2 points, and anterior infarction, a history of prior infarction, hyper-
tension, diabetes and time to treatment later than 4 hours scored as 1 point. 
Abortion of myocardial infarction
The diagnosis of aborted myocardial infarction was made if the following con-
ditions were met: (1) the combination of chest pain and ECG changes suggest-
ed transmural ischaemia before treatment, and (2) a rise in creatine kinase or
creatine kinase-MB-fraction more than two times the normal value failed to
appear after treatment, and (3) the cumulative ST-segment elevation and
depression decreased to less than 50% of the value at presentation within 2
hours after treatment. Unjustified thrombolysis was defined as a rise of crea-
tine phosphokinase less than 2 times the upper level of normal, and no change
in the ST-segment elevation on the ECG at presentation during 48 hours fol-
lowing thrombolytic therapy. Unjustified diagnosis of myocardial infarction
for primary angioplasty was defined by normal coronary arteries, or, in the case
of an open vessel at angiography, no shift in ST-segment elevation, combined
with a lack of enzyme rise larger than twice the normal range. 
Time to reperfusion
For the supposed reperfusion time in the prehospital thrombolysis group a 60-
minute interval was added to the time to treatment of each patient. For the
reperfusion time of the primary angioplasty group the time from onset of symp-
toms to balloon dilatation of the infarct related vessel was taken.
Statistical methods
Statistical analysis was performed by standard methods, comparing the base-
line characteristics of two groups by means of the Student t test and frequen-
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cies in each group by means of Chi-squared analysis. In the database of patients
treated with primary angioplasty, a stepwise logistic regression analysis was
used to test the incidence of aborted myocardial infarction against time to treat-
ment, prior myocardial infarction, hypertension, smoking habit at presentation,
diabetes, anterior myocardial infarction, Killip class greater than 1, TIMI-risk
score, systolic blood pressure and heart rate at presentation.
8.4 Results
Prehospital thrombolysis
In the prehospital thrombolysis group 17 (3%) patients were retrospectively
diagnosed as having received unjustified therapy. These patients were exclud-
ed from analysis.  Table 8.4-1 shows the characteristics of patients treated with
prehospital thrombolysis, excluding these patients. Table 8.4-2 shows the esti-
mated time to reperfusion, together with the number of patients fulfilling the
criteria of aborted myocardial infarction. The incidence of abortion of myocar-
dial infarction associated with prehospital thrombolysis was 16%.
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Table 8.4-1. Baseline characteristics of patients treated with prehospital thrombolysis
(unjustified therapy excluded)
Characteristic Prehospital thrombolysis
(n=545 )
Age (year) 61.4 + 11.9
Men (n, %) 393 (72.1)
Anterior infarction (n, %) 223 (40.9)
Previous infarction (n, %) 79 (14.5)
Diabetes (n,%) 49 (9.0)
TIMI-risk score 2.9
 ST-segment (mV) 1.7
Killip class 3 & 4 at
presentation (n, %)
15 (2.8)
Primary angioplasty with prehospital triage
In the primary angioplasty group 27 patients (10.3%) did not have an acute ST-
segment elevation myocardial infarction, either on arrival at hospital, or from
findings at angiography, contrary to the prehospital computer analysis. These
patients were excluded from the study. Table 8.4-3 shows the characteristics of
the patients treated with primary angioplasty, excluding those patients just
mentioned. Table 8.4-4 shows the time to reperfusion, and the number of
patients fulfilling the criteria of aborted myocardial infarction. The incidence
of abortion of myocardial infarction associated with primary angioplasty is
11%.
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Table 8.4-2. Reperfusion times and outcome of patients treated with prehospital thrombolysis
Prehospital thrombolysis
(n=545 )
Time to reperfusion (min)
median
mean + SD
150
182 + 99
Aborted myocardial
infarction (n, %)
87 (16.0)
Haemorraghic
stroke (n, %)
10 (1.8)
30 day mortality (n, %) 38 (7.0)
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Table 8.4-3. Baseline characteristics of patients treated with primary angioplasty (unjustified
therapy excluded)
Characteristic Primary angioplasty;
prehospital triage
(n=236)
Age (year) 61.4 + 11.8
Men (n, %) 169 (71.6)
Anterior infarction (n, %) 111 (47.0)
Previous infarction (n, %) 22 (9.3)
Diabetes (n, %) 27 (11.4)
TIMI-risk score 2.5
 ST-segment (mV) 2.0
Killip 3 & 4 at presentation
(n, %)
13 (5.5)
Table 8.4-4. Reperfusion times and outcome of patients treated with primary angioplasty
Primary angioplasty;
prehospital triage
(n=236)
Time to reperfusion (min)
median
mean + SD
170
209 + 125
Aborted myocardial infarction
(n, %)
26 (11.0)
Haemorraghic
stroke (n, %)
0
30 day mortality (n, %) 10 (4.2)
Outcome according to reperfusion time
The patients were divided into two groups, showing time to reperfusion short-
er or longer than 2 hours. The percentage of patients (about 23%) being reper-
fused within 2 hours after onset of pain was the same in both groups (table 8.4-5). 
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Table 8.4-5. Reperfusion time
All patients Reperfusion
time
< 2 hours
n (%)
Reperfusion
time
> 2 hours
n (%)
Reperfusion
time
unknown
n (%)
p value
Prehospital
thrombolysis
545 126 (23.1) 415 (76.1) 4 (0.7)
Primary
angioplasty;
prehospital
triage
236 54 (22.9) 175 (74.2) 7 (3.0)
0.99
Table 8.4-6. Thrombolysis patients, divided into early and late time to reperfusion (= time to
treatment + 60 minutes)
Prehospital
thrombolysis
All patients
n=545
Reperfusion
time
< 2 hours
n = 126 (23.1)
Reperfusion
time
> 2 hours
n = 415 (76.1)
Reperfusion
time
unknown
n = 4 (0.7)
p
Haemorrhagic
Stroke
(n,%)
10 (1.8) 1 (0.8) 9 (2.2) 0 0.53
Aborted MI
(n,%)
87 (16.0) 26 (20.6) 60 (14.5) 1 (25.0) 0.13
30 day
mortality
(n,%)
38 (7.0) 5 (4.0) 33 (8.0) 0 0.18
Table 8.4-6 gives the clinical results of patients treated with prehospital throm-
bolysis, and table 8.4-7 those with primary angioplasty, divided according to 
the time to reperfusion. In the prehospital thrombolysis group the median time
to reperfusion of the patients having an aborted myocardial infarction was 78
minutes (mean 114 minutes, ranging from 6 to 557 minutes). In the primary
angioplasty group the median time to reperfusion was 115 minutes (mean 138
minutes, ranging from 61 to 344 minutes). There was no significance in stroke,
or in 30-day mortality in early and late reperfusion groups in both the throm-
bolysis and the primary angioplasty populations, although former showed a
trend to a lower mortality in the early reperfusion group. Aborted infarction is
significantly higher in the early angioplasty group.
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Table 8.4-7. Primary angioplasty patients, divided into early and late reperfusion
Primary
angioplasty;
prehospital
triage
All patients
n = 236
Reperfusion
< 2 hours
n = 54 (22.9)
Reperfusion
> 2 hours
n = 175 (74.2)
Unknown
n = 7 (3.0)
p
Haemorrhagic
stroke
n
0 0 0 0 1.00
Aborted MI
(n,%)
26 (11.0) 13 (24.1) 12 (6.9) 1 (14.3) 0.0004
30 day
mortality
(n,%)
10 (4.2) 3 (5.6) 6 (3.4) 1 (14.3) 0.76
Tables 8.4-8 and 8.4-9 show the clinical and angiographic characteristics of
aborted infarctions compared with the established infarctions in both throm-
bolysis and primary angioplasty populations. Apart from a lower median time
to treatment in aborted myocardial infarctions in both groups, patients showed
no other differences.
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Independent variables of aborted myocardial infarction and primary angio-
plasty
A stepwise logistic regression analysis, showed in table 8.4-10, that time to
treatment and a lower ST-segment elevation on the presenting ECG are inde-
pendent variables of aborted myocardial infarction.
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Table 8.4-10 Regression analysis for prediction of aborted myocardial infarction in
primary angioplasty.
p odds ratio 95% confidence intervals
Reperfusion > 2 hours 0.005 0.237 0.087 – 0.643
ST-deviation > 1.0 mV 0.011 0.282 0.106 – 0.749
Table 8.4-9. Characteristics at coronary angiography
Primary angioplasty
n = 236
Prehospital thrombolysis
n = 545
Aborted
Infarction
n = 26
Established
infarction
n = 210
Aborted
infarction
n = 87
Established
infarction
n = 458
Coronary
angiography
performed (n,%)
 no significant
disease
 1 vessel
 2 vessel
 3 vessel
 mainstem
 not available
26 (100)
0
11 (42.3)
10 (38.5)
5 (19.2)
0
-
210 (100)
1 (0.5)
95 (45.2)
64 (30.5)
48 (22.9)
2 (1.0)
-
55 (63.2)
4 (7.3)
28 (50.9)
13 (23.6)
9 (16.4)
0
1 (1.8)
187 (40.8)
4 (2.1)
76 (40.6)
48 (25.7)
38 (20.3)
7 (3.7)
14 (7.5)
8.5 Discussion 
This is the first study to assess the differences in time to reperfusion in pre-
hospital thrombolysis and primary angioplasty with prehospital triage in acute
ST elevation myocardial infarction. Both prehospital thrombolysis and primary
angioplasty with prehospital triage resulted in short reperfusion time, with
about 23% of patients reperfused within 2 hours. This is considerably shorter
than reported in the National Registry of Myocardial Infarction, with 27,080
patients treated with primary angioplasty, a median time from onset of chest
pain to hospital arrival of 1.6 hours and the median time from pain onset to
angioplasty of 3.9 hours.
8
Recently, a meta-analysis of 23 trials randomising
hospital thrombolysis and primary angioplasty was published.
9
Time to reper-
fusion varied from 4.0 to 4.6 hours with primary angioplasty and time to treat-
ment form 3.0 to 4.1 hours with thrombolysis, all much longer than our results.
There is no doubt that the prehospital triage is responsible for these short treat-
ment times. 
Time to reperfusion and outcome
The advantages and disadvantages of mechanical reperfusion therapy are well
known. The alternative of prehospital thrombolysis and rescue angioplasty are
recommended as combining the convenience of the former with the higher
reperfusion rate of the latter.
10,11
A recently published meta-analysis of clinical
outcomes of 1302 patients treated with primary angioplasty and 1333 treated
with in-hospital thrombolytic therapy showed a lower cardiac event rate in the
primary angioplasty group.
12
The event rate of the patients treated with throm-
bolysis depends on the time of presentation at the hospital. However, the event
rate of the patient group being treated with primary angioplasty does not seem
to be time dependent. This difference is partially explained by the fact that
angioplasty restores epicardial blood flow regardless of time to presentation,
contrary to thrombolysis which is less effective in achieving patency after 2 to
4 hours after symptom onset.
12
In the above-mentioned meta-analysis, only
patients with in-hospital thrombolysis and primary angioplasty without pre-
hospital triage were compared. The authors correctly state in their discussion
that patients actually undergoing reperfusion time in the first 1 to 2 hours after
onset of symptoms are an exception, and that the number of patients treated
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very early in their study is too small to allow analysis.
12
Abortion of myocardial infarction 
In the angioplasty group, patients are included on the basis of an ECG with ST-
segment elevation; some are excluded because of angiographic results. In the
thrombolysis group, patients are also included on the basis of the ECG, but
some are excluded on clinical grounds. Obviously, this affects the structure of
the groups, making them difficult to compare. Nevertheless, abortion of
myocardial infarction is not confined to thrombolytic treatment; it is also asso-
ciated with primary angioplasty of acute myocardial infarction. In thrombolyt-
ic therapy, abortion of myocardial infarction is not confined to the early treat-
ment group, which can be explained by stuttering of the infarction, which has
been described earlier.
13
Abortion of myocardial infarction is significantly more
frequent in the patients treated with primary angioplasty within 2 hours after
symptom onset, which can be explained by early and complete opening of the
infarct-related vessel. 
Aborted infarction is rarely mentioned in the primary angioplasty literature.
One report comparing primary angioplasty with in-hospital thrombolysis in
acute myocardial infarction mentioned two patients in an angioplasty group of
109 patients and one patient in a fibrinolysis group of 111 patients as having no
rise in enzymes,
5
while all the other patients had an enzyme profile typical of
acute myocardial infarction. This percentage is rather low, even compared with
a 4% aborted infarction rate in a hospital treatment group.
1
Apart from time to reperfusion, a lower amount of ST elevation is an inde-
pendent predictor of aborted myocardial infarction in the primary angioplasty
group. As has been reported earlier, in the group treated with prehospital
thrombolysis time to treatment, a lower amount of ST elevation and pre-infarct
angina were reported as independent variables.
6
One must realise that the
amount of ST elevation is not a sensitive predictor of the area at risk.
Nevertheless, it is likely that timely opening of an occluded coronary artery
will result in preservation of myocardial tissue only if the area at risk is not too
extensive.
Looking at the data of patients divided into early and late treatment groups it
seems there are two kinds of aborted myocardial infarction: one by early and
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complete reperfusion, the other by intermittent occlusion or late occlusion
accompanied by collateral blood flow, which protects myocardial tissue at risk
(stuttering infarction). Early, (prehospital) thrombolysis induces the former,
and early angioplasty the latter. 
Study limitations
This study is not a comparison between primary angioplasty and prehospital
thrombolysis. Only a prospective randomised study will be able to reveal dif-
ferences or agreement in the incidence of aborted myocardial infarction in
these two groups. However, the findings observed in our two groups can pave
the way for such a study. Time to reperfusion by thrombolysis was more or less
arbitrarily chosen by adding 60 minutes to the time to treatment from symptom
onset. Adding 90 instead of 60 minutes results in a reperfusion time of 160
minutes with prehospital thrombolysis. The total number of aborted myocardial
infarctions will then not change of course, but their percentage in early reper-
fusion group will be lower. 
One of the pitfalls of the diagnosis of aborted myocardial infarction is the
administration of thrombolytic therapy in the absence of ST-segment elevation
myocardial infarction (unjustified fibrinolysis); both have the absence of a rise
in cardiac enzymes in common. Although the specificity of computer-assisted
or cardiologist-assisted electrocardiographic diagnosis of ST elevation myocar-
dial infarction is high,
14
unjustified fibrinolysis is mentioned in the literature of
thrombolysis only in 1-2.5% of cases.
15,16
Patients for primary angioplasty are referred to the intervention centre from a
larger region than those for prehospital thrombolysis, so the reperfusion time
for primary angioplasty can be confounded by longer transport times.
Nevertheless, the symptom-to-balloon times of the Zwolle group are shorter
than those mentioned in the literature, making a comparison with prehospital
thrombolysis in agreement with the real world.
8.6 Conclusion
Both prehospital thrombolysis and primary angioplasty for ST-segment eleva-
tion myocardial infarction are associated with abortion of myocardial infarc-
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tion in a considerable number of patients. With primary angioplasty aborted
myocardial infarction was especially evident in the patient group treated with-
in 2 hours, with time to reperfusion < 2 hours and a lower amount of ST-ele-
vation as independent predictors. This outcome underlines the importance of
early treatment with prehospital triage when choosing between primary angio-
plasty or prehospital thrombolysis. 
8.7 References
1. Lamfers EJP, Hooghoudt THE, Uppelschoten A, Stolwijk PWJ, Verheugt
FWA. Effect of prehospital thrombolysis on aborting acute myocardial
infarction. Am J Cardiol 1999;84:928-930
2. Boersma E, Maas ACP, Dekkers JW, Simoons ML. Early thrombolytic
treatment in acute myocardial infarction: reappraisal of the Golden Hour.
Lancet 1996;348:771-775.
3. Zijlstra F, Hoorntje JCA, De Boer M-J, Reiffers S, Miedema K,
Ottervanger JP, Van t Hof AWJ, Suryapranata H. Long-term benefit of
primary angioplasty as compared with thrombolytic therapy for acute
myocardial infarction. N Engl J Med 1999;341:1413-1419.
4. Ross AM, Coyne KS, Reiner JS, Greenhouse SW, Fink C, Frey A, Moreyra
E, Traboulsi M, Racine N, Riba AL, Thompson MA, Rohrbeck S,
Lundergan CF. A randomized trial comparing primary angioplasty with a
strategy of short-acting thrombolysis and immediate planned rescue
angioplasty in acute myocardial infarction. J Am Coll Cardiol
1999;34:1954-1962.
5. Garcia E, Elizaga J, Perez-Castellano N, Serrano JA, Soriano J, Abeytua
M, Botas J, Rubio R, Lopez de sa E, Lopez-Sendon JL, Delcan JL. Primary
angioplasty versus systemic thrombolysis in anterior myocardial infarc-
tion. J Am Coll Cardiol 1999;33:605-611.
-136-
Chapter 8                                                                                                                    PCI
6. Lamfers EJP, Hooghoudt TEH, Hertzberger DP, Schut A, Stolwijk PWJ,
Verheugt FWA. Abortion of acute st-segment elevation myocardial infarc-
tion after reperfusion therapy. Heart 2003; 89:469-501.
7. Morrow DA, Atman EM, Charlesworth A, Cairns R, Murphy SA, De
Lemos JA, Gugliano RP, McCabe CH, Braunwald E. TIMI-risk score for
ST-elevation myocardial infarction: a convenient, bedside, clinical score
for risk assessment at presentation. Circulation 2000;102:2031-2037.
8. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ,
Gore JM, Weaver WD, Rogers WJ, Tiefenbrunn AJ. Relationship of symp-
tom-onset-to-balloon time with mortality in patients undergoing angio-
plasty for acute myocardial infarction. JAMA 2000;283:2914-2917.
9. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction: a quantitive review
of 23 randomised trials. Lancet 2003;361:13-20.
10. Oude Ophuis AJM, Vermeer F, Vd Berg EJ, Brunninkhuis LG, Werter CJ,
Boehmer AG, Lousberg AH, Dassen WR, B r FW. Prospective ran-
domised comparison between thrombolysis, rescue PTCA and primary
PTCA in patients with extensive myocardial infarction admitted to a hos-
pital without PTCA facilities. Heart 1999;82:426-431.
11. Loubeyre C, Lefevre T, Louvard Y, Dumas P, Piechaud J-F, Lanore J-J,
Angellier J-F, Le Tarnec J-Y, Karrillon G, Margent A, Pouges C, Morice
M-C. Outcome after combined reperfusion therapy for acute myocardial
infarction, combining prehospital thrombolysis with immediate percuta-
neous coronary intervention and stent. Eur Heart J 2001;22:1128-1135.
12. Zijlstra F, Patel A, Jones M, Grines CL, Ellis S, Garcia E, Grinfeld L,
Gibbons RJ, Ribeiro EE, Ribichini F, Granger C, Akhras F, Weaver WD,
Simes RJ. Clinical characteristics and outcome of patients with early (<2
h), intermediate (2-4 h) and late (4 h) presentation treated with primary
coronary angioplasty or thrombolytic therapy for acute myocardial infarc-
-137-
Chapter 8                                                                                                                    PCI
tion. Eur Heart J. 2002;23:550-557.
13. Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlu-
sion in acute myocardial infarction. N Engl J Med 1987;317:1055-1059.
14. Kudenchuk PJ, Ho MT, Weaver WD. Accuracy of computer-interpreted
electrocardiography in selecting patients for thrombolytic therapy. J Am
Coll Cardiol 1991;17:1486-91.
15. Khoury NE, Borzak S, Gokli A, Havstad SL, Smith ST, Jones M.
Inadvertent thrombolytic administration in patients without myocardial
infarction: clinical features and outcomes. Ann Emerg Med 1996;28:289-93.
16. Schreiber WS. Pieper O, Herkner H, Laggner AN, Huber K. Unjustified
thrombolysis in patients with suspected myocardial infarction. Wien Klin
Wochenschr 2000;112:912-16.
-138-
CHAPTER 9
PREHOSPITAL THROMBOLYSIS WITH RETEPLASE; 
THE NIJMEGEN/ROTTERDAM STUDY
Evert J.P. Lamfers, MD 1
Astrid Schut, MSc 1
Ton E.H. Hooghoudt, MD 1
Don P. Hertzberger, MD 1
Eric Boersma, PhD 2
Maarten L. Simoons, MD 2
Freek W.A. Verheugt, MD 3
From the Departments of Cardiology of the 
1 Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands, the 
2 Heartcenter, Academic Hospital Dijkzigt, Rotterdam, The Netherlands and the
3 Heartcenter, University Hospital St Radboud, Nijmegen, The Netherlands.
Accepted for publication in the American Heart Journal.
-139-
Chapter 9                                                                                                            Reteplase
9.1 Abstract
Objective: The objective of this observational study was to assess time from
ECG-diagnosis to treatment and time from pain onset to treatment of double
bolus reteplase compared to current therapy with streptokinase or bolus anistre-
plase in two cities (Rotterdam and Nijmegen) in the Netherlands, where pre-
hospital thrombolysis is an established way of treatment of acute myocardial
infarction. 
Methods: Prehospital thrombolysis is performed using ECG-diagnosis by the
ambulance service and bolus anistreplase for treatment in Nijmegen and strep-
tokinase infusion in Rotterdam. Reteplase or anistreplase/streptokinase was
assigned open label to patients according to order of presentation on a 1 to 1
basis. All patients were treated with nitrates sublingually and aspirin orally.
Time intervals were recorded by the ambulance staff. 
Results: In total 250 patients were treated between April 1, 1999 and August
1, 2000. Reteplase was used in 120 patients and anistreplase/streptokinase in
130 patients. Using double bolus reteplase resulted in a significantly shorter
time of treatment of a median of 81 minutes compared to a median of 104 min-
utes with the established therapy (p<0.0001). There were no differences in
mortality, aborted myocardial infarction, hemorrhagic stroke and the need for
rescue angioplasty in both groups. 
Conclusion: In prehospital thrombolysis double bolus reteplase is associated
with a shorter time to treatment than bolus anistreplase or infusion of streptok-
inase. 
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9.2 Introduction
In the development of new thrombolytic agents for acute myocardial infarction
much emphasis is put on the patency of the infarct artery and the speed of
reperfusion. Reteplase (rPA) is a mutant of the first generation recombinant
plasminogen activator rt-PA. It has a prolonged half-life of 18 minutes, which
permits administration as a double bolus 30 minutes apart. Its clinical and
angiographical efficacy is comparable to front-loaded rt-PA.
1-3
Because of its
bolus administration, reteplase is a favorable thrombolytic to be used in pre-
hospital thrombolysis. Therefore, in the cities of Rotterdam and Nijmegen,
where prehospital diagnosis and treatment is already an established strategy of
therapy, and where time to treatment is reduced with a median of 1 hour com-
pared to in-hospital treatment,
4
reteplase was introduced. 
We performed an observational study to compare prehospital reteplase to the
current prehospital treatment of bolus anistreplase in Nijmegen and intra-
venous streptokinase infusion in Rotterdam. The principal endpoint of the
study was the further reduction of the time gain using treatment with bolus
reteplase, compared with established prehospital therapy. Furthermore, the
incidence of mortality, haemorrhagic stroke, rescue angioplasty, and aborted
myocardial infarction was investigated. 
9.3 Patients and methods
Two cities in The Netherlands, Rotterdam and Nijmegen, have extensive expe-
rience in treating acute ST-segment elevation myocardial infarction with pre-
hospital administered thrombolysis. Nijmegen started this program in 1987,
Rotterdam in 1988. Nijmegen uses transtelephonic transmission of ECG for
diagnosis and intravenous bolus anistreplase for treatment. Rotterdam uses a
computerized ECG for diagnosis and streptokinase infusion for treatment.
Differences and similarities of their schemes are showed in table 9.3-1. Time
intervals were noted by the ambulance staff on specially designed charts.  Time
from pain onset to treatment was deducted from the patient history and the
moment the treatment was administrated by the ambulance staff.
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For this study reteplase or anistreplase in Nijmegen and reteplase or streptoki-
nase in Rotterdam was assigned open-label and one to one in order of presen-
tation. All patients treated in both cities received nitrates sublingually and
aspirin orally. No heparin was given before prehospital treatment of either
agent. 
The Nijmegen patients were transported to one of the two city hospitals; the
Rotterdam patients were admitted to one of eight hospitals in that region. All
reteplase patients received 5000 U of bolus heparin i.v. immediately after hos-
pital arrival, followed by heparin infusion. Names of the patients treated were
given by both ambulance services, regardless of the diagnosis at discharge. 
Rescue angioplasty was done at the discretion of the attending cardiologist, if
there were no clinical signs of reperfusion within 2 hours after start of the treat-
ment. 
A diagnosis of aborted myocardial infarction was reached as follows: 1) when
the combination of chest pain and transient ECG changes suggested transmur-
al ischaemia, and 2) a rise in creatine kinase or creatine kinase-MB-fraction
more than double the normal value failed to appear, and 3) the cumulative ST-
segment elevation and depression decreased to less than 50% of the value at
presentation within 2 hours of treatment.4 Fibrinolysis was considered to be
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Table 9.3-1. Differences and similarities in the Nijmegen and Rotterdam prehospital
thrombolysis schemes.
Rotterdam Nijmegen
Diagnosis Computer ECG Transtelephonic
transmission
Criteria ST-elevation in
at least 2 subsequent leads
> 0.6 or 0.8 mV* > 0.6 mV**
Conventional fibrinolysis 1.5 million U streptokinase
infusion
30 mg anistreplase bolus
iv
* dependent on age: > 0.6 mV in patients younger than 70 years, > 0.8 mV in patients
younger than 80 years
** no age restriction.
unjustified  when 1) creatine phosphokinase levels remained less than twice
the upper level of normal, and 2) the ST elevation on the ECG at presentation
did not change during 48 hours following thrombolytic therapy. 
Statistical analysis was performed by standard methods, comparing the base-
line characteristics of two groups by means of the Student t test and frequen-
cies in each group by means of chi-square analysis. The time intervals of both
groups were compared using the Wilcoxon rank test. The level of significance
used was 5%.
9.4 Results
A total of 250 patients were included between April 1, 1999 and August 1,
2000. Reteplase was used in 120 patients, and 130 patients were treated with
anistreplase or streptokinase. Of these 250 patients 132 were treated in
Nijmegen and 118 in Rotterdam. Table 9.4-1 gives the results of the baseline
characteristics of the reteplase and the anistreplase/streptokinase group. Age,
sex, infarct location, risk factors and details of presentation were similar in both
groups. 
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Table 9.4-2 shows that there is a significant difference in time to treatment with
reteplase in comparison to therapy using anistreplase or streptokinase. The
median time from arrival of ambulance to treatment was 27 minutes in the
streptokinase group and 12 minutes in the reteplase group. The median time
from ECG-diagnosis to administration of thrombolysis was 18 minutes in the
streptokinase group and 7 minutes in the reteplase group. The total time to
treatment, from pain onset to thrombolysis, was 104 minutes in the streptoki-
nase and 81 minutes in the reteplase group. From the patients treated with
streptokinase or anistreplase, 21% were treated within 1 hour; this was 27% in
the patient group treated with reteplase. 
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Table 9.4-1. Basic characteristics of both groups
Streptokinase/
anistreplase
n = 130
Reteplase
n = 120
p
Age (mean, years) 61.9 62.5 0.70
Men, n (%) 86 (66) 78 (65) 0.85
Infarct site, n (%)
 anteroseptal
 inferior
 inferior + right
ventricle
 other
45 (35)
38 (29)
41 (31)
6 (5)
53 (44)
32 (26)
30 (25)
5 (4 )
0.16
0.15
0.15
0.90
Risk factors, n (%)
 hypertension
 prior myocardial
infarction
 current smoker
 diabetes
32/130 (25)
15/130 (12)
67/125 (54)
13/130 (10)
30/118 (25)
20/120 (17)
61/119 (51)
12/120 (10)
0.94
0.24
0.63
1.00
Presentation
 heart rate
(beats/min)
 systolic blood
pressure (mm Hg)
 diastolic blood
pressure (mm Hg)
 Killip class
II-IV (n,%)
77
128
73
16 (12)
75
130
76
9 (8)
0.49
0.66
0.18
0.21
Thrombolytic therapy, n
 anistreplase
 streptokinase
 reteplase
67
63
---
---
---
120
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Table 9.4-3. Time intervals of established prehospital therapy.
symptoms
-
arrival of
GP
median,
mean+sd
arrival of
GP
–
alarm
median,
mean+sd
alarm
–
arrival of
ambulance
median,
mean+sd
arrival of
ambulance
-
ECG
diagnosis
median,
mean+sd
ECG
diagnosis
–
thrombolysis
median,
mean+sd
preparation
for transport
median,
mean+sd
transport
time to
hospital
median,
mean+sd
streptokinase
n = 63
55
78 + 85
12
15 + 18
11
10 + 3
8
9 + 9
16
17 + 8
10
11 + 8
10
9 + 4
anistreplase
n = 67
55
73 + 68
12
12 + 7
10
10 + 4
9
9 + 3
19
19 + 7
10
9 + 7
10
9 + 5
Table 9.4-3 gives the time intervals of 63 patients, treated with streptokinase
infusion and 67 patients with bolus anistreplase, showing no difference
between either therapies.
Table 9.4-4 shows that the incidence of aborted myocardial infarction does not
differ between therapy with reteplase and conventional therapy. There is a trend
towards a higher use of rescue angioplasty in the reteplase group. Also, all
adverse events together, i.e. 30-day mortality, stroke and rescue angioplasty,
did not reach a statistical significant difference in both groups.
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Table 9.4-4. Differences in the use of anistreplase/streptokinase or reteplase in prehospital
thrombolysis.
streptokinase/
anistreplase
n = 130 (%)
reteplase
n = 120 (%)
p
Time to treatment
(minutes)
median
mean + sd
104
122 + 78
81
108 + 78
0.04
Aborted
myocardial
infarction, n (%)
20 (15.4) 22 (18.3) 0.53
30-day mortality,
n (%)
6 (4.6) 8 (6.7) 0.48
Stroke
(haemorrhagic),
n (%)
1 (0.8) 2 (1.7) 0.52
Rescue
angioplasty, n (%)
11 (8.5) 17 (14.2) 0.15
Table 9.4-5 gives the final diagnosis of all patients. In 8 patients (3.2%) throm-
bolysis was unjustified. Most of the patients who underwent angiography had
1 vessel disease; in 3 patients (1.2%) no significant stenosis was present, 3
patients (1.2%) had main stem stenosis.
9.5 Discussion
This study shows that treatment of acute myocardial infarction with reteplase
in a prehospital setting seems to be faster than the conventional therapy using
anistreplase or streptokinase. The difference is apparent in the time from symp-
tom onset to treatment, but also in the time interval between ECG-diagnosis
and administration of thrombolysis. There is no difference in time to treatment
using bolus anistreplase or infusion of streptokinase. Streptokinase has to be
prepared in an infusion form and anistreplase has to be dissolved very careful-
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Table 9.4-5. Final diagnosis of patients in both groups
streptokinase/
anistreplase
n = 130 (%)
reteplase
n = 120 (%)
Development of new Q-
waves, n (%)
No development of new
Q-waves, n (%)
Aborted myocardial
infarction, n (%)
Unjustified fibrinolysis,
n (%)
85 (65.4)
21 (16.2)
20 (15.4)
4 (3.1)
78 (65.0)
16 (13.3)
22 (18.3)
4 (3.3)
Angiography performed,
n (%)
 no significant
disease
 1 vessel
 2 vessel
 3 vessel
 main stem stenosis
63 (48.5)
2 (3.2)
23 (36.5)
24 (38.1)
12 (19.0)
2 (3.2)
53 (44.2)
1 (1.9)
25 (47.2)
12 (22.6)
14 (11.7)
1 (1.9)
ly to prevent foam formation. Both properties possibly cause delays in admin-
istration in prehospital situations. The bolus administration of reteplase does
not have these disadvantages, probably an explanation of the difference in time
to treatment. Most of the time intervals are shorter in the reteplase group,
although these differences did not reach significance. The shorter intervals of
time from alarm to the arrival of the ambulance and from their arrival to ECG
diagnosis may be explained by the open nature of the study. However, the dif-
ference in time intervals before the ambulance arrived clearly can not, because
the patient nor the general practitioner were informed about the nature of the
thrombolytic drug that was going to be used in the event of an acute myocar-
dial infarction. The difference of a median of 23 minutes in favor of reteplase
seems to be large, but is mentioned in the literature before: using bolus
reteplase rather than an intravenous rt-PA was associated with a median time
gain of 17 minutes in a study of 500 in-hospital treated patients.
5
A prehospital
study using reteplase
6
(TIMI-19) found a median time between arrival of the
ambulance service and administration of the medication of 31 minutes and a
time gain of a median of 33 minutes compared with in-hospital therapy. 
Our study focused on time to treatment and is not powered to discern differ-
ences in clinical outcome. However, clinical outcome is likely to be better in
early treated patients, as has been showed in meta-analyses of time to treat-
ment
7
and of prehospital versus in-hospital thrombolysis.
8
This was also appar-
ent in angiographic results of thrombolysis: recently published data from the
TIMI 14 and InTime-II study showed that in patients treated with different
reperfusion regiments (reteplase, alteplase, lanoteplase combined with abcix-
imab) the development of TIMI 3 flow was related to time to treatment and not
to the thrombolytic agent used. 
9
Aborted myocardial infarction is not confined to the use of streptokinase in pre-
hospital thrombolysis, as has been shown before
4
, but is also apparent in the
reteplase group. The TIMI-19 prehospital study of reteplase found 29% of
patients showing 50% resolution of their elevated ST-segments by the time
these patients arrived at the emergency room, and over 70% of ST segment res-
olution in 15% of patients,
6
similar to the 15% and 18% of aborted myocardial
infarction in our two therapy groups. 
Although the 30-day mortality in our study is the same as in-hospital reg-
istries,
10-12
it is important to note that a prehospital strategy selects patients who
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present early and with explicit ST-segment changes, both aspects characteristic
of a large infarction.
The incidence of stroke of 1.6% (95% confidence interval 0 to 3.8%) in our
reteplase group may be higher than expected, but the figures are small. A meta-
analysis has shown that bolus treatment with thrombolytics is associated with
a risk of intracranial hemorrhage, varying between 0.6% and 1.1%, whereas in
infusion therapy this risk varies between 0.4% and 0.9%.
13
In a study compar-
ing double bolus reteplase with alteplase, intracranial hemorrhage is the same
in both treatment groups, 0.91% and 0.87% respectively.
1
Our study was obser-
vational in character, without blinded randomization, and not powered to assess
a difference in mortality or stroke between conventional and reteplase therapy.
The meta-analysis suggested that the incidence of stroke in bolus therapy is pri-
marily associated with the method of administration rather than the properties
of the drug. An association with the time to treatment (early or late) is not to be
expected, although not studied in the meta-analysis.  Bolus heparin was not
administered prehospitally in this study. It was initiated as soon as the patient
arrived at the hospital, and was, therefore, given before or at the same time of
the second bolus reteplase. Given the half-life of 18 minutes of reteplase it
seems unlikely that the administration of heparin a median of 20 minutes after
the first bolus would have changed the clinical outcome. In fact, this strategy
was also used in the recently published prehospital ER-TIMI 19 trial,
6
where
heparin was administered as soon as possible after enrolment and administra-
tion of the first bolus of reteplase, either in the field or in the hospital. 
There is a trend towards more clinical events in the reteplase group. This is
especially apparent in the incidence of rescue angioplasty, which is about 1.5
times higher in the reteplase group. Although not statistically significant, this
could be the result of the open nature of the study, in which the attending car-
diologist might choose a more liberal intervention strategy when a new
thrombolytic agent is used. However, compared to studies describing 29-35%
rescue angioplasty after failed thrombolytic therapy,
14,15
14.2% rescue angio-
plasty in our reteplase group is not unexpectedly high.
Limitations
This was not a double-blinded trial, but an observational study to assess treatment
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times using prehospital strategies. The study was not powered to discriminate
differences in mortality, intracranial hemorrhage or rescue angioplasty. 
For the sake of simplicity heparin bolus therapy was withheld prehospitally in
the reteplase group. We do not think elimination of the heparin bolus in the
reteplase group is sufficient explanation for the differences in time to treatment
in our study.
9.6 Conclusion and implications
Double bolus reteplase in prehospital thrombolysis is associated with a statis-
tically significant shorter time to treatment compared with anistreplase/strep-
tokinase. The new bolus thrombolytics, like reteplase and tenecteplase, not
only provide an equivalent efficacy with regard to 30-day mortality and bleed-
ing complications compared with established therapy
1-3,16
but also facilitate the
administration of the drug. Our study shows that the reduction of time to treat-
ment with bolus thrombolytics is considerable. This may implicate that in the
case of prehospital treatment with drugs, like thrombolytic therapy, for which
time is essential, bolus administration is preferable to infusion therapy.  
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10.1 Abstract
Background: This study investigated the incidence of abortion of myocardial
infarction and of unjustified fibrinolysis using automated versus cardiologist
assisted diagnosis of acute ST elevation myocardial infarction. The results of
prehospital diagnosis and treatment (2 cities in the Netherlands) were com-
pared to those of in-hospital treatment. Unjustified fibrinolysis must be differ-
entiated from justified thrombolysis resulting in aborted myocardial infarction.
Both have the absence of a significant rise in cardiac enzymes in common. In
aborted myocardial infarction this is a result of timely reperfusion, in unjusti-
fied thrombolysis the result of an incorrect diagnosis. 
Methods: In the city of Rotterdam 118 patients were prehospitally treated for
myocardial infarction, diagnosed using a mobile computer ECG; in the city of
Nijmegen 132 patients were treated prehospitally, using transtelephonic trans-
mission of the ECG to the CCU and judged by a cardiologist. Their data were
compared with those of 269 patients treated in-hospital in the city of Arnhem,
using the same ECG-criteria. Abortion of myocardial infarction was diagnosed
as the absence of a significant rise in cardiac enzymes and the presence of res-
olution of chest pain and 50% of ST-segment deviation within 2 hours after
onset of therapy. Lacking these, the diagnosis of unjustified fibrinolytic thera-
py was made.
Results: Unjustified treatment occurred in 8 (3.2%) prehospitally treated
patients (4 in Rotterdam and 4 in Nijmegen). Of the in-hospitally treated
patients in Arnhem, 5 (1.9%) were treated unjustifiably (p=0.49). Aborted
myocardial infarction occurred in 15.3% and 18.2% in Rotterdam and
Nijmegen respectively, against 4.5% in in-hospital treatment in Arnhem
(p<0.001).
Conclusion: Abortion of myocardial infarction is associated with prehospital
thrombolysis. Unjustified fibrinolysis for acute myocardial infarction occurs in
prehospital fibrinolysis as frequent as in the in-hospital setting. The use of dif-
ferent ECG methods for diagnosing acute myocardial infarction does not seem
to make any difference. 
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10.2 Introduction
The importance of reducing the time between onset of pain and fibrinolysis in
patients with evolving myocardial infarction has been investigated extensive-
ly.1 Using a strategy of prehospital triage and subsequent treatment, 25% of
patients can be treated within one hour, a result not matched by in-hospital
triage and therapy.2 Considering the Reimer and Jennings experiments, where
the amount of myocardial damage brought about by temporary closure of a
coronary artery is found to be time dependant,3 the possibility of aborted
myocardial infarction suggested itself. We earlier reported that prehospital fib-
rinolysis is strongly associated with abortion of myocardial infarction.2 One of
the characteristics of aborted myocardial infarction is a rise in cardiac enzymes
less than 2 times the upper limit of normal. However, this can also be a char-
acteristic of inadvertent administration of thrombolytic therapy. The adminis-
tration of fibrinolytic therapy to patients without acute myocardial infarction
can be disastrous, as already emphasized in a few case reports from the early
days of fibrinolysis.4-7 On the other hand, failure to give fibrinolytic therapy
early after the onset of pain may deprive the patient of a potentially life saving
therapy. Unjustified administration of fibrinolysis can have undesirable med-
ical and legal repercussions, especially if paramedics or nurses in the prehos-
pital setting initiate such treatment. Two cities in the Netherlands, Rotterdam
and Nijmegen, set up a prehospital thrombolysis program, working in close
cooperation with local general practitioners and ambulance services, using dif-
ferent means of diagnosing acute infarction. 
We hypothesized that prehospital thrombolysis would result in a higher inci-
dence of aborted myocardial infarction than in-hospital treatment.
Furthermore, we expected the incidence of unjustified fibrinolysis to be the
same in both cities, and comparable to in-hospital fibrinolysis. To investigate
this, we examined all the prehospital treated patients in both cities during one
year, and compared them with patients treated in a different city (Arnhem)
where no prehospital program is operational. Consequently, our study was per-
formed to determine 1) if automated versus cardiologist-assisted ECG-diagno-
sis is associated with an increased incidence of unjustified fibrinolytic therapy
(Rotterdam versus Nijmegen and Arnhem), and 2) whether prehospital throm-
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bolysis causes an increased incidence of aborted myocardial infarction
(Rotterdam and Nijmegen versus Arnhem). 
10.3 Methods
Diagnosis
For use in prehospital thrombolysis in Rotterdam, a portable 12-lead comput-
erized ECG system is used. This is adjusted in such a way that acute myocar-
dial infarction is diagnosed if more than 0.2 mV of ST-segment elevation in >
2 precordial leads (one at least 0.3 mV) is measured, or more than 0.2 mV ST-
elevation in > 2 extremity leads (one at least 0.2 mV). Using these criteria this
computer system has a sensitivity of 60% and a specificity of 97% for detect-
ing both anterior and inferior myocardial infarction.8 Furthermore, this com-
puter system can differentiate the ST-segment elevation concave to the iso-
electric line of right bundle branch block, left ventricular hypertrophy and early
repolarisation from the ST-segment elevation convex to the iso-electric line of
acute myocardial infarction with a specificity of 98% compared to an electro-
cardiographer, albeit at the cost of a sensitivity of 52%.9 The decision to treat
the patient is made by the ambulance staff and is based on the result of the com-
puter system. In Nijmegen ECG’s of patients with chest pain are made by the
ambulance staff and transmitted to the cardiac care unit using a transtelephon-
ic data transmission system. There the diagnosis of acute myocardial infarction
is confirmed by the attending cardiologist if more than 0.2 mV of ST-segment
elevation is seen in > 2 extremity leads or more than 0.3 mV in > 2 precordial
leads. Thrombolytic therapy was given by the ambulance staff. In-hospital fib-
rinolysis in Arnhem is initiated after cardiologist confirmed ECG using the
Nijmegen criteria. These criteria have a sensitivity of 62% and a specificity of
98% for detecting both anterior and inferior myocardial infarction.10 The com-
puter ECG in Rotterdam and the ECG protocol in Nijmegen excludes patients
showing left bundle branch block or signs of Wolf-Parkinson-White syndrome.
Patients with electronic pacemakers are excluded from the prehospital diagno-
sis. In all three cities a similar checklist of contraindications for the adminis-
tration of thrombolytic therapy is used, and all patients are treated with nitro-
glycerin and aspirin before fibrinolysis is given. Intravenous heparin is started
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in all patients after hospital admission. At the time the study was conducted no
eligible patients for reperfusion were treated with primary angioplasty.
For this analysis names of treated patients were collected by the ambulance
staff in both cities using prehospital thrombolysis, or by the hospital pharma-
cist, where in-hospital fibrinolysis was given. In this way all patients treated
with fibrinolysis were included in the study, regardless of the diagnosis at hos-
pital discharge. For comparison of the 3 groups, risk factors, characteristics at
presentation and the TIMI-risk score for ST elevation myocardial infarction11
was used.
Definition of aborted myocardial infarction or of unjustified fibrinolysis (Table
10.3-1)
Absence of a significant rise in cardiac enzymes will erroneously identify a so-
called aborted myocardial infarction as unjustified treatment. Both aborted
myocardial infarction and unjustified fibrinolysis were examined in all patients
having a smaller than 2 times rise of the upper limit of cardiac enzymes (either
CPK or CK-MB, and ASAT). We defined an aborted myocardial infarction if
chest pain and the ST-segment deviation subsided more than 50% within 2
hours after treatment, together with a lack of a rise of more than 2 times the
upper limit of normal of the above mentioned cardiac enzymes.2 All ST-seg-
ment shifts were measured by the same observer, using handheld calipers at 80
msec after the J-point in all 12 leads. This observer was not informed about the
cardiac enzyme concentration of the patients. Aborted myocardial infarction
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could be ruled out if both enzymes did not rise and the ST-segment elevation
of the prehospitally registered ECG did not change during a 48-hour period fol-
lowing administration of fibrinolysis. If, by retrospect the ST-segment devia-
tion did not fulfill the above-mentioned criteria and there was no rise in cardiac
enzymes, fibrinolysis was also designated as unjustified. Persistent ST-eleva-
tion of remote infarction, without a lack of enzyme rise, is classified as unjus-
tified therapy, if there was no dynamic ST-segment change. All patients with
unjustified fibrinolysis were classified as having definitive (confirmed by coro-
nary angiography) or probable (chest pain and/or ECG abnormalities at an
exercise test or at single photon emission tomography) coronary artery disease,
or as having had nonischaemic or noncardiac chest pain. 
Statistics
For statistical comparison of the number of patients having aborted myocardial
infarction or unjustified fibrinolysis, use was made of the chi-square test. For
difference in time intervals use was made of the Student t-test.
10.4 Results
Between April 1, 1999 and August 1, 2000 a total of 250 patients received pre-
hospital treatment, using anistreplase, streptokinase or reteplase: 118 patients
were treated in Rotterdam and 132 patients in Nijmegen. Their data were com-
pared with 269 consecutive in-hospital diagnosed and treated patients in
Arnhem during 1995-1997. 
Patient characteristics
Table 10.4-1 shows the basic characteristics of the prehospital (Nijmegen and
Rotterdam) and in-hospital (Arnhem) treated patients. There were no signifi-
cant differences in risk factors and presentation features between the prehospi-
tal and the in-hospital fibrinolytic treatment groups. Prehospital fibrinolysis,
using both means of diagnosis myocardial infarction, resulted in about 60 min-
utes earlier time to treatment than in-hospital therapy (p<0.01). 
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Table 10.4-2 presents the results of the 3 groups. Haemorrhagic stroke (neuro-
logical symptoms characteristic of intracranial bleeding, confirmed by CT-
scanning of the brain) occurred in 3 patients (1.2%) treated prehospitally, and
in 3 patients (1.1%) treated in-hospitally. No other severe bleeding complica-
tions occurred in the prehospital treated patients. Of the in-hospital group 2
patients had a severe bleeding complication. A total of 42 of the 250 (16.8%)
prehospital treated patients and 12 of the 269 (4.5%) in-hospital treated patients
fulfilled the criteria for aborted myocardial infarction (p<0.001). Unjustified
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therapy in prehospital treatment (3.2%) was not significantly different from in-
hospital therapy (1.9%). 
Remote infarction with persistent ST-segment elevation was seen in 4 patients
(1 in Rotterdam and 3 in Arnhem). Although the 4 patients with persistent ST-
segment elevations of remote infarction could be diagnosed as having aborted
myocardial infarction, the lack of dynamic ST-segment changes lead us to clas-
sify those patients as having had unjustified therapy. Although left bundle
block was excluded, in Nijmegen 2 patients with this ECG characteristic were
treated prehospitally. Coronary artery disease could not be confirmed by
angiography in these 2 patients. Pericarditis with persistent ST-segment eleva-
tion for more than 2 hours was seen in 1 patient (Arnhem). The time to treat-
ment of the patients with unjustified fibrinolysis (median 89 minutes) is not dif-
ferent from the total prehospital treated group (median 95 minutes). Table 10.4-
3 presents the discharge diagnosis and 1 year clinical follow-up treatment of
the 13 patients who received unjustified fibrinolytic therapy. Statistically, there
was no difference, regardless in which way the prehospital ECG-diagnosis of
acute myocardial infarction was made. Ten patients had an uneventful recov-
ery; 1 patient has acute myocardial infarction 3 days later, 1 patient was treat-
ed for heart failure and 1 had coronary bypass; all were alive at 1-year follow up.
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10-5 Discussion
In this analysis we found a fourfold increase of abortion of myocardial infarc-
tion, associated with prehospital thrombolysis, compared with in-hospital treat-
ment. Aborted myocardial infarction has not previously been suggested as an
indicator for the efficacy of prehospital thrombolysis, although most studies
emphasize the importance of very early thrombolytic treatment. The GREAT
study found less q-wave infarctions in the prehospital group, which could indi-
cate a greater number of aborted infarctions.12 Also, in a ECG-substudy, the
GREAT authors found that the proportion of patients showing a reduction in ST
elevation of >25% or even >50% between the home and hospital recordings
was significantly greater in the early than in the late group.13 The same was
found in 13,100 patients treated with either tenecteplase or alteplase and ana-
lyzed according to resolution of ST-segment on the ECG at presentation.14 This
study observed a significantly lower peak creatine kinase MB level in patients
with complete ST resolution, compared with patients with partial or no resolu-
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tion. Furthermore, the extent of ST resolution became significantly en less with
increasing time to treatment. An electrocardiographic analysis from the TIMI
14 and the InTime-II study shows that for each additional hour from symptom
onset to initiation of pharmacological reperfusion, the chance of achieving
early, complete ST resolution decreases by 6%.15 This is all suggestive of the
phenomenon of abortion of myocardial infarction.
Unjustified fibrinolysis
Although prehospital thrombolysis is associated with a higher incidence of
abortion of myocardial infarction compared to in-hospital treatment, this analy-
sis shows the same incidence of unjustified fibrinolysis in two cities with a pre-
hospital strategy and different methods of ECG-diagnosis. Ever since the initi-
ation of intravenous fibrinolysis unpreceded by angiography, physicians have
been troubled by the prospect of administering treatment in the absence of
acute myocardial infarction. Case reports of unjustified fibrinolysis date from
the late eighties (Table 10.5-1). 
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Pericarditis is the most common, and aortic dissection the most dreaded trigger
leading to unjustified fibrinolysis. In the large fibrinolytic trials, percentages of
nonconfirmed myocardial infarction range from 1.4% with stringent ECG cri-
teria for acute myocardial infarction, to 23% in trials were no ECG confirma-
tion was needed (Table 10.5-2).12,16-23
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study
year
patients ECG
criteria
unstable
angina
unjustified
thrombolysis
causes of unjustified thrombolysis
ASSET
17
1988
5005 4 855 (17.1%) 556 (11.1%) 400 (7.9%): noncardiac causes
154 (3.1%): other causes
2 (0.04%): missing
TEAHAT
18
1990
352 4 81 (23%) 14 (4.0%) 14 (4.0%): noncardiac causes
MITI
20
1993
175 prehospital
185 in-hospital
1
1
5 (1%) 2 (0.5%) 1 (0.27%): pericarditis
1 (0.27%): peptic ulcer
EMIP
21
1993
2750
prehospital
2719
in-hospital
2,3
2,3
206 (7.5%)
184 (6.8%)
90 (3.2%)
97 (3.6%)
9 (0.3%): pericarditis
6 (0.2%): aortic diss
25 (0.9%): other causes
50 (1.8%): noncardiac causes
12 (0.4%): pericarditis
3 (0.1%): aortic diss
32 (1.2%): other causes
50 (1.8%): noncardiac causes
GREAT
12
1994
163 prehospital
148 inhospital
4
4
n.a.
n.a.
12 (7%)
14 (10%)
59 (36%): nonspecific causes
12 (7%): normal ECG
45 (30%): nonspecific causes
14 (10%): normal ECG
GISSI
16
1986
11712 2,3 328 (2.8%) 351 (3.0%) 351 (3.0%): MI not confirmed
TAMI
19
1993
1387 1 8 (0.6%) 12 (0.9%) 4 (2.9%): early repolarisation
3 (2.2%): pericarditis
3 (2.2%): vasospasm
1 (0.07%): left ventricle hypertrophy
1 (0.07%): esophagitis
Khoury
22
1996
609 2,3 20 (3.3%) 15 (2.5%) 8 (1.3%): noncardiac causes
3 (0.5%): pericarditis
2 (0.3%): pancreatitis
1 (0.2%): esophagitis
1 (0.2%): dissection
Schreiber
23
2000
1077 5 28 (2.6%) 11 (1.0%) 6 (0.6%): other causes
5 (0.5%): pericarditis
Table 10.5-2  Reports from the literature of unjustified thrombolysis
legends: Ecg criteria see table 10.5-1
In these trials unstable angina, non-q myocardial infarction and pericarditis are
the most common causes of unjustified fibrinolysis. It is important to note that
in the early days of fibrinolysis unstable angina was not seen as a case of unjus-
tified treatment. It is understandable that the highest percentage of unstable
angina is in those trials treating patients without ECG documentation, and
varies between 17 and 23%. Furthermore, none of these reports differentiate
between unjustified fibrinolysis and aborted infarction, although the likelihood
of the latter is mentioned.12,21 It is possible that patients with aborted myocar-
dial infarction are classified as having unstable angina in these trials. In the tri-
als with ECG confirmation, the percentage of unstable angina ranges from 0.6
to 7.5%. Discarding unstable angina from those trials, the percentage of unjus-
tified fibrinolysis ranges from 0.5% with ECG confirmation to 11.1% without
ECG confirmation. Using only the trials with ECG diagnosis, the average per-
centage of unjustified fibrinolysis is 2.1%. Unlike our observations, pericardi-
tis is here one of the most common diagnoses. 
One of the reasons prehospital thrombolysis is not generally implemented may
be the fear of unjustified fibrinolysis. Our data are supported by those from the
literature,12,21 showing that the risk of unjustified fibrinolysis is not significant-
ly higher in a prehospital treatment group compared with in-hospital treatment.
In contrast to the EMIP study21, where ECG-diagnosis on the ambulance was
made by a physician, and the GREAT study,12 where no strict ECG criteria were
used, our observations are close to current practice: prehospital assessment by
nurses and in-hospital triage by physicians. Although unjustified fibrinolysis
infarction is defined in our study on clinical grounds and thus clearly distin-
guished from aborted myocardial infarction, it will probably never be diag-
nosed with a 100% sensitivity and specificity in a strategy without immediate
angiography. Assuming a risk of intracerebral hemorrhage of 1% and a risk of
unjustified fibrinolysis of 5% the risk of hemorrhagic stroke will be 1 in 2000
prehospitally treated patients.23 This risk is acceptable in comparison with com-
plications of other medical interventions in life-threatening disorders. 
There seems to be no reason to change the indications for fibrinolytic therapy,
as currently used in cardiology practice and advocated by guidelines. For pre-
hospital implementation computer diagnosis compares well with cardiologist-
assisted diagnosis. This has also been confirmed in comparative ECG-studies.8,9
Sensitivity for acute myocardial infarction varied between 53% and 81%,
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depending of the amount of ST-elevation used. Specificity varied between 87%
and 99%, depending on the amount of ST-elevation or reciprocal ST-segment
depression used. Computers tend to have a lower sensitivity for anterior
myocardial infarction than for inferior infarction and a lower sensitivity than
cardiologist-assisted diagnosis,9 possibly because some computer programs
face problems in distinguishing early repolarisation from acute anterior
myocardial infarction. When in doubt we adhere to the presence of reciprocal
ST-segment depression24 as a means for differentiating the ST-elevation of
acute myocardial infarction from pericarditis or early repolarisation.
Limitations
The study was not randomized and not performed prospectively. Determination
of serum troponins was not in routine use at the time the study was performed.
This could have helped in establishing the difference in unjustified thromboly-
sis (normal values of CK, CK-MB and troponin) and aborted myocardial
infarction (normal values of CK and possibly raised concentration of troponin),
although no studies are available about the value of troponins for the diagnosis
of abortion of acute myocardial infarction. 
10.6 Conclusion
Using a prehospital strategy of diagnosing and treating acute ST-segment ele-
vation myocardial infarction, we found a fourfold increase in abortion of
myocardial infarction, compared with in-hospital treatment. Unjustified fibri-
nolytic therapy for acute myocardial infarction occurs as frequently in the pre-
hospital as in the in-hospital setting. The use of different ECG methods for
diagnosing acute myocardial infarction does not seem to make a difference.
Our results in a nurse-ambulance setting are comparable with data from large
trials with physician-initiated fibrinolysis. Most of our patients with incorrect
fibrinolytic therapy in our database suffered from acute coronary syndrome,
while in the literature unjustified therapy was mainly seen in patients with
acute pericarditis. Aborted myocardial infarction, which in our data is associ-
ated with prehospital treatment and which can be seen as the ultimate goal of
fibrinolytic therapy, must be differentiated from unjustified treatment.
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11.1 Abstract 
Background: The purpose of this study was to analyze the cost-effectiveness
of prehospital thrombolysis compared with in-hospital thrombolysis.
Objectives: Prehospital thrombolysis in acute myocardial infarction is associ-
ated with a time gain of one hour in time to treatment. To guide budget alloca-
tions needed for prehospital treatment, a cost benefit analysis was made.
Methods: Two approaches were used: 1. The median time gain of prehospital
thrombolysis, compared with in-hospital thrombolysis was matched with the
associated risk reduction calculated on the basis of the literature. Costs of pre-
hospital diagnosis and treatment were added to the survival after 30 days, and
cost effectiveness was estimated as the additional costs due to prehospital
thrombolysis divided by the number of life years gained. 2. A mathematical
model was used to simulate patient histories, each drawn from a certain risk
profile, whereby two histories were simulated for each patient, one with pre-
hospital, and one with in-hospital treatment.
Results: In the first model, with a risk reduction of 30% for in-hospital, and
35% for prehospital treatment, prehospital treatment resulted in costs per life
year gained at EUR 2,800. Using the second model, the average 30-day sur-
vival with prehospital thrombolysis was 93.73% compared to 93.32% with in-
hospital thrombolysis. This results in an estimated cost per life year gained of
EUR 1,837, assuming an average life expectancy of 10 years after being dis-
charged.
Conclusion: Prehospital fibrinolysis costs EUR 1,800 to 2,800 per life year
gained and seems, therefore, at least as cost-effective as other evidence-based
infarct treatments.
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11.2 Introduction   
During the last decades, survival after acute ST-segment elevation myocardial
infarction has improved substantially, partly related to the success of throm-
bolytic therapy. Time from symptom onset to treatment is one of the most
important determinants of the success of thrombolytic therapy. If initiated with-
in 1 to 2 hours after onset of symptoms 30-day mortality can be reduced by 40-
50% as compared to placebo.1 Several investigations have demonstrated that
initiation of thrombolytic treatment prehospitally reduces treatment delay by
about one hour.2,3 Although considered safe and feasible, the strategy of pre-
hospital diagnosis and treatment has not lead to widespread application.4
Probably, one of the main obstacles is the organisation needed to implement
such a strategy, implying fundamental changes such as budget-reallocations.
The acceptance of a new program - with numerous financial implications - is
best guided by a cost effectiveness analysis. This analysis should ideally be
based on data from randomised trials that compare prehospital versus in-hos-
pital treatment, with data collected on costs and effects. However, no such data
are available. Moreover, large numbers of patients are needed to obtain suffi-
cient power. Some simple calculations suggest that prehospital thrombolysis
may lower 30-day mortality with an absolute reduction of 0.5 percent. This
implies that one would need more than 30,000 patients per arm to show a sig-
nificant mortality reduction with a power of 80%. Therefore, alternative
approaches are needed and two are followed here. The first approach consists
of a simple combination of some estimates, calculated as it were “on the back
of an envelope”. In the second approach mathematical simulation techniques
are applied, based on a combination of data from literature and detailed empir-
ical data obtained in our local setting. The latter approach allows for many
interdependencies between patient’s characteristics, survival probabilities and
costs.
5
In this report we performed a cost-effectiveness analysis, in which we used
both approaches with data obtained from a detailed registration of time inter-
vals of treatment of patients with acute myocardial infarction, with prehospital
or in-hospital treatment. 
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11.3 Methods
Most estimates included in both approaches were based on data from 732
patients having acute ST elevation myocardial infarction: 468 patients treated
in prehospital setting in Nijmegen during 1995-1999 and 264 patients treated
inhospitally in the neighbouring city of Arnhem during 1995-1997. The city of
Nijmegen has 150,000 inhabitants, and its two hospitals serve 240,000 inhabi-
tants with 13 ambulances. The city of Arnhem has the same degree of urbani-
sation as Nijmegen, 140,000 inhabitants and the municipal hospital serves
240,000 inhabitants with 13 ambulances. The median time from onset of pain
to arrival of ambulance (Nijmegen 78 minutes, Arnhem 88 minutes) and the
median transport time of patients with acute myocardial infarction to the hos-
pital (Nijmegen 10 minutes, Arnhem 11 minutes) do not differ significantly in
these two cities. There was a 56-minute median time gain in patients treated
prehospitally compared with in-hospital treatment, the first treated with a medi-
an of 89 minutes and the latter of 153 minutes. Except for the time to treatment
both treatment groups were comparable according to age, sex, localisation of
infarction, TIMI-risk score and 12 month follow up regarding treatment and
mortality (table 11.3-1).
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I. “Back of the envelope” model
In the first approach, the one to be drawn simply “on the back of an envelope”,
the median delay from symptom onset to treatment in the setting of prehospi-
tal (Nijmegen) and in-hospital (Arnhem) thrombolysis were determined.
Subsequently, the obtained 30-day mortality reduction as compared to placebo
was estimated for both settings, applying data from the literature.1,6,7 Costs asso-
ciated with prehospital thrombolysis are those of implementing diagnosis sys-
tems in ambulances and base station, according to the financial administration
of 2001. The effectiveness of prehospital thrombolysis over in-hospital treat-
ment is calculated as the absolute difference in 30-day survival, multiplied with
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Table 11.3-1. Characteristics of all patients.
Prehospital thrombolysis
(Nijmegen)
n = 468
In-hospital thrombolysis
(Arnhem)
n = 264
p
Age (mean) (years)
Men, n (%)
63
322 (68)
62
190 (71)
n.s.
Minutes to treatment 97 153 p< 0.05
Transmural ischaemia,
n (%)
 anteroseptal
 inferior
 other
201 (44)
240 (51)
27 (6)
117 (44)
138 (51)
9 ( 3)
n.s.
n.s.
n.s.
TIMI-risk score at
presentation 2.9 2.6 n.s.
Treatment 12 months,
n (%)
 Conservative
 PCI (incl rescue
PCI)
 Bypass surgery
352 (75.2)
73 (15.6)
43 ( 9.2)
202 (76.5)
38 (14.4)
24 ( 9.1)
n.s.
n.s.
n.s.
Mortality at 12 months,
n (%)
51 (10.9) 25 (9.5) n.s.
an estimate of the average life expectancy, assumed to be 10 years after dis-
charge.8 Finally, the cost effectiveness of prehospital thrombolysis was esti-
mated as the ratio between the additional costs and the absolute effects,
expressed as the number of life years gained. 
II. Simulation model
The “back on the envelope” calculation may lead to biased results for at least
three reasons. The relation between treatment delay and treatment effect is sup-
posed to be non-linear, so the estimated gains in life expectancy are relatively
high in patients treated early (i.e. within 2 hours) after onset of pain, that is to
say, a decrease from 4 to 2 hours is less effective than a decrease from 1 to 1/2
hour).1 Consequently, when time gains are obtained in patients who present rel-
atively late, survival gains on the basis on mean or median values may be over-
estimated. Secondly, survival gains are mainly obtained in high-risk patients,
who tend to seek medical attention earlier than low-risk patients. In contrast,
time gains are most easily obtained in patients presenting late after symptom
onset, a cohort at relatively low risk. Then again, the benefits of prehospital
thrombolysis may be overestimated by using means or medians. Thirdly, keep-
ing high-risk patients alive may increase the average length of stay. This may
increase costs with much more than just the costs of the home thrombolysis
program. When taking all these aspects into account the balance between costs
and effects may end up less favourably for home thrombolysis than when dis-
regarding them.
Therefore, a more subtle approach was followed, using a mathematical model
that simulates patient histories. Within this model the following phases were
distinguished:
• The time from the onset of symptoms until treatment 
• The time on the CCU until either death or discharge to the ward
• The time on the ward until discharge from the hospital
• The time from discharge until death
The model simulated 1,000,000 patient histories. Each patient history started
with a certain risk profile, drawn from a distribution of certain risk-scores. Two
histories were simulated for each patient, one assuming prehospital treatment
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and one assuming in-hospital treatment. Subsequently, the patient is supposed
to be treated at the CCU where he may either die or may be discharged alive.
After the patient has left the CCU, treatment is supposed to be at the ward, fol-
lowed by discharge alive. The dependencies that are taken into account are
those between 
a The risk score and the time to treatment  
b The time to treatment and the risk of dying
c The risk of dying and the length of stay on the CCU
d The risk of dying and the length of stay on the ward
Using the history of the same patient in the hospital scenario, the simulation
program started with a different distribution of time to treatment. All subse-
quent interdependencies were identical; all outcomes were of course different
due to this different duration until treatment that effects all other durations and
probabilities later onwards. Finally, after the patient has been discharged alive,
he is supposed to live for 10 years8 and no account is taken of a dependency
between the patients’ original risk score and survival after discharge.
For risk assessment data are used from the TIMI-risk score of ST elevation
myocardial infarction.9 Herein, certain parameters are weighed in such a way
that age over 75 years and systolic blood pressure lower than 100 mm Hg is
scored as 3 points, age from 65-74, heart rate more than 100 beats per minute
and Killip class II-IV scored as 2 points and a anterior myocardial infarction, a
history of prior infarction, hypertension and diabetes scored as 1 point.
Allocation of 1 point to patients treated later than 4 hours was discarded, as
patients are divided into groups treated before and after 2 hours in our assess-
ment. Mortality at 30 days ranges from 0.9% with score 0 till 32.2% with more
than 8 points. 
The relationship between the TIMI risk score and time to treatment is investi-
gated by comparing patients treated within and after two hours after the onset
of pain and by Cox-regression analysis.
The distribution of the time from onset of pain to prehospital treatment is based
on the data from Nijmegen.  The distribution of the time from onset of pain to
treatment in hospital is based on the data from Arnhem.
The initial risk of dying within 30 days without any thrombolytic therapy is
based on this TIMI score and the corresponding survival probability as pub-
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lished by Morrow et al.9 These probabilities are multiplied with a factor 1.4* to
correct for the fact that all patients in Morrows analysis had received throm-
bolytic therapy and that thrombolysis reduces the mortality risk with 0.3.
The effect of the time to treatment on 30-day survival is estimated using a 1-1
relationship between the time to treatment and the risk reduction in comparison
to no thrombolytic treatment. This relationship is estimated based on the data
as published by Boersma et al (figure 11.3-1).1
The days spent in the CCU and on the ward are analysed on the basis of data
from Nijmegen for the prehospital treated patients and from Arnhem for the
hospital treated patients. The relationship between the patients TIMI-risk score
and the days spent on the CCU and on the ward is analysed using parametric
survival models. Data are used from all patients treated in Nijmegen and
Arnhem.
Cost-effectiveness
Costs are estimated per patient as the sum of the costs of the thrombolytic agent
and the cost of in hospital treatment calculated as the length of stay multiplied
with the unit costs per day on CCU and ward. In case of prehospital thrombolysis,
* factor 1.4 = 1 divided by (1-0.30)
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Figure 11.3-1. Relationship between relative risk and time to treatment. Derived from
Boersma et al
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the costs of the infrastructure are added, assuming a programme of approxi-
mately 100 patients per year, and a service of 13 ambulances with crew. 
11.4 Results
I. Mortality reduction by early treatment. 
Figure 11.4-1 presents the relationship between time to treatment and corre-
sponding relative risk in terms of the corresponding risk reduction in combina-
tion with the observed durations in Nijmegen and Arnhem. The median dura-
tion between onset of symptoms and in-hospital treatment (Arnhem) is 153
minutes (interquartile range) The delay between onset of symptoms and pre-
hospital treatment (Nijmegen) is 89 minutes (interquartile range).
II. “Back of the envelope” model
The 30-day relative mortality reduction by in-hospital thrombolysis compared
to control therapy is estimated at 30%, whereas the relative mortality reduction
by prehospital treatment is estimated at 35% (figure 11.4-1). Thus, assuming a
10% 30-day mortality rate after control therapy in-hospital treatment would
reduce the risk to 7% and prehospital treatment to 6.5%. Therefore, assuming
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a life expectancy of 10 years after discharge, 5 additional life years would be
gained per 100 patients treated. The additional costs of treating an annual num-
ber of 100 patients with prehospital thrombolysis can be estimated at EUR
70,000 per 5 years (implementing ECG-transmission systems on EUR 5,000
per ambulance and 13 ambulances, plus base station, assuming 5 year depreci-
ation) or at EUR 14,000 per year. Consequently the costs per life year gained
can be estimated at EUR 2,800.
III. Simulation model 
Time to treatment and high risk
The simulation analysis starts with simulating patients with a distribution of
TIMI scores. When developing the model it was hypothesised that high-risk
patients would have a shorter time to treatment. However, using the prehospi-
tal treatment group, this could not be confirmed by a Cox regression analysis
with time to treatment as the dependent variable and TIMI score as the explana-
tory variable. Figure 11.4-2 shows this, picturing the distribution of TIMI-score
for patients treated before and after two hours after onset of the pain. Given the
fact that no clear relationship could be identified between the time to treatment
and TIMI score, we simulated time to treatment independent of the TIMI
scores. 
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Figure 11.4-2. TIMI-risk score and time to treatment. See text
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High risk and CCU/ward duration
A proportional hazards model assuming an exponential distribution addressed
the relationship between the duration at the CCU and the duration at the ward.
Running this model yielded the following estimates: patients with a TIMI score
of 0 were estimated to stay 3.5 days on the CCU and 6.0 days on the ward.
Hospital survivors with an initial TIMI score of 3 were estimated to stay 4.2
days on the CCU and 6.8 days on the ward, whereas those with an initial TIM
score of 10 were estimated to stay 7.2 days on the CCU and 9.8 days on the
ward. According to the model non-survivors died on the CCU after 4.3 days.
Prehospital thrombolysis and gain in 30-day survival
All results as presented above were implemented in our simulation model,
which estimates 30-day survival with prehospital thrombolysis at 93.7% and
with hospital thrombolysis at 93.3% (figure 11.4-3). As a result from our sim-
ulation analysis, it is estimated that prehospital thrombolysis will lead to 4.1
additional 30-day survivors per 1000 patients treated when compared to in-hos-
pital treatment.
Estimates of costs can now be obtained by using the same costs as in our “back
of the envelope” approach while estimating the costs of a CCU day at EUR 700
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Figure 11.4-3. Expected 30 day survival according to simulation of 1.000.000 patients with
in-hospital and prehospital treatment.
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and the costs of a ward day at EUR 350. Table 11.4-1 presents the results in
terms of resource use and costs, assuming a program of 100 patients per year.
The results suggest that part of the initial investment of EUR 14,000 can be
recouped by savings in relationship to a decrease in length of stay leading to a
net annual cost of EUR 7350 for a prehospital thrombolysis program running
for 100 patients, or 73500 for 1000 patients. The costs effectiveness is EUR
73500 divided by 4 survivors per 1000 patients treated equals to EUR 18,375.
When assuming an average life expectancy of 10 years after being discharged,
costs per life gained are EUR 1,837.
SENSITIVITY ANALYSIS
To some surprise, our simulation approach leads to almost the same estimates
as our “back to the envelope” approach. Following the latter, it is relatively
simple to analyse what effects are of different assumptions. Here there are only
three variables of importance: the costs of the program, the effectiveness of
prehospital thrombolysis and the life expectancy after being discharged alive.
The question raised here is what estimates would lead to the conclusion that
prehospital thrombolysis is not acceptable from a cost effectiveness point of
view. For that purpose, we set the limit for cost effectiveness at EUR 20,000
per life year gained. First, there are the costs of the program. A 10% increase
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Volumes Unit cost Costs
Prehospital In- hospital Prehospital In hospital
Program costs 1 -- 14,000 14,000 --
CCU days 417 424 700 291,900 296,800
Ward days 630 635 350 220,500 222,250
Total Costs 526,400 519,050
Table 11.4-1. Costs of prehospital diagnosis and treatment, compared with
inhospital treatment, with 100 patients per year.
in the costs would imply a 10% increase in the costs effectiveness ratio. So, one
would need to estimate the annual program costs at EUR 100,000, instead of
EUR 14,000 to reach to the limit of EUR 20,000 per life year gained. Such a
high estimation would be rather implausible. Second, there is the estimate
about effectiveness. Given the estimate of EUR 14,000 for the program and the
estimate of the remaining life expectancy of 10 years, the reduction in 30 days
survival would need to be 0.07% instead of 0.5% to reach the limit of EUR
20,000 per life year gained. Here it is noted that almost no doubt exists about
the negative relationship that favours early treatment. Additionally, almost no
doubt exists, looking at the Nijmegen experience, that prehospital thromboly-
sis leads to an earlier treatment. The question may than be how much earlier,
and at what point in time. The risk reduction of 0.5% can as well be obtained
by bringing the time to treatment back with almost an hour from 153 minutes
to 97 (as in our case) as by a reduction of 30 minutes from 82 to 52 minutes.
Finally, doubts may exist about our estimate of a remaining life expectancy of
10 years after having been discharged alive. Given our other estimates, this life
expectancy might decrease to less than 1 year and one would still end up with
an estimate of the costs per life year gained that is under EUR 20,000. 
11.5 Discussion
A prehospital thrombolysis program that decreases the median duration
between the onset of symptoms and time to treatment with – on average – one
hour, seems to result in a cost of EUR 1,800 to 2,800 per life year gained.
Using the simulation analysis, patients stay on average 4.2 days at the CCU
(95% interval 1.1-11.8) and 6.3 days at the ward (95% interval 0-15.4). Shorter
length of stay was in favour of prehospital treatment. On the one hand, average
length of stay increased in patients who would have died with hospital throm-
bolysis and are kept alive by prehospital treatment. On the other hand, length
of stay decreases in patients who would survive their infarction after hospital
thrombolysis, but whose mortality risk has decreased due to prehospital throm-
bolysis. The latter decrease consistently outweighs the first increase. 
The GREAT study, a randomised trial of 163 prehospital treated patients ver-
sus 148 patients treated inhospitally, with a median time gain of 130 minutes,10
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evaluated the cost effectiveness of prehospital thrombolysis. Costs were con-
sisted of drug costs, training of general practitioners and their visits, and costs
of electrocardiographs and defibrillators. With an additional probability of 0.11
of survival due to prehospital thrombolysis and a 4-year survival probability of
0.65 for hospital treatment and 0.76 for prehospital administration, the cost
effectiveness ratio of prehospital thrombolysis was estimated at EUR 5,835 to
EUR 12,000 per life saved.11
Capital expenditure and general practitioner’s visits were not take into account,
but included training for giving prehospital treatment, and of the costs of the
drug. Training costs are difficult to assess and in our case is part of the usual
refresher course of the ambulance crew. The costs of the drug (EUR 1,000) can
be disregarded, because for cost effectiveness it does not matter where the drug
is given, prehospital or in-hospital. Taking these costs into account, the
GREAT results can be compared with our “back to the envelope” model.
Although the “ back of an envelope” approach resulted in the same conclusion
as the more sophisticated estimate, we thought the latter necessary for a vari-
ety of reasons. Firstly, a calculation of the costs and effects on the basis of aver-
ages may – in case of non-linear relationships – lead to biased estimates and
account should be taken of the various heterogeneities. Secondly, one should
realise that prehospital thrombolysis especially saves patients with high mor-
tality risks at potentially high costs. So, not only the costs of the program
should be taken into account but also the costs of the hospitalisation. Thirdly,
the uncertainty surrounding the relationship between survival and the duration
between the onset of symptoms and the time of treatment should be considered.
Moreover, realising that the ‘back of the envelope” calculation looks highly
beneficial we thought it necessary to use conservative estimates. However,
even then, a program with prehospital thrombolysis appears to have a very
attractive economic profile. The question may then be raised why such an
approach is not widely used. Here, some speculative reasons are put forward. 
The first reason for the lack of widespread use might be found in the fact that
the potential gain in time by treating patient’s prehospitally depends on the cur-
rent standards. According to the literature, the door to needle time in hospital
may be substantial, 83 minutes when treatment is given at the CCU and 53
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minutes when treatment is given in the emergency room. A recent survey
even12 showed that the delay between arrival of the patient at the hospital and
starting of the treatment has not improved lately. It is still at least 40 minutes,
suggesting that prehospital treatment is currently the best way to shorten
delays. The potential gains, as well as the potential cost effectiveness, may
depend on the organisation in the various hospitals. The better the current
organisation, the better the cost effectiveness profile, the worse the organisa-
tion, the better the profile. So, one might come to the conclusion that the intro-
duction of a prehospital thrombolysis program is like admitting that the current
standards are sub-optimal.
A second reason may lie in the numbers needed to treat. Our conservative esti-
mate implies that one has to treat about 125 patients prehospitally to save one
additional life. On average general practitioners see 2 to 3 patients with acute
ST elevation myocardial infarction per year and may feel that they have to con-
tinue practice for more then 40 years before they save one life. This may not
look very worthwhile, and they - maybe supported by the situation and the rel-
atives of the patient - may feel more comfortable by referring these patients to
hospital as fast as possible. 
A third reason may be found in the costs and organisation. One needs to install
ambulances and a department of cardiology with the necessary equipment and
moreover, one needs to equip the ambulances with thrombolysis agents. This
asks for education and communication with ambulance staff and general prac-
titioners, and reallocations of budgets. 
Study limitations
The estimates of the simulation model are based on the risk score of the TIMI-
study. This risk score excluded cardiogenic shock, systolic and diastolic hyper-
tension and history of stroke. Because these are not necessarily exclusion cri-
teria in prehospital thrombolysis one includes patients with a potential high risk
of death or complications, balancing the cost effectiveness in a less desirable
way.  
The true natural history and 10-year survival of acute myocardial infarction is
difficult to assess, because more than half of the deaths occur outside hospital,
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with uncertain causes of death and with unreliable death certificates. An aver-
age survival after discharge of 10 years is certainly not a high estimate, with
the cost per life year gained even lower if the real survival would indeed be
longer.
Ideally, one would have used data from patients randomised in prehospital or
in-hospital thrombolysis. However, with the numerous results of the impor-
tance of early treatment, this is not ethically justifiable. So we used the data of
patients treated in one city (Nijmegen) prehospitally, and in another city
(Arnhem) inhospitally. The Arnhem situation is comparable to that of
Nijmegen in terms of population, degree of urbanization, transport times for
ambulances and CCU-facilities, the key difference being that no pre-hospital
treatment was available in Arnhem during the period of the study. This, togeth-
er with the fact that both patient groups reveal baseline characteristics in rea-
sonable agreement with those occurring in the literature, we expect them to be
comparable. In doing so one approximates an unblinded randomisation as best
as possible, accepting the difference patient care of the two cities.
11.6 Conclusion
Prehospital thrombolysis seems to be cost effective: EUR 2,800 per life gained
using a simple calculation method of risk reduction associated with early treat-
ment. When a more sophisticated mathematical model using patient’s histories
and risk profiles is used the result is an estimate of EUR 1,837 per life year
gained. The balance between the costs and effects seems attractive and our
conclusion is that hospitals, general practitioners and health care authorities
should support a widespread use of prehospital thrombolysis.
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CHAPTER 12
SUMMARY AND CONCLUSIONS
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12.1 Summary
Fifteen years of experience in prehospital thrombolysis for acute ST elevation
myocardial infarction in our region has formed the basis of this thesis, togeth-
er with data from Rotterdam, one of the other centres applying this strategy,
and with data from Zwolle, where prehospital triage and primary angioplasty
is practised. 
Chapter 1. Introduction
The questions this thesis tries to answer are threefold. 
Firstly, questions are answered, which are all related to the importance of time
to treatment: the time gain of a prehospital strategy, the difference in time gain
using bolus or infusion thrombolytics and the reduction of 30-day mortality
and heart failure. Secondly, the concept of aborted myocardial infarction is
investigated in prehospital thrombolysis, in in-hospital thrombolysis and in pri-
mary angioplasty with prehospital triage. Furthermore, linked with aborted
myocardial infarction, attention is given to unjustified fibrinolysis, both in the
Nijmegen and the Rotterdam experience and in the literature. Thirdly, some
practical aspects of prehospital thrombolysis are reviewed, focusing on its costs
and effectiveness.
Chapter 2. Overview
The acute coronary syndrome for which treatment with thrombolytics is indi-
cated is characterized by ST-segment elevation on the electrocardiogram. It is
defined by typical symptoms, ECG-signs of transmural ischaemia (ST-segment
elevation), development of Q-waves on the ECG, and signs of myocardial cell
death, as reflected by the rise of typical biochemical markers. The latter char-
acteristic can be absent, if treatment is given in such a way that cell death is
averted, and this is called in this thesis an aborted myocardial infarction. An
acute ST elevation myocardial infarction is suspected, and thus followed by
treatment; if after serial ECG’s and measurement of biochemical markers the
diagnosis was correct, the infarction is proven or established. If the results of
serial measurements of biochemical markers is less than two times the upper
value, the infarction is aborted. In both cases the treatment was justified. If the
diagnosis after serial ECG’s and biochemical markers appeared to be incorrect,
the treatment was unjustified. 
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In the last 25 years much research has been done to salvage ischaemic myocar-
dial tissue. The overall conclusion is that time is of utmost importance. This has
been demonstrated in animal experiments, by inducing myocardial ischaemia
followed by interventions at various time intervals, and by analysing time to
treatment after onset of symptoms in the first published trials with acute ST ele-
vation myocardial infarctions and thrombolytic therapy. From the late eighties
of the last century onwards, reports have been published about the feasibility
of diagnosing acute myocardial infarction prehospitally, with the introduction
of the administration of fibrinolysis before the patient is transported to the hos-
pital. Since the first publication by Gotsman many reports about early and pre-
hospital thrombolysis have been published. Pivotal for this thesis were the
results of Boersma’s meta-analysis of early thrombolytic treatment, in which
treatment within 1 hour after onset of symptoms appeared to reduce mortality
more than expected as treatment later than 1 hour. This resulted in the “Golden
Hour” of treatment, and laid the foundation of the concept of aborted myocar-
dial infarction. Boersma concludes that the assessment of prehospital treatment
is likely to be better by dividing all patients (prehospital and hospital) in an
early and a late treatment group, rather than comparing prehospital with in-hos-
pital patients. Comparing only in-hospital treated patients yields too few
patients to compile an early treatment group, as only an average of 6% of in-
hospitally treated patients are treated within 1 hour. Prehospital thrombolysis is
thus the only way to collect a 1- and 2-hour treatment group large enough to
make such an assessment possible.
Chapter 3. Study of Time Intervals in Myocardial Ischaemic Syndromes
(STIMIS)
In the STIMIS-study the various points in time of every event between onset
of chest pain and completed hospital admission were assessed in 1,152 patients
with chest pain of possible cardiac origin. This study was part of the Nijmegen
Home Thrombolysis Program. Of these patients 200 were actually treated with
thrombolytic therapy: 141 at home and 59 after hospital arrival. After final
analysis, 393 patients proved to have myocardial infarction. In comparison
with the whole group of patients with chest pain, the time points of every event
occurred earlier in patients with myocardial infarction. There was a median
time interval of 89 minutes between onset of symptoms and treatment in
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patients treated prehospitally, and 152 minutes in patients treated in-hospitally.
Of the prehospital thrombolysis group 28% of the patients and of the hospital
thrombolysis group no patients were treated within one hour. Within two hours
these values were 65 and 25%, respectively.
Chapter 4. Registration of symptom onset-to door and door-to-needle times in
4 hospitals outside the Nijmegen region
To facilitate discussions about the need for prehospital thrombolysis in regions
other than Nijmegen, where such a strategy already exists, in-hospital time
intervals of diagnosing and treating patients with chest pain have been collect-
ed and an estimation of percentages of patients that can be treated within 2
hours with this strategy have been made. In 4 regional hospitals around the city
of Nijmegen time intervals were noted on a special form. To calculate the time
gain prehospital treatment could have provided in the 4 regions to the median
time from onset of pain to arrival of the ambulance 27 minutes was added,
which is the time it takes in Nijmegen to diagnose and treat the patient in a pre-
hospital strategy. Door-to-needle times in the 4 regions varied between 39 and
50 minutes and are comparable with the 48 minutes of in-hospital treatment in
Nijmegen. Total time to treatment varied between 145 and 167 minutes. If a
prehospital strategy had been present, there would have been a time gain in the
4 regions varying between 32 and 51 minutes, resulting in 55% patients treat-
ed within 2 hours instead of the current 25%. In conclusion, with a prehospital
strategy the 4 regions could reduce the time to treatment, resulting in doubling
the number of patients treated within 2 hours.
Chapter 5. Time from symptom onset to treatment and outcome in prehospital
thrombolysis for acute myocardial infarction
Because the prehospital thrombolysis program has created a considerable data-
base of patients treated within 1 and 2 hours after symptom onset, we analyzed
this database in search for patients’ characteristics with a better outcome in the
early treatment group. From 1994 to 2000 a total of 475 patients were treated
because of acute myocardial infarction using prehospital administration of
anistreplase (in 407 patients) or reteplase (in 68 patients) after diagnosis was
confirmed with transtelephonic transmission of the ECG. There was no age
limit. The patient data were divided into 2 groups: one with treatment within 2
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hours after onset of pain, and one treated later than that.  Thirty-day mortality
and symptoms and clinical signs of heart failure were used as parameters of
outcome. Both univariate and stepwise logistic regression analyses were used
to test 30-day mortality against age, actual time to treatment, prior myocardial
infarction, hypertension, diabetes, hyperlipidamia, anterior myocardial infarc-
tion, Killip class, systolic blood pressure and heart rate at presentation. Overall
30-day mortality was 9.0%. Overall heart failure was in 16.4% of patients.
Both mortality (5.5% vs. 15.2%, p<0.02) and heart failure (12.7% vs. 23.2%,
p<0.02) were significantly lower in the early treatment group compared to the
group treated late. Independent parameters showing a relation with 30-day
mortality were age, time to treatment, hypertension and prior myocardial
infarction. Age, time to treatment, hypertension and hyperlipidaemia were
identified as predicting heart failure within the first 30 days. In conclusion, pre-
hospital thrombolysis results in about two thirds of patients being treated with-
in 2 hours after onset of symptoms. Independent variables for 30-day mortali-
ty were age, hypertension, prior myocardial infarction and time to treatment.
Age, hypertension, hyperlipidaemia and time to treatment were independent
predictors for heart failure. 
Chapter 6. Effect of prehospital thrombolysis on aborting myocardial infarction
Hypothesizing that aborted ST elevation myocardial infarction is associated
with prehospital thrombolysis a comparison was made between prehospital and
in-hospital treated patients. A total of 227 patients were treated in the prehos-
pital setting (bolus anistreplase i.v.) and compared retrospectively with those of
269 patients who underwent in-hospital thrombolytic therapy (1.5 million units
of intravenous streptokinase or 100 mg of intravenous recombinant tissue plas-
minogen activator (rt-PA) and intravenous heparin) in the same period in a
nearby hospital not using a prehospital thrombolysis program. The diagnosis of
aborted myocardial infarction was made for both groups if 1) the combination
of chest pain and transient electrocardiographic changes suggested transmural
ischaemia and 2) if a rise in creatine kinase and its iso-enzym > 2 times the nor-
mal value failed to appear, and 3) the cumulative ST-segment elevation and
depression decreased to less than 50% within 2 hours of treatment. Unjustified
treatment was excluded in 3 prehospital and 5 in-hospital patients. A total of 30
of the 224 patients (13.4 %) of the prehospital group and 12 of the 266 (4.5 %)
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in-hospital group thus fulfilled the criteria for an aborted myocardial infarction
(p < 0.05). None of these patients of either group died during their stay in hos-
pital or before the follow up at 12 months. 
Chapter 7. Extended studies on aborted myocardial infarction in reperfusion
therapy
Using an extended database we investigated the timespan, in which abortion of
myocardial infarction can be expected and the differences in parameters of
aborted compared to established ST elevation myocardial infarction. From
patients suspected of acute myocardial infarctions ECG’s were transmitted by
the ambulance service to the coronary care units of one of the Nijmegen hos-
pitals. After confirmation of myocardial infarction 475 patients were included
and treated with thrombolysis before transport. Their data were retrospectively
compared with those of 269 patients treated in hospitally with streptokinase or
rt-PA in a nearby hospital without a prehospital thrombolysis program. A step-
wise regression analysis was used to test independent predictors for abortion of
myocardial infarction. After correction for unjustified thrombolysis 80 patients
(17.1%) of the 468 prehospital treated patients and 12 (4.5%) of the 264 in-hos-
pital treated patients fulfilled the criteria of aborted myocardial infarction.
There was no difference in age, sex, risk factors, and location of infarction of
aborted myocardial infarction compared to established ST elevation myocar-
dial infarction. More than 30% of these abortion infarction patients who under-
went angiography had 2- or 3-vessel disease. Apart from time to treatment,
which was significantly shorter in the patients with aborted myocardial infarc-
tion, a lower ST-segment elevation and a higher incidence of pre-infarction
angina were independent predictors for abortion of myocardial infarction. The
prognosis of patients with aborted myocardial infarction is significantly better
compared with established myocardial infarction: 12 month mortality of 2.2%
and 11.6% respectively. In conclusion, prehospital thrombolysis is more often
associated with abortion of myocardial infarction when compared to in-hospi-
tal treatment. A shorter time to treatment, a lower amount of ST elevation and
a higher incidence of pre-infarction angina were predictors of abortion of
myocardial infarction. 
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Chapter 8. Primary angioplasty or prehospital thrombolysis and abortion of
myocardial infarction
Combining prehospital infarct triage with angioplasty has reduced symptom-
to-balloon times considerably. Reperfusion times with primary angioplasty
with prehospital triage were compared to prehospital thrombolysis. The inci-
dence of aborted myocardial infarction was assessed in groups of patients treat-
ed with either strategy. A total of 545 patients were treated prehospitally in the
cities Rotterdam and Nijmegen and compared with 236 patients treated with
primary angioplasty after prehospital triage in Zwolle. All patients were treat-
ed with nitroglycerine and aspirin, and those prior to angioplasty with heparin
i.v. Prehospital therapy consisted of streptokinase or anistreplase in Nijmegen
or Rotterdam before transport. Time to reperfusion is defined as symptom to
balloon time in primary angioplasty or symptom to thrombolysis plus 60 min-
utes in prehospital thrombolysis. Aborted myocardial infarction was present in
16% of the prehospital thrombolysis patients and 11% in the primary angio-
plasty with prehospital triage group. In primary angioplasty, reperfusion time
categorised as earlier and later than 2 hours, showed a significantly higher inci-
dence of aborted myocardial infarction in the early treated group.  Mortality of
30-days is not significantly different in both early and late angioplasty and
early and late prehospital thrombolysis, and in comparison of both treatment
strategies.  
In conclusion, both prehospital thrombolysis and primary angioplasty with pre-
hospital triage is associated with abortion of myocardial infarction, showing
comparable reperfusion times. In the case of primary angioplasty a significant-
ly higher incidence of aborted myocardial infarction is seen in patients treated
within 2 hours after symptom onset. 
Chapter 9. Prehospital thrombolysis with reteplase; the Nijmegen/Rotterdam study
An observational study was performed to assess time to treatment and clinical
parameters of double bolus reteplase compared to current therapy with strep-
tokinase or bolus anistreplase in two cities (Rotterdam and Nijmegen) in the
Netherlands. Reteplase or anistreplase/streptokinase was assigned to patients
according to order of presentation. All patients were treated with nitrates sub-
lingually and aspirin orally. In total 250 patients were treated between April 1,
1999 and August 1, 2000. Reteplase was used in 120 patients and anistre-
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plase/streptokinase in 130 patients. Using double bolus reteplase resulted in a
significantly shorter time of treatment of a median of 81 minutes compared to
a median of 104 minutes with the established therapy (p<0.05). There were no
differences in mortality, aborted myocardial infarction, hemorrhagic stroke and
the need for rescue angioplasty in both groups. Within 2 hours 64% of patients
were treated. 
In conclusion, in prehospital thrombolysis double bolus reteplase is associated
with a shorter time to treatment than bolus anistreplase or infusion of streptok-
inase. 
Chapter 10. Prehospital versus hospital fibrinolytic therapy using automated
versus cardiologist ECG diagnosis of myocardial infarction: abortion of
myocardial infarction and unjustified fibrinolytic therapy.
The purpose of this study was to investigate the percentages of unjustified fib-
rinolytic therapy in prehospital settings in The Netherlands using different
means of diagnosing myocardial infarction. Unjustified fibrinolysis for pre-
sumed acute ST elevation myocardial infarction can be disastrous, but must be
differentiated from justified thrombolysis resulting in aborted myocardial
infarction. In the city of Rotterdam 118 patients were prehospitally treated for
myocardial infarction, diagnosed using a mobile computer ECG; in the city of
Nijmegen 132 patients were treated prehospitally, using transtelephonic trans-
mission of the ECG to the CCU and judged by a cardiologist. Their data were
compared with those of 269 patients treated in-hospital in the city of Arnhem,
using the same ECG-criteria. Abortion of myocardial infarction was diagnosed
in the absence of a significant rise in cardiac enzymes and in the presence of
resolution of 50% of ST-segment deviation within 2 hours after onset of thera-
py. Lacking these, the diagnosis of unjustified fibrinolytic therapy was made.
Unjustified treatment occurred in 8 prehospitally treated patients: 4 in
Rotterdam (3.3%), 4 in Nijmegen (3.0%) and in 5 (1.9%) of the in-hospitally
treated patients in Arnhem. Aborted myocardial infarction occurred in 14.4%
and 17.4% in Rotterdam respectively Nijmegen against 4.5% in in-hospital
treatment in Arnhem (p<0.001). In conclusion, although unjustified fibrinolysis
for acute myocardial infarction is undesirable, it occurs in the same frequency
in prehospital as in in-hospital settings. The use of different ECG methods for
diagnosing acute myocardial infarction does not seem to make any difference
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Chapter 11. Cost-effectiveness of prehospital thrombolysis
The purpose of this study was to analyze the cost-effectiveness of prehospital
thrombolysis compared with in-hospital thrombolysis. Although prehospital
thrombolysis in acute myocardial infarction is associated with a time gain of
one hour in time to treatment, this strategy has not lead to widespread applica-
tion. To guide budget allocations needed for prehospital treatment, a cost ben-
efit analysis was made of this treatment strategy. Two approaches were used:
in one method the median time gain of prehospital thrombolysis, compared
with in-hospital thrombolysis was matched with the associated risk reduction
calculated on the basis of the literature. Costs of prehospital diagnosis and
treatment were added to the survival after 30 days, and cost effectiveness was
estimated as the additional costs due to prehospital thrombolysis divided by the
number of life years gained. In the other method a mathematical model was
used to simulate patient histories, each drawn from a certain risk profile,
whereby two histories were simulated for each patient, one with prehospital,
and one with in-hospital treatment. The time intervals were based on data of
736 patients with acute myocardial infarction, 468 patients prehospitally and
268 patients in hospitally treated. For risk assessment, data were used from the
TIMI-risk score of ST-segment elevation myocardial infarction.
In the first model, with a risk reduction of 30% for in-hospital, and 35% for
prehospital treatment, prehospital treatment resulted in costs per life year
gained at EUR 2,800. Using the second model, simulation of patient histories
and according risk profiles, the average 30-day survival with prehospital
thrombolysis was 93.73% compared to 93.32% with in-hospital thrombolysis.
This results in an estimated cost per life year gained of EUR 1,837, assuming
an average life expectancy of 10 years after being discharged. In conclusion,
prehospital thrombolysis seems cost-effective: EUR 1,800 to 2800 per life year
gained which compares well with other evidence-based therapies in acute
myocardial infarction.
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12.2 Conclusions
We can now answer the questions we set out in the introduction of this thesis. 
1. Time to treatment in ST elevation myocardial infarction is 152 minutes in
Nijmegen and varies between 145 minutes and 160 minutes in other
regions. Prehospital thrombolysis in Nijmegen results in a time to treat-
ment of 89 minutes with a median time gain of 63 minutes. With prehos-
pital thrombolysis 28% of patients could be treated within 1 hour and 65%
within 2 hours, and 25% of in-hospital treated patients within 2 hours.
Between 32 and 51 minutes could be gained if a prehospital strategy
would have been present in the other regions. 
2. Both mortality and heart failure were significantly lower in the early treat-
ment group (treatment within 2 hours) compared to the group treated late
(treatment later than 2 hours). Independent parameters showing a relation
with 30-day mortality were age, time to treatment, hypertension and prior
myocardial infarction. Age, time to treatment, hypertension and hyperlip-
idaemia were identified as predicting heart failure within the first 30 days.
Aborted myocardial infarction is diagnosed in 17% of the prehospital
treated patients and 4.5% of in-hospital treated patients, and is associated
with a significantly better 12-month mortality than established myocar-
dial infarction (2.2% and 11.6% respectively).
3. Abortion of myocardial infarction is not confined to prehospital throm-
bolysis, but can also be achieved using primary angioplasty with prehos-
pital triage. The incidence of abortion of myocardial infarction is signifi-
cantly higher in patients treated within 2 hours with primary angioplasty
compared with patients treated later.
4. Using newer generation bolus therapy in a prehospital strategy is associ-
ated with a significantly lower time to treatment as compared with a cur-
rent therapy of infusion of streptokinase or bolus anistreplase.
5. The incidence of unjustified fibrinolysis in prehospital therapy, using 2
different ways of diagnosis, compares well with in-hospital false diagnosis.
6. Prehospital thrombolysis is very cost-effective: EUR 1,800 and EUR
2,800 per life year gained and compares very well with other evidence-
based therapies in acute myocardial infarction. 
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12.3 Future aspects
Prehospital thrombolysis
This thesis shows that prehospital administration of thrombolytic therapy is
essential in shortening time to treatment of acute ST elevation myocardial
infarction. However, implementation of such a strategy still encounters various
obstacles:
• Contrary to in-hospital thrombolysis, a prehospital strategy asks a consid-
erable investment, both in organisation of other parties, like general prac-
titioners and ambulance staff, and in money.
• Many health workers, especially members of hospital staff, do not realize
the delays in treatment. They underline the importance of rapid transport
to the hospital, and do not notice the substantial door-to-needle time in
hospital.
• Fear of unjustified thrombolysis in a prehospital setting.
• Lack of a consensus of treatment of acute myocardial infarction with
thrombolysis or primary angioplasty, which divides large regions with
preferences for one therapy, thus delaying implementation of prehospital
thrombolysis.
Prehospital triage
This thesis, combined with the literature, underline the importance of time in
the treatment of the acute ST elevation myocardial infarction. Prehospital diag-
nosis paves the way for prehospital thrombolysis or prompt primary angio-
plasty. It is advisable to organize prehospital triage regionally, in cooperation
with the regional ambulance service, the local and referral hospitals in that
region and the district association of general practitioners. The Netherlands
Society of Cardiology holds this view and included prehospital triage and
thrombolysis in their recently updated guidelines. In our fifteen years experi-
ence of prehospital thrombolysis the cooperation of local general practitioners
was very important, especially in the Nijmegen region where general practi-
tioners play a large role in the first consultation of patients with chest pain and
where little self-referral of patients to emergency departments exists.
Furthermore, the ambulance staff, more than many hospital and health author-
ities, was conscious of the delays of patients with chest pain, and therefore was
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willing to expand their responsibility of diagnosing and treating acute ST ele-
vation myocardial infarction before transport to the hospital. Thus, the imple-
mentation of a prehospital strategy can only be successful if it is done in coop-
eration with local general practitioners and ambulance services.
Prehospital thrombolysis or primary angioplasty
Many studies comparing in-hospital thrombolysis with primary angioplasty
show advantages for the latter.1 However, the last word on this subject has not
been written, especially considering the results from recent studies 2,3 where
prehospital thrombolysis, combined with rescue angioplasty, is compared to
primary angioplasty. It seems that the time to reperfusion dictates the outcome
and not the means of realizing this; in other words, if the time to reperfusion
using either angioplasty or thrombolysis becomes similar, it is expected that the
benefit of thrombolysis becomes comparable to the benefit of angioplasty.
Furthermore, newer thrombolytic agents have been developed, facilitating pre-
hospital administration considerably, with additional reduction in treatment
delays. In addition, reduced-dose thrombolytic therapy in combination with the
administration of a potent antiplatelet agent like a glycoprotein IIb/IIIa
inhibitor restores antegrade flow at least as effectively as full-dose throm-
bolytic therapy, but is associated with a lower rate of reinfarction.4 This com-
bined approach seems likely to reduce reocclusion. 5,6,7 Finally, in the case of
facilitated primary angioplasty, this will mean prehospital triage, administra-
tion of a thrombolytic, GP IIb/IIIa or its combination and transport to an expert
regional catheterization facility; in the case of thrombolysis it will mean pre-
hospital diagnosis and treatment.
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SAMENVATTING EN CONCLUSIES
De basis van deze dissertatie wordt gevormd door de ervaring, die is opgedaan
in Nijmegen met 15 jaar prehospitale trombolyse van het acute ST elevatie
myocardinfarct. Daarnaast zijn gegevens gebruikt afkomstig uit Rotterdam,
één van de andere centra in Nederland waar ervaring met prehospitale trom-
bolyse is opgedaan, en uit Zwolle, waar een strategie bestaat met prehospitale
triage en primaire angioplastiek.
Hoofdstuk 1. Inleiding
Deze dissertatie probeert drie vraagstellingen te beantwoorden. In de eerste
plaats worden vragen beantwoord die allemaal te maken hebben met het belang
van vroege behandeling van het acute myocardinfarct: de tijdwinst van een pre-
hospitale strategie, het verschil in tijdwinst wanneer bolus- dan wel infusie-
therapie wordt gebruikt en de reductie in de mortaliteit na 30 dagen en de
ontwikkeling van hartfalen bij vroege behandeling. In de tweede plaats wordt
het concept van het verijdelde infarct onderzocht, zoals dit zich voordoet bij
prehospitale trombolyse, bij in-hospitale trombolyse en bij primaire angioplastiek
met prehospitale triage. Verder wordt aandacht gegeven aan onterechte behande-
ling, hetgeen onlosmakelijk verbonden is met het concept van het verijdeld
infarct; dit is onderzocht in de Nijmeegse en Rotterdamse prehospitale patiënten-
groep en in de trombolyse-literatuur. In de derde plaats zijn praktische aspecten
van prehospitale trombolyse onderzocht, waarbij de nadruk werd gelegd op
kosten en effectiviteit.
Hoofdstuk 2. Overzicht
Het acute coronaire syndroom waarvoor behandeling met trombolyse is
geïndiceerd wordt gekenmerkt door ST-segment elevatie op het elektrocardio-
gram. Het wordt gedefinieerd door typische symptomen, ECG-tekenen van
transmurale ischaemie (ST-segment elevatie), de ontwikkeling van Q-golven
op het ECG, en tekenen van myocardcelnecrose, hetgeen wordt gekarak-
teriseerd door de stijging van bepaalde enzymconcentraties in het bloed. Het
laatste kenmerk kan afwezig zijn, en wel indien de therapie zodanig is ingesteld
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dat celdood wordt verijdeld; in deze dissertatie wordt dit een verijdeld infarct
genoemd (aborted myocardial infarction). Een acuut ST elevatie myocard
infarct wordt vermoed (suspected) en op grond van dit vermoeden behandeld.
Indien na beoordeling van meerdere ECG’s en bloedbepalingen van myocard-
enzymen de diagnose correct is, noemen we het infarct bewezen of bevestigd
(proven, established). Indien de enzymbepalingen de waarde van tweemaal de
bovengrens van normaal niet overschrijdt noemen we het infarct verijdeld
(aborted). In beide gevallen was de behandeling terecht (justified) toegediend.
Indien de diagnose na het beoordelen van meerdere ECG’s en bepalingen van
myocardenzymen incorrect blijkt te zijn, spreken we van onterechte (unjusti-
fied) therapie.
In de laatste 25 jaar is veel onderzoek verricht naar methoden om ischaemisch
myocard te redden van celdood. Uiteindelijk bleek de tijd van begin van de
symptomen tot behandeling van het allergrootste belang te zijn. Dit werd
gedemonstreerd  in het diermodel, waarbij ischaemie werd geïnduceerd, gevolgd
door interventies om de ischaemie weer op te heffen op verschillende
momenten na de ischaemie-inductie. Verder toonden de eerste gepubliceerde
trials met trombolyse versus placebo het belang aan van vroege behandeling.
Vanaf de jaren tachtig van de vorige eeuw zijn studies verschenen over pre-
hospitale trombolyse, waarin de uitvoerbaarheid van prehospitale diagnostiek,
gevolgd door trombolyse vòòrdat de patiënt op transport naar het ziekenhuis
werd gesteld, werd bevestigd. Sinds de eerste publicatie van Gotsman hebben
vele studies over vroege en prehospitale trombolyse het licht gezien. Van groot
belang voor deze dissertatie waren de resultaten van een meta-analyse van
Boersma over vroege behandeling, waarin de start van de trombolyse binnen 1
uur na begin van de klachten de mortaliteit veel meer wist te verlagen dan werd
verwacht. Boersma onderstreepte het belang van “het gouden uur” van infarct-
behandeling en zijn meta-analyse dient als basis voor het concept van het
verijdelde infarct. Boersma concludeerde dat het voor het beoordelen van de
voordelen van prehospitale trombolyse essentieel is alle patienten (zowel
inhospitaal als prehospitaal behandeld) te verdelen in een vroege en een laat-
behandelde groep, en niet door prehospitale patiënten te vergelijken met
ziekenhuispatiënten. Indien men die verdeling alleen met in-hospitaal behan-
delde patiënten zou doen, dan is de groep vroeg behandelden veel te klein, daar
immers niet meer dan 6% van de in-hospitaal behandelde patiënten binnen 1
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uur wordt getrombolyseerd. Prehospitale trombolyse is de enige manier om een
groep patiënten samen te stellen die binnen 1 à 2 uur behandeld is en die groot
genoeg is om een dergelijke analyse mogelijk te maken. 
Hoofdstuk 3. Tijdsintervallen studie (STIMIS)
In de STIMIS-studie werden verschillende momenten in de tijd tussen begin
van de symptomen tot opname in het ziekenhuis beoordeeld, en wel in 1152
patiënten met verdenking op een acuut coronair syndroom. Deze studie was
onderdeel van het Nijmeegse thuistrombolyse project. Van deze patiënten wer-
den er uiteindelijk 200 behandeld met trombolyse: 141 prehospitaal en 59 na
opname in het ziekenhuis. In de uiteindelijke analyse werd bij 393 van deze
1152 patiënten een infarct bevestigd. In vergelijking met alle patiënten bleken
diegenen met een bevestigd  myocardinfarct vroeger te worden behandeld. Er
was een mediaan tijdsinterval van 89 minuten tussen begin van klachten en
behandeling bij prehospitale trombolyse en 152 minuten bij patiënten die in-
hospitaal werden behandeld. Van de prehospitale patiëntengroep bleek 28% te
zijn behandeld binnen 1 uur, tegen geeneen van de in-hospitale groep. Binnen
2 uur was 65%, respectievelijk 25% van de patiënten behandeld. 
Hoofdstuk 4. Registratie van de tijdsintervallen tussen begin van de symptomen
en start van de behandeling in 4 ziekenhuizen buiten de regio Nijmegen
Teneinde te beoordelen of in regio’s buiten Nijmegen prehospitale trombolyse
van nut zou zijn, werden in-hospitale tijdsintervallen van diagnose en behan-
deling verzameld van patiënten met pijn op de borst, waarmee een schatting
kon worden gemaakt van het percentage van patiënten dat binnen 2 uur zou
kunnen worden behandeld indien een prehospitale behandeling in deze regio’s
aanwezig zou zijn geweest. Om de tijdwinst van mogelijke prehospitale behan-
deling in deze 4 regio’s uit te rekenen werd 27 minuten toegevoegd aan de tijd
vanaf aankomst van de ambulancedienst. Deze 27 minuten is de tijd die de
ambulancedienst in Nijmegen nodig heeft om de diagnose myocardinfarct te
stellen en om prehospitale trombolyse te geven. De tijd tussen aankomst van de
ambulance in het ziekenhuis en behandeling aldaar (door-to-needle time)
varieerde van 39 tot 50 minuten in deze 4 regio’s en is dus vergelijkbaar met
de 48 minuten in de Nijmeegse ziekenhuizen. De totale behandelingsduur
varieerde van 145 tot 167 minuten. Indien een prehospitale behandeling aan-
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wezig zou zijn geweest, dan zou er  een tijdwinst van 32 tot 51 minuten zijn,
waarbij 55% van de patiënten binnen 2 uur zou kunnen worden behandeld in
plaats van de huidige 25%. Concluderend, prehospitale trombolyse in deze 4
regio’s zou de tijd tot behandeling belangrijk verkorten, met een verdubbeling
van het aantal patiënten dat binnen 2 uur behandeld zou kunnen worden.
Hoofdstuk 5. Tijd van begin van symptomen tot behandeling en resultaten in
prehospitale trombolyse voor het acute myocardinfarct
Het prehospitale trombolyseprogramma heeft een aanzienlijke database
gecreëerd van patiënten die binnen 1 en 2 uur na begin van de klachten zijn
behandeld. We hebben deze database geanalyseerd voor kenmerken van patiën-
ten met een goede prognose in de vroege behandelingsgroep. Vanaf 1994 tot
2000 zijn in totaal 475 patiënten behandeld voor acute ST elevatie myocardin-
farct met prehospitale trombolyse met anistreplase (407 patiënten) of reteplase
(68 patiënten); dit nadat de diagnose bevestigd was met een transtelefonisch
doorgezonden ECG (cardiofonie). Er was geen leeftijdsgrens. Het bestand
werd in twee groepen verdeeld: een groep behandeld binnen 2 uur na begin van
de symptomen en een groep later dan 2 uur. Als parameters werden de
30-dagen mortaliteit en klinische symptomen van hartfalen gebruikt. Zowel
een univariate als een stapsgewijze regressie analyse werden gebruikt om de
30-dagen sterfte uit te zetten tegen leeftijd, tijd tot behandeling, vroeger
doorgemaakt infarct, hypertensie, diabetes, hyperlipidaemia, voorwandinfarct,
Killip-klasse, systolische bloeddruk en hartfrequentie bij binnenkomst. De
totale 30-dagen mortaliteit bleek 9,0% te zijn, waarbij 16,4% van de patiënten
hartfalen ontwikkelden. Zowel het hartfalen (12,7% versus 23,2%, p<0,02) als
de 30-dagen mortaliteit (5,5% versus 15,2%, p<0,02) waren significant lager in
de vroege behandelingsgroep, vergeleken met de laat behandelden. Leeftijd,
tijd tot behandeling, hypertensie en vroeger doorgemaakt infarct waren
onafhankelijke voorspellers van 30-dagen mortaliteit. Voor de voorspelling van
hartfalen was dit leeftijd, tijd tot behandeling, hypertensie en hyperlipidaemia.
Concluderend, prehospitale trombolyse resulteert in een behandeling binnen 2
uur bij tweederde van de patiënten. Onafhankelijke voorspellers voor 30-dagen
sterfte waren leeftijd, tijd tot behandeling, een doorgemaakt infarct en hyper-
tensie. Leeftijd, hypertensie, tijd tot behandeling en hyperlipidaemia waren dit
voor de ontwikkeling van hartfalen. 
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Hoofdstuk 6. Het effect van prehospitale trombolyse op het verijdelen van een
myocardinfarct
Ervan uitgaand dat het verijdelen van een ST elevatie myocard infarct geasso-
cieerd is met prehospitale trombolyse, hebben we prehospitaal behandelde
patiënten vergeleken met in-hospitaal behandelde patiënten. In totaal werden
227 patiënten  prehospitaal behandeld in Nijmegen (bolus anistreplase) en
retrospectief vergeleken met 269 patiënten die in-hospitale trombolyse
ondergingen (1,5 miljoen eenheden streptokinase intraveneus of 100 mg rt-PA,
gecombineerd met heparine) in Arnhem. De diagnose verijdeld infarct werd
gesteld indien 1) de combinatie van klachten en dynamische ECG-veranderingen
overeenkwamen met de verdenking van acuut ST elevatie myocardinfarct, 2)
indien de stijging van myocardenzymen in het bloed niet meer was dan twee
keer de normaalwaarde en 3) indien de cumulatieve ST veranderingen tot meer
dan 50% verbeterden binnen 2 uur na begin van de therapie. Patiënten met
onterechte trombolytische behandeling werden uitgesloten, hetgeen in 3 van de
prehospitaal behandelde patiënten en 5 van de in-hospitaal behandelde patiën-
ten het geval bleek. In totaal 30 van de 224 prehospitaal behandelde patiënten
(13,4%) en 12 van de 266 in-hospitaal behandelde patiënten (4,5%) voldeden
aan de criteria van verijdeld infarct (p<0,05). Geen van deze patiënten overleed
tijdens de ziekenhuisperiode of binnen de 12 maanden follow-up. 
Hoofdstuk 7. Uitgebreidere analyse van patienten met verijdeld infarct na
reperfusie therapie
Gebruikmakend van een uitgebreider bestand van prehospitaal behandelde
patiënten hebben we onderzocht binnen welke tijdslimiet verijdeling van het
acute myocardinfarct verwacht kan worden, waarbij tevens gezocht werd naar
verschillen in parameters vergeleken met het bevestigde infarct. Van patiënten
die verdacht werden van een acuut ST elevatie myocard infarct werden ECG’s
vanaf de ambulancedienst doorgezonden naar de CCU van één van de 2
Nijmeegse ziekenhuizen. Na bevestiging van de diagnose acuut infarct werden
475 patiënt geïncludeerd en behandeld met trombolyse. De gegevens van deze
patiënten werden vergeleken met 269 patiënten die in-hospitaal behandeld
waren met streptokinase of rt-PA in een nabijgelegen stad zonder prehospitaal
trombolyseprogramma. Een stapsgewijze regressie-analyse werd gebruikt om
onafhankelijke voorspellende parameters op het spoor te komen van verijdeling
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van infarct. Na correctie voor onterechte behandeling bleken 80 patiënten
(17,1%) van de 468 prehospitaal behandelde patiënten en 12 (4,5%) van de 264
in-hospitaal behandelde patiënten te voldoen aan de criteria van een verijdeld
infarct. Er was geen verschil in leeftijd, geslacht, risicofactoren en locatie van
het infarct bij het verijdelde infarct vergeleken met het bevestigde infarct. Meer
dan 30% van de patiënten met een verijdeld infarct had 2- of 3-vatslijden bij
coronairangiografie. Behalve de tijd tot behandeling, die significant korter
bleek te zijn in de patiëntengroep met een verijdeld infarct, waren eveneens
minder ST segment veranderingen en een hogere incidentie op pre-infarct angina
pectoris onafhankelijke voorspellers te zijn voor het optreden van een verijdeld
infarct. De prognose van een verijdeld infarct is significant beter dan van een
bevestigd infarct: de mortaliteit na 12 maanden is 2,2% vergeleken met 11,6%.
Concluderend, prehospitale trombolyse is vaker geassocieerd met het optreden
van een verijdeld infarct vergeleken met ziekenhuisbehandeling. Een kortere
tijd tot behandeling, minder ST segmentverandering en meer pre-infarct angina
pectoris zijn onafhankelijke voorspellers hiervoor.
Hoofdstuk 8. Primaire angioplastiek of prehospitale trombolyse en verijdeling
van het acute myocardinfarct
Het combineren van prehospitale triage met primaire angioplastiek heeft het
tijdsinterval tussen begin van de klachten en mechanisch openen van het afge-
sloten coronairvat aanzienlijk verkort. We hebben reperfusietijden van primaire
angioplastiek en prehospitale triage vergeleken met die van prehospitale trom-
bolyse. De incidentie van het optreden van een verijdeld infarct werd vastgesteld
in patiëntengroepen die met één van deze methoden behandeld werden. In
totaal werden 545 patiënten prehospitaal behandeld in de steden Rotterdam en
Nijmegen en vergeleken met 236 patiënten die met primaire angioplastiek
waren behandeld in Zwolle. Alle patiënten waren voorbehandeld met nitro-
glycerine en aspirine, en de angioplastiekpatiënten met heparine iv. Voor pre-
hospitale trombolyse werd streptokinase of anistreplase gebruikt in Nijmegen
of Rotterdam. Als tijd tot reperfusie werd gebruikt de tijd vanaf symptomen tot
aan mechanisch openen van het aangedane coronairvat; bij trombolyse werd
gebruikt de tijd vanaf begin van de symptomen tot aan behandeling met trom-
bolyse plus 60 minuten. Een verijdeld infarct kwam in 16% van de patiënten
voor behandeld met prehospitale trombolyse en in 11% van de patiënten met
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primaire angioplastiek. In primaire angioplastiek, bij indeling van de reper-
fusietijd in vroeger en later dan 2 uur, zagen we significant meer verijdelde
infarcten in de vroeg gereperfundeerde groep. De 30-dagen sterfte was niet
significant verschillend in vroeg en laat gereperfundeerde groepen, in zowel
prehospitale trombolyse als primaire angioplastiek met prehospitale triage.
Geconcludeerd, zowel prehospitale trombolyse als primaire angioplastiek is
geassocieerd met het optreden van een verijdeld infarct, met vergelijkbare
reperfusietijden. In het geval van primaire angioplastiek is de incidentie van het
optreden van verijdeld infarct het hoogst in de vroeg behandelde groep.
Hoofdstuk 9. Prehospitale trombolyse met reteplase; de Nijmegen/Rotterdam
studie
Teneinde de tijd tot behandeling en de klinische parameters van dubbelbolus
reteplase te vergelijken met de reeds gangbare behandeling met streptokinase
infuus of bolus anistreplase werd een observationele studie uitgevoerd in twee
steden met prehospitale trombolyse (Rotterdam en Nijmegen). Reteplase of
streptokinase, dan wel anistreplase werd toegewezen aan patiënten al naar
gelang de volgorde van presentatie. Alle patiënten waren voorbehandeld met
nitraten en aspirine. In totaal werden 250 patiënten behandeld tussen 1 april
1999 en 1 augustus 2000. Reteplase werd in 120 patiënten gebruikt en de gang-
bare therapie van streptokinase in Rotterdam of anistreplase in Nijmegen in
130 patiënten. Het gebruik van dubbel bolus reteplase resulteerde in een sig-
nificant kortere behandelingstijd met een mediaan van 81 minuten vergeleken
met een mediaan van 104 minuten met gangbare behandeling (p<0,05). Er
waren geen verschillen in sterfte, verijdeld infarct, bloedig CVA of de nood-
zaak tot rescue-angioplastiek in beide groepen. Binnen 2 uur was 64% van de
patiënten behandeld. Concluderend, dubbel bolus reteplase is geassocieerd met
een veel kortere behandelingstijd bij prehospitale trombolyse dan bolus anistre-
plase of streptokinase.
Hoofdstuk 10. Prehospitale versus ziekenhuistrombolyse met computerdiag-
nostiek versus diagnostiek a vue van het acute myocardinfarct: verijdeld infarct
en onterecht gegeven behandeling
Het doel van deze studie betrof het analyseren van de incidentie van onterecht
gegeven fibrinolyse bij een prehospitaal uitgevoerde strategie in Nederland
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wanneer verschillende methoden van ECG-diagnostiek worden gebruikt.
Onterechte fibrinolyse bij patiënten verdacht voor een acuut myocardinfarct
kan desastreus uitvallen, maar moet worden gedifferentieerd van terecht
gegeven behandeling die een verijdeld infarct tot gevolg heeft. In Rotterdam
werden 118 patiënten  prehospitaal behandeld voor acuut ST elevatie
myocardinfarct, waarbij gebruik gemaakt werd van een geautomatiseerd com-
puter ECG. In Nijmegen werden 132 patiënten prehospitaal behandeld,
gebruikmakend van transtelefonische transmissie naar de CCU en daar be-
oordeeld door de cardioloog aldaar. De gegevens van deze patiënten werden
vergeleken met die van 269 patiënten die in Arnhem in het ziekenhuis werden
behandeld, met de overal gangbare methode van beoordeling van het ECG door
de cardioloog op de CCU. Alle patiënten werden behandeld met trombolyse
volgens dezelfde ECG-criteria. Een verijdeld infarct werd vastgesteld indien er
geen stijging optrad van meer dan tweemaal de normale bovengrens van
myocardenzymen in het bloed en wanneer minstens 50% van de ECG-
afwijkingen verdween binnen 2 uur na toediening. Indien dit niet het geval was
werd de diagnose onterecht gegeven fibrinolyse gesteld. Dit trad op in 8
prehospitaal behandelde patienten: 4 in Rotterdam (3,3%) en 4 in Nijmegen
(3,0%) en in 5 van de ziekenhuisbehandelde patiënten in Arnhem (1,9%). Een
verijdeld infarct werd in 14,4% en 17,4% in Rotterdam respectievelijk
Nijmegen tegen 4,5% in Arnhem (p<0,001). Concluderend, hoewel het optreden
van onterecht gegeven fibrinolyse ongewenst is, gebeurt dit in dezelfde mate in
de prehospitale als in de ziekenhuissituatie. Het gebruik van verschillende
manieren van ECG-diagnostiek lijkt hierin geen verschil te maken.
Hoofdstuk 11. Kosteneffectiviteit van prehospitale trombolyse
Met behulp van deze studie werd de kosteneffectiviteit van prehospitale
trombolyse geanalyseerd, en vergeleken met ziekenhuistrombolyse. Hoewel
prehospitale trombolyse gepaard gaat met een tijdwinst van een uur is deze
methode van behandeling nog niet algemeen geaccepteerd. Teneinde budget-
veranderingen te sturen die voor prehospitale trombolyse nodig zijn, werd een
kosten-effectiviteitanalyse uitgevoerd van deze behandelingsstrategie. We
hebben twee benaderingen gebruikt. Met een methode werd de mediane tijd-
winst van prehospitale trombolyse ten opzichte van ziekenhuistrombolyse
toegepast op de met deze tijdswinst geassocieerde risicoreductie, zoals bekend
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uit de infarctliteratuur. De kosten van prehospitale trombolyse werden opgeteld
bij de 30 dagen sterfte, en de kosteneffectiviteit werd bepaald als de
extrakosten van prehospitale strategie gedeeld door het aantal gewonnen
levensjaren. Met de tweede methode gebruikten we een wiskundig model om
ziektegeschiedenissen van patiënten te simuleren, elk met een bepaald risico-
profiel, met steeds per patiënt twee strategieën: één met prehospitale behandeling
en één met ziekenhuisbehandeling. De tijdsintervallen die nodig waren voor
deze wiskundige benadering waren gebaseerd op de gegevens van 736 patiën-
ten met een acuut myocardinfarct, 468 prehospitaal behandeld in Nijmegen en
268 in-hospitaal behandeld in Arnhem. Voor het opstellen van de risicoprofielen
werd gebruik gemaakt van de TIMI-risikoscore van ST elevatie myocard-
infarct. Gebruikmakend van het eerste model, met een risicoreductie van 30%
voor in-hospitale behandeling en 35% voor prehospitale behandeling, vonden
we een kosten-effectiviteit van prehospitale trombolyse van EUR 2800 per
gewonnen levensjaar. Gebruikmakend van het tweede model, met simulatie
van ziektegeschiedenissen en bijpassende risicoprofielen, kwamen we uit op
een gemiddelde sterfte na 30 dagen van 93,73% met prehospitale trombolyse
en van 93,32% met ziekenhuistrombolyse. Dit resulteerde in een kosten-effec-
tiviteit van prehospitale trombolyse van EUR 1837 per gewonnen levensjaar,
er van uitgaand dat de gemiddelde levensverwachting van een patiënt 10 jaar
is na ontslag uit het ziekenhuis. Concluderend, prehospitale trombolyse is
kosteneffectief: EUR 1800 tot 2800 per gewonnen levensjaar, hetgeen zeer
goed afsteekt vergeleken met andere therapieën in de behandeling van het acute
myocardinfarct.
Conclusies
Tijd tot behandeling in het ST elevatie myocardinfarct is 152 minuten in
Nijmegen en varieert van 145 tot 160 minuten in andere regio’s. Prehospitale
trombolyse in Nijmegen resulteert in een tijd tot behandeling van 89 minuten
met een mediane tijdswinst van 63 minuten. Met prehospitale trombolyse kan
28% van de patiënten binnen 1 uur behandeld worden en 65% binnen 2 uur,
vergeleken met slechts 25% van de ziekenhuispatiënten binnen 2 uur. In andere
regio’s zouden 32 tot 51 minuten tijdwinst behaald kunnen worden met een
prehospitale strategie, en 55% van de patiënten binnen 2 uur behandeld kunnen
worden in plaats van 25%.
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Zowel sterfte als het optreden van hartfalen was significant lager in de vroeg
behandelde groep (behandeld binnen 2 uur) vergeleken met de groep die later
dan 2 uur is behandeld. Leeftijd, tijd tot behandeling, hypertensie en vroeger
doorgemaakt infarct waren onafhankelijke variabelen voor de ziekenhuis-
mortaliteit. Leeftijd, tijd tot behandeling, hypertensie en hyperlipidaemia
waren onafhankelijke risicofactoren voor het optreden van hartfalen. Het
optreden van een verijdeld infarct is geassocieerd met prehospitale trombolyse
en treedt in 17% van de gevallen op, vergeleken met 4,5% van de ziekenhuis-
patiënten, en is verder geassocieerd met een significant betere 1-jaarsover-
leving dan het gevestigde infarct (2,2% respectievelijk 11,6%).
Het optreden van een verijdeld infarct komt niet alleen bij prehospitale
trombolyse voor, maar ook bij primaire angioplastiek met prehospitale triage.
Bij deze laatste behandelingsstrategie is de incidentie van het optreden van een
verijdeld infarct significant hoger in de patiëntengroep die binnen 2 uur
gereperfundeerd wordt.
Het gebruik van de nieuwe generatie bolus thrombolytica, zoals reteplase, is
geassocieerd met een significant kortere behandelingstijd dan met de gangbare
infusietherapie met streptokinase, of bolus anistreplase.
Het voorkomen van onterechte fibrinolyse in prehospitale strategie met
verschillende methoden van ECG-diagnostiek is niet anders dan bij zieken-
huisdiagnostiek.
Prehospitale trombolyse is zeer kosteneffectief: EUR 1800 en EUR 2800 per
gewonnen levensjaar, berekend met behulp van verschillende methoden, en dus
goed vergelijkbaar met andere infarctbehandelingen.
Toekomstverwachtingen
Prehospitale trombolyse
Ik hoop met deze dissertatie aangetoond te hebben dat een prehospitale strategie
voor trombolysebehandeling essentieel is om de behandelingstijd te verkorten
voor het acute ST elevatie myocardinfarct. Desalniettemin ontmoet de imple-
mentatie van deze strategie diverse obstakels:
In tegenstelling tot ziekenhuisbehandeling vraagt prehospitale trombolyse om
een aanzienlijke investering in tijd, organisatievermogen en geld, bij alle
betrokkenen, zoals huisartsen en ambulancediensten.
Veel gezondheidsfunctionarissen, met name ziekenhuismedewerkers, realiseren
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zich niet zo dat er aanzienlijke vertragingen bestaan in de behandeling van
infarctpatiënten. Wel worden korte transporttijden naar het ziekenhuis
benadrukt, maar de substantiële ziekenhuisvertraging gaat veelal ongemerkt.
Er is de angst voor onterechte fibrinolyse bij prehospitale strategie.
Er is onvoldoende consensus over dan wel trombolyse, dan wel primaire angio-
plastiek, waardoor in bepaalde regio’s verdeeldheid optreedt en het imple-
menteren van de ene dan wel de andere strategie wordt vertraagd.
Prehospitale triage
In deze dissertatie wordt het belang van een korte behandelingstijd onder-
streept, met eigen onderzoeksgegevens gecombineerd met die uit de literatuur.
Prehospitale diagnostiek maakt de weg vrij voor prehospitale trombolyse of
snelle primaire angioplastiek. Men dient prehospitale triage regionaal te
organiseren, in samenwerking met de plaatselijke ambulancedienst, de plaat-
selijke ziekenhuizen, de angioplastiekcentra van die regio en de plaatselijke
huisartsenvereniging. De Nederlandse Vereniging voor Cardiologie is deze
mening eveneens toegedaan en heeft prehospitale triage en trombolyse in de
recent bijgewerkt richtlijnen voor het acuut ST elevatie myocardinfarct
opgenomen. In onze 15 jaar ervaring met prehospitale trombolyse bleek de
samenwerking met de plaatselijke huisartsen van essentieel belang te zijn, met
name in Nijmegen waar de huisartsen een belangrijke rol spelen in de eerste
opvang van patienten met pijn op de borst. Bovendien bleek de ambulance-
dienst, meer nog dan andere gezondheidswerkers, zich bewust te zijn van de
vertragingen die patienten met pijn op de borst omgeven, en daardoor zeer
bereidwillig hun verantwoordelijkheid in de behandeling van infarctpatiënten
uit te breiden. Met andere woorden, de implementatie van een prehospitale
strategie kan alleen succesvol zijn in samenwerking met de plaatselijke huis-
artsen en ambulancediensten.
Prehospitale trombolyse en primaire angioplastiek
Veel studies waarin gerandomiseerd wordt tussen ziekenhuistrombolyse en
primaire angioplastiek tonen voordelen voor de laatste behandelingsmogelijk-
heid. Het laatste woord hierover is echter nog niet gezegd, met name indien de
resultaten van recent gepubliceerde studies in aanmerking worden genomen,
waarbij prehospitale trombolyse, gecombineerd met rescue angioplastiek
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wordt vergeleken met primaire angioplastiek. Het lijkt zo te zijn dat de reper-
fusietijd de resultaten gaat bepalen, en niet zozeer de manier waarop reperfusie
wordt bewerkstelligd. Met andere woorden: indien de reperfusie tijd van zowel
trombolyse als primaire angioplastiek overeen gaan komen, dan is de
verwachting dat de resultaten van trombolyse die van primaire angioplastiek
gaan evenaren. Bovendien zijn er nieuwe generatie thrombolytica ontwikkeld,
die prehospitale behandeling aanzienlijk vergemakkelijken, met daarmee
gepaardgaande vermindering van vertragingen in de behandeling. Daarbij
komt dat lagere doseringsschema’s van trombolytische behandeling gecombi-
neerd kunnen worden met sterk werkende plaatjesremmers zoals de glyco-
proteine IIb/IIIA receptorantagonisten, waarbij een net zo effectief herstel van
de coronairflow verkregen kan worden, maar met een lagere incidentie in het
optreden van re-infarcering. Tenslotte, indien men gefaciliteerde primaire
angioplastiek wil gaan uitvoeren, dan is prehospitale triage zeer wenselijk, met
toediening van trombolyse of GP IIB/IIIA blokker of een combinatie hiervan
en transport naar een regionaal catheterisatielaboratorium met ervaren inter-
ventiecardiologen; in het geval van trombolyse betekent dit prehospitale diag-
nostiek en behandeling.
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DANKWOORD
Menigeen die na het The End van een bioscoopfilm nog even blijft zitten voor
de aftiteling, zal zich verbazen over het enorme aantal medewerkers dat nodig
is voor de realisatie van zo’n film. Na regisseur, producenten en acteurs wordt
meestal een lange reeks namen genoemd, met soms onbegrijpelijke functies
erachter, zoals gaffer, clapper loader en key grip. Men realiseert zich aldus dat
ieder op zijn of haar manier medewerking heeft gegeven om de film gestalte te
geven. Je mag dan nog zulke goede acteurs hebben, en een eersteklas regisseur,
zonder de gaffer (verlichtingsman), de clapper loader (zorgt dat er film in de
camera terechtkomt) en de key grip (bouwt stellages en rails waarover de camera
gereden kan worden en helpt de cameraman hiermee) komt er uiteindelijk niets
op het witte doek. 
Zo is het in feite ook met het realiseren van een proefschrift. De promovendus
is vergelijkbaar met een regisseur, die ook een rol in zijn eigen film meespeelt,
en daarnaast zorgt voor scenario, script-editing en continuity op de set.
Promotor en copromotor zijn de producer en co-producer. Alle medeauteurs
zijn te vergelijken met de acteurs, en de casting van de auteurs is afhankelijk
van het onderwerp van de film of van het hoofdstuk van het proefschrift. De
statistische hulp is misschien nog het best vertaalbaar in de synchronisation van
het camera- en geluidswerk: zorgen dat de werkelijkheid betrouwbaar op het
witte doek of op het papier terechtkomt. En zo kun je nog wel uren doorgaan
met fantaseren, maar nu ter zake.
Als je van producers van dit proefschrift spreekt dan zijn dit wel Ton
Hooghoudt en Don Hertzberger. Beste Ton en Don, jullie hadden de visie om
in 1986 met prehospitale trombolyse in Nijmegen te beginnen. Dit was in een
tijd met alleen de GISSI studie als bewijsmateriaal, en zonder de geavanceerde
apparatuur die er nu is om ECG’s over te brengen van thuis naar de CCU. Nog
altijd piept en rammelt het ouderwetse faxapparaat, dat toen voor prehospitale
diagnosestelling werd aangeschaft, bij mij op zolder. Ook was er maar kort
ervaring met streptokinase, en dan alleen in-hospitaal, dus het is niet verwon-
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derlijk dat jullie veel weerstand hebben moeten overwinnen om prehospitale
behandeling te starten. Financiering van prehospitaal toegediende medica-
menten was totaal onduidelijk en de zorgverzekeraars hadden er helemaal geen
zin in. Maar jullie hebben doorgezet en dankzij dit pionierswerk is de ervaring
opgebouwd die als basis heeft gediend voor dit proefschrift; ik heb erg veel
respect voor dit pionierswerk en ben erg dankbaar dat ik de gelegenheid heb
gekregen er een proefschrift mee te bewerken.
Mijn promotor professor Freek Verheugt dient eveneens genoemd te worden in
de lijst met producers. Beste Freek, voordat je naar Nijmegen kwam had je al
in een aantal publicaties het belang uiteengezet van de time to treatment bij de
acute infarctbehandeling. Het is enorm belangrijk dat de regio Nijmegen in zijn
geheel kon profiteren van prehospitale therapie, en dat het Academisch
Centrum St Radboud met veel enthousiasme aan deze strategie heeft meege-
werkt. Ik ben je erg dankbaar voor het vertrouwen dat je in mij als promovendus
hebt gesteld. Ik heb heel veel gehad aan je adviezen over de hoofdstukken en
je hulp bij de publicaties; voor de vele commentaren en toevoegingen aan de
tekst ben ik je veel dank verschuldigd.
En dan de casting van acteurs: zonder acteurs geen film en zonder maten geen
proefschrift. Naast Ton Hooghoudt en Don Hertzberger heeft ieder van onze
maatschap op zijn manier een bijdrage geleverd waar ik erg dankbaar voor ben.
Leon Bouwels, Bart-Jan Meursing, Ton Oude Ophuis en natuurlijk ook Jo
Tummers, hartelijk dank voor de vele stimulerende woorden en om stand-in te
zijn wanneer ik weer eens een week montage achter de laptop had gepland.
Ieder van jullie is “vereeuwigd” in een stelling. Naast het producerschap van
Ton Hooghoudt dienen de vele gezellige dagen met hem niet onvermeld te
blijven, al dan niet genoodzaakt door presentaties over prehospitale trombolyse,
waarbij niet alleen de script editing, de special effects supervision en het con-
tinuity report aan de orde kwamen, maar ook tijd werd besteed aan de
algemene ontwikkeling. Vooral van de dagen in Berlijn heb ik veel opgestoken,
met het bezoek aan het filmpark Babelsberg en de verschillende filmmusea die
deze stad rijk is. 
Bijna vergeet ik de stills: Fred Marcus, Piet en (alweer) Ton Hooghoudt, dank
voor de plaatjes! Hartelijk dank voor de medewerking van de andere auteurs:
de cardiologen Peter Stolwijk uit Arnhem, Wilma Smits uit Boxmeer, Henk
Groeneveld uit Deventer en John van Hal uit Zevenaar. Jullie bijdragen aan de
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opbouw van de time to treatment hoofdstukken en aan de hoofdstukken over
verijdelde infarcten zijn zeer op prijs gesteld. De Rotterdamse cardiologen en
hun medewerksters bedank ik hierbij voor hun hulp bij het verzamelen van de
gegevens van de Rotterdamse patiënten. Jaap Hartman en Kees de Ruiter van
de Rotterdams ambulancedienst moeten even extra worden vermeld. Dr. Eric
Boersma, met jouw baanbrekend werk over het belang van de time to treatment
zou je zeker een Golden Globe hebben gewonnen en het Gouden Uur, zoals
gepubliceerd in de Lancet, is de basis geweest voor vele hoofdstukken in dit
proefschrift; ik ben jou en professor Maarten Simoons erg erkentelijk voor
jullie hulp. Datzelfde geldt voor dr. Menko-Jan de Boer uit Zwolle en professor
Felix Zijlstra uit Groningen. Dankzij de uitgebreide Zwolse database van
infarctpatiënten, behandeld na prehospitale triage met primaire angioplastiek,
weten we dat het verijdeld infarct ook in deze patiëntenpopulatie voorkomt.
Peter Elsman heeft een sleutelrol hierin gespeeld, waarvoor dank; Peter, leuk
dat je in Nijmegen terecht bent gekomen en dat je maar veel rescue- en
primaire angioplastieken mag doen. Marc Brouwer uit Nijmegen heeft ook nog
een rolletje gespeeld: hartelijk dank voor je steun bij het verdedigen van het
concept van het verijdelde infarct. Wij verwachten een filmprijswinnende rol-
prent van jou. Theo de Boo, statisticus aan de Medische Faculteit, dank voor
de regressie-analyses waarmee je beeld en geluid aan elkaar vast hebt
geknoopt. De middagen in Utrecht en Nijmegen met kosten-baten-professor
Ben van Hout, met de bierviltjesmethode (in hoofdstuk 11 back of the envelop
methode genoemd) als basis voor de simulatiemethode is mijn inzicht in, en
respect voor health economics aanzienlijk vergroot. Beste Ben, je hebt het vaak
in slow motion moeten uitleggen, dank voor je geduld. Wij waren bijzonder
verguld dat je ons werk als voorbeeld noemde in je inaugurale rede en ik ben
enorm vereerd dat je als cameo (hoofdrolspeler die met een bijrol genoegen
neemt) in mijn proefschrift hebt willen optreden.
Prehospitale trombolyse staat of valt met de ambulancedienst. Ik speel nu even
voor gaffer (verlichting) om de Nijmeegse ambulancedienst en die van Grave,
onder leiding van respectievelijk Frans Spee, dr. Pierre van Grunsven en Piet
Hoving, in de schijnwerpers te zetten. Jullie al vijftien jaar durend enthousiasme
voor prehospitale diagnostiek en behandeling heeft uiteindelijk geleid dat in
den lande de prehospitale triage en trombolyse routine gaat worden. Ook de
huisartsen van de regio Nijmegen, met name Jaap Schreuder te Malden en Paul
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Giesen te Nijmegen dienen in het zonnetje gezet te worden. Dat Nijmegen
alom in de “prehospitale” literatuur wordt genoemd is voor een groot deel aan
jullie te danken.
En nu een close-up van Astrid Schut. Astrid, als de functie key grip op iemand
van toepassing is, dan is dat wel op jou. “Key”, omdat je een sleutelfiguur bent
geweest in alles wat maar met de organisatie van prehospitale trombolyse in
Nijmegen te maken heeft. “Grip”, omdat je zowel de successen als de
cliffhangers in je greep had. Je hebt het ontwerp gemaakt voor de database, mij
het gebruik van Excel geleerd, met huisartsen en ambulancepersoneel overlegd,
met de apotheker, met het Radboud, de tijdsintervallen verzameld, de artikelen
doorgenomen, de statistiek nagekeken, posters opgehangen, mij aangehoord als
het goed ging, mij ook aangehoord als het niet goed ging en op dat allemaal
adequaat gereageerd. 
Tenslotte verlaten we studio CWZ en gaan we met de camera (een Debrie
Parvo, compleet, te bezichtigen bij Ton Hooghoudt) filmen on location. In Den
Haag groet ik Hans en Jo Cornet, met een huis vol boeken en een leven vol
eruditie. Beste oom Hans en tante Jopie, met alle mooie herinneringen uit mijn
jeugd is een prachtige documentaire te vullen. Je zult het nooit zo vermoed
hebben maar jullie zijn voor mij altijd een voorbeeld geweest, vooral op die
momenten in mijn leven toen ik een voorbeeld zo nodig had. En nu naar de
Johannaweg in Nijmegen. Mijn vriend Lee Sallows, vergezeld door twee
poezebeesten, wandelt daar in de tuin tussen de bluebells. Lieve Lee, dit proef-
schrift is één van de projecten die we met zijn tweeën hebben afgerond. Of het
nu Toovervierkanten zijn, of “geen dag zonder Bach”, de verbouw van de zolder
of de aanbouw van de serre, met de rugzak door de Pindos, of naar the last
homely house east of the sea, het zijn allemaal weerspiegelingen van een
gelukkige tijd. De liefdevolle, sturende en steunende rol die jij in mijn leven
speelt komt niet voor in de credits van welke film dan ook. Ik ben er dankbaar
voor, en trots, als op een Oscar…
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